Design and development of novel therapeutic strategies targeting K-Ras driven Pancreatic Ductal Adenocarcinoma by Blasco Lázaro, María Teresa
 UNIVERSIDAD AUTÓNOMA DE MADRID 
DEPARTAMENTO DE BIOQUÍMICA 
 
 
 
Design and development of novel therapeutic 
strategies targeting K-Ras driven Pancreatic 
Ductal Adenocarcinoma 
 
 
 
 
DOCTORAL THESIS 
María Teresa Blasco Lázaro 
  
  
DEPARTAMENTO DE BIOQUÍMICA 
Facultad de Medicina 
UNIVERSIDAD AUTÓNOMA DE MADRID 
 
Design and development of novel therapeutic 
strategies targeting K-Ras driven Pancreatic 
Ductal Adenocarcinoma 
 
DOCTORAL THESIS 
 
María Teresa Blasco Lázaro 
Biology B.S 
Biochemistry and Biomedicine M.S 
 
Directors: 
Dr. Mariano Barbacid 
Dr. Carmen Guerra 
Centro Nacional de Investigaciones Oncológicas
  
  
  
 
 
 
 
Dr. Mariano Barbacid Montalbán, director of the Experimental Oncology Group at the 
Spanish National Cancer Research Center (CNIO)  
and 
Dr. Carmen Guerra González, staff scientist of the Experimental Oncology group at the 
Spanish National Cancer Research Center (CNIO)  
Hereby certify that the Doctoral Thesis “Design and development of novel therapeutic 
strategies against K-Ras driven Pancreatic Ductal Adenocarcinoma”, submitted by María 
Teresa Blasco Lázaro for the degree of Dr. of Philosophy and carried out under of the 
undersigned in the Experimental Oncology Group at Spanish National Cancer Research Center 
(CNIO), duly meets the requirements laid out by the Spanish RD 1393/2007 and the Autonoma 
University of Madrid.  
 
Madrid, April 24th 2017 
 
 
 
 
Mariano Barbacid Montalbán                                                Carmen Guerra González 
       PhD Thesis Director                                                            PhD Thesis Director   
 
 
 
 
 
 
Dr. Mariano Barbacid Montalbán, director of the Experimental Oncology Group at the 
Spanish National Cancer Research Center (CNIO)  
and 
Dr. Carmen Guerra González, staff scientist of the Experimental Oncology group at the 
Spanish National Cancer Research Center (CNIO)  
Hereby certify that the Doctoral Thesis “Design  development of novel therapeutic 
strategies against K-R s driven Pancreatic Ductal Adenocarcinoma”, submitted by María 
Teresa Blasco Lázaro for the egree of Dr. of Philosophy and carried out under of the 
undersigned in the Experimental Oncology Group at Spanish National Cancer Research Center 
(CNIO), duly meets the requirements laid out by the Spanish RD 1393/2007 and the Autonoma 
University of Madrid.  
 
Madrid, April 24th 2017 
 
 
 
 
Mariano Barbacid Montalbán                                                Carmen Guerra González 
       PhD Thesis Director                                                            PhD Thesis Director   
  
  
  
 “En la vida no hay nada que temer, sólo hay que comprender” 
“Nothing in life is to be feared, it is only to be understood” 
 
Marie Curie
  
  
Acknowledgements 
I would like to acknowledge Mariano Barbacid for giving me the opportunity to carry out 
my PhD in Experimental Oncology Laboratory. Especially, Carmen Guerra for her support, 
guidance and positivity over these years.  
I am very grateful to all the people that have participated in this work and all heads and 
technicians of the CNIO Core Units, especially the Animal Facility, Molecular Imaging, 
Histopathology, Confocal Microscopy and Transgenic Mice units.   
Thank you to all past and present members of Experimental Oncology group for their 
support and help and for making me smile everyday. It was a pleasure to do the PhD at the 
CNIO where I have found so many good people and friends.  
And finally, I want to dedicate this thesis to my friends, Javi and my lovely family for their 
unwavering support. Thank you, because without you it would have been impossible to reach 
the end.  
Y finalmente, quiero agradecer a mis amigos, a Javi y a mi querida familia su apoyo 
incondicional durante todos estos años. Gracias, porque sin vosotros hubiera sido imposible 
llegar hasta el final. 
  
  
i. Summary
  
 
 SUMMARY 
 
13 
Summary 
Genetic elimination of Egfr in a K-Ras driven Pancreatic Ductal Adenocarcinoma (PDAC) 
mouse model prevents tumor development. However, it was unknown whether the inhibition of 
Egfr tyrosine kinase activity could be a suitable therapy for K-Ras driven PDAC patients. In this 
thesis, we have demonstrated that Egfr catalytic activity is essential for PanIN and PDAC 
initiation even in the context of chronic pancreatitis and in the absence of p16Ink4a/p19Arf 
tumor suppressor genes. Nevertheless, inactivation of Egfr is not sufficient to inhibit tumor 
development of aggressive K-RasG12V;p53-null adenocarcinomas. In this context, it has been 
determined that ErbB2 plays a critical role triggering Egfr phosphorylation and MAPK signaling 
activation.  
Recently, it was demonstrated that c-Raf, a downstream mediator of K-Ras, is essential 
for the initiation of K-Ras driven PDAC. Unfortunately, in a p53 deficient background, ablation 
of either Egfr or c-Raf, as well as expression of an Egfr kinase dead receptor is not sufficient to 
inhibit tumor appearance although tumors develop with significant longer latencies. The 
extensive crosstalk between redundant signaling pathways in tumor cells suggests that 
concurrent inhibition of multiple effector pathways could be a promising therapeutic strategy to 
induce conclusive responses. Consistent with this, it was determined that simultaneous 
elimination of Egfr and c-Raf, in a p53 deficient context, completely blocks PDAC initiation. 
Of note, these and other studies were performed using GEMMs that only reveal the 
effect of selected targets in first stages of pancreatic tumorigenesis. The development of a new 
PDAC therapeutic mouse model has allowed us to address the therapeutic value of Egfr 
inhibition and its combination with c-Raf in full-blown tumors. Elimination or inhibition of Egfr in 
established tumors demonstrates that its function is dispensable for PDAC maintenance and 
progression, whereas combined ablation of Egfr and c-Raf results in a significant therapeutic 
effect. Nonetheless, few tumors can progress upon target elimination, suggesting the 
existence of tumor heterogeneity and indicating that other signaling pathways are involved in 
this response. Future studies will address this issue to find better therapeutic combinations.   
 
 
  
  
 
 SUMMARY 
 
15 
Resumen 
La eliminación genética de Egfr en un modelo murino de Adenocarcinoma Ductal 
pancreático (PDAC) inducido por el oncogén K-Ras impide el desarrollo tumoral. Sin embargo, 
se desconoce si la inhibición de la actividad tirosina quinasa de Egfr podría ser una terapia 
adecuada para pacientes de PDAC. En esta tesis hemos demostrado que la actividad 
catalítica de Egfr es esencial para desarrollo de lesiones PanIN y PDAC incluso en el contexto 
de pancreatitis crónica y en la ausencia de los genes supresores de tumores p16Ink4a/p19Arf. 
Sin embargo, la inactivación de Egfr no es suficiente para inhibir el desarrollo tumoral en 
ausencia de p53. En este contexto, se ha determinado que ErbB2 juega un papel importante 
en la fosforilación de Egfr y en la activación de la vía de señalización MAPK.  
Recientemente se ha demostrado que c-Raf, un intermediario de la vía de K-Ras, es 
esencial para la iniciación de PanIN y PDAC inducidos por el oncogén K-Ras. 
Lamentablemente, en ausencia de p53, la eliminación o inhibición de Egfr así como de c-Raf 
retrasa pero no impide la aparición de PDAC. La gran interacción y redundancia entre distintas 
vías de señalización en células tumorales sugiere que la inhibición simultánea de varias vías de 
señalización podría ser una estrategia terapéutica prometedora para inducir respuestas más 
concluyentes. De acuerdo con esto, se ha descubierto que la deleción simultánea de Egfr y c-
Raf, en ausencia de p53, bloquea completamente la aparición de tumores. 
Cabe destacar, que estos y otros estudios se han realizado utilizando modelos animales 
que sólo permiten estudiar el efecto de las dianas de interés durante las primeras etapas del 
desarrollo tumoral. La generación de un nuevo modelo de ratón terapéutico de PDAC nos ha 
permitido abordar el efecto de inhibir Egfr y su combinación con c-Raf en la progresión 
tumoral. La eliminación o inhibición de Egfr en tumores ya establecidos es prescindible para la 
progresión de PDAC, mientras que la eliminación simultánea de Egfr y c-Raf resulta en un 
efecto terapéutico significativo. No obstante, en ausencia de las dianas, algunos de los 
tumores continúan progresando, lo que sugiere la existencia de heterogeneidad tumoral y de 
otras vías de señalización implicadas en esta respuesta. Futuros estudios abordarán este 
problema en busca de mejores combinaciones.  
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1.1. Pancreatic Ductal Adenocarcinoma 
1.1.1. Epidemiology and risk factors 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in 
developed countries. Worldwide, PDAC accounts for more than 200,000 deaths every year. 
Total deaths are currently increasing, and it is predicted to be the second leading cause of 
cancer death by 2030 (Siegel et al., 2017).   
PDAC is associated with a very poor prognosis, with a 5-year survival rate of only 6% 
and a median survival of less than 6 months (Ying et al., 2016). This low survival rate is 
attributed to several factors, of which perhaps the most important is the late stage at which 
most of the patients are diagnosed. Most of them are asymptomatic until the disease develops 
to an advanced stage. Only less than 20% of the patients are eligible for initial resection. Even 
after potential curative resection, most patients will eventually have recurrence, and 5-year 
survival of completely resected patients increases only up to 25%. In addition, PDAC is an 
aggressive type of cancer, and 80% of patients have locally advanced or metastatic PDAC at 
the time of diagnosis. Tumor biology of pancreatic cancer contributes to early recurrence and 
metastasis, and also resistance to chemotherapy and radiotherapy (Kamisawa et al., 2016).  
Minimal improvements have been made in prevention, early diagnosis and treatment in 
patients with advanced disease. For more than a decade, gemcitabine has been the treatment 
of choice (Hidalgo, 2010). This chemotherapeutic agent became the standard regimen for 
treating advanced PDAC patients after a clinical trial in which was shown a significant 
improvement in the overall survival of gemcitabine comparing with 5-fluorouracil treated 
patients (Burris III et al., 1997). Since then, the combination of gemcitabine with a variety of 
cytotoxic and targeted agents has generally shown small or no significant benefit as compared 
to gemcitabine alone. Only the combination of gemcitabine with erlotinib, an Epidermal Growth 
Factor Receptor (EGFR) inhibitor, resulted in a significant but small improvement in overall 
survival, coming along with uncomfortable rash in patients (Moore et al., 2007). Following a 
phase III clinical trial, current treatment of choice is gemcitabine plus nab-paclitaxel 
(nanoparticle albumin-bound paclitaxel, a novel formulation of the classical chemotherapeutic 
paclitaxel), which is considered the gold standard of care (Von Hoff et al., 2013). However, 
there is still a lot of scope in improving the treatment of pancreatic cancer. The ability of 
preclinical models that recapitulate the human disease and a better understanding of PDAC 
biology are opening newer opportunities for treatment and increasing the number of new 
agents that are in clinical development (Ying et al., 2016).  
Several risk factors for pancreatic cancer, such as a family history, as well as cigarette 
smoking, chronic pancreatitis, and diabetes mellitus have been identified. On top of this, 
pancreatic adenocarcinoma is a disease that is associated with advancing age.  PDAC is rare 
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before the age of 40, but it culminates in a 40-fold increased risk by the age of 80 (Bardeesy 
and DePinho, 2002). 
Environmental factors might modulate pancreatic adenocarcinoma risk. The most well 
established risk factor for pancreatic cancer is cigarette smoking, causing a 75% increased 
risk that persists at least 10 years after smoking cessation (Iodice et al., 2008). In addition, 
several studies provide evidence for a strong association between chronic pancreatitis and 
PDAC (Lowenfels et al., 1993; Malka et al., 2002). Importantly, pancreatitis is also considered 
an early indicator of PDAC (Malka et al., 2002; Raimondi et al., 2010). The risk correlates with 
the duration of recurrent pancreatitis and chronic inflammation (Raimondi et al., 2010). An even 
higher risk was found in patients with rare types of pancreatitis, such as hereditary pancreatitis 
and tropical pancreatitis (Lowenfels et al., 1997). However, it has been described that only 
about 4% of chronic pancreatitis patients will develop PDAC within 20 years of diagnosis 
(Lowenfels et al., 1993). In PDAC mouse models, it has been illustrated that pancreatitis is an 
essential component for tumor development when the expression of the K-Ras oncogene in 
acinar cells starts during adulthood (Guerra et al., 2007). Due to the connection between 
inflammatory processes and their role in carcinogenesis and neoplastic progression, aspirin 
and other non-steroidal anti-inflammatory drugs (NSAIDs) have attracted interest in cancer 
prevention. Notably, epidemiological studies have suggested a possible protective effect for 
long-term NSAIDs users in pancreatic cancer risk (Bonifazi et al., 2010; Rothwell et al., 2011; 
Streicher et al., 2014). Likewise, NSAIDs have shown a preventative and therapeutic effect in 
mice (Guerra et al., 2011).  
 Patients with diabetes have a 30% additional risk of pancreatic cancer, which persists 
for more than 20 years after initial diagnosis of the disease. At the time of the diagnosis about 
25% of PDAC patients suffer from diabetes mellitus, and another 40% are pre-diabetic (Chari 
et al., 2008). Several studies suggest that hyperglycemia, abnormal glucose metabolism, and 
insulin resistance are correlated with increased risk of PDAC (Stocks et al., 2009).  
Although the majority of pancreatic tumors appear to be sporadic, it is estimated that 
10% of pancreatic cancers are due to an inherited predisposition (Hruban et al., 2010). 
However, the genetic basis for most familial pancreatic cancer remains unknown. PDAC 
development is a feature of several genetic syndromes, but these account for a few cases of 
familial pancreatic cancer (Solomon et al., 2012). Germline mutations in Breast Cancer 2 
(BRCA2) cause increased risk of breast, ovarian, and pancreatic cancer. According to this fact, 
Genetically Engineered Mouse Models (GEMMs) with loss of Brca2 in pancreas display 
preneoplasic ductal lesions and even PDAC tumors when p53 is lost (Rowley et al., 2011). 
Germline mutations in Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) which encodes two 
tumor suppressors, p16INK4A and p14ARF, cause familial atypical mole melanoma syndrome, 
in which patients have increased risk of both melanoma and pancreatic cancer (Slater et al., 
2010). Patients with Peutz-Jeghers syndrome, caused by germline alterations in 
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Serine/Threonine Kinase 11 Interacting Protein (STK11 or LKB1), have a markedly increased 
risk of pancreatic cancer (Hearle et al., 2006). In GEMMs, homozygous loss of Lkb1 in early 
pancreatic precursors promotes development of pancreatic mucinous cystadenomas with very 
short latencies (Morton et al., 2010). Patients with hereditary pancreatitis, which is associated 
with germline mutations in the cationic trypsinogen Protease Serine 1 (PRSS1) gene, 
experience a 53-fold increased incidence of pancreatic adenocarcinoma. In this case the 
resulting inflammation promotes tumorigenesis, in part, by producing growth factors, cytokines 
and reactive oxygen species (ROS), thus inducing cell proliferation, disrupting cell 
differentiation and selecting for oncogenic mutations (Lowenfels et al., 1997). And finally, there 
is also accumulating evidence linking family history with PDAC, which refers to families with 
two or more first-degree relatives with PDAC that do not fulfill the criteria for another inherited 
predisposition syndrome explained above (Hruban et al., 2010).  
1.1.2.  Anatomy of pancreas 
The pancreas is constituted of separate functional units that regulate two different 
processes: digestion and glucose metabolism. The exocrine pancreas is composed of acinar, 
centro-acinar and ductal cells.  The acinar cells, which are organized in clusters, produce 
digestive enzymes and constitute approximately the 95% of total cells in the pancreas. The 
ducts, which add mucous and bicarbonate to the enzyme mixture in the pancreas, form a 
network of increasing size culminating in main pancreatic ducts that empty into the duodenum 
in response to the intestinal hormones secretin and cholecystokinin. Centro-acinar cells are 
defined as specialized ductal epithelial cells located at the terminal ductal tree in the acinar-
ductal cell junction. Centro-acinar cells have been proposed to be adult multipotent 
progenitors that proliferate in response to chronic epithelial injury (Rovira et al., 2010). The 
endocrine pancreas consists of specialized cells that are organized into compact islets 
embedded within acinar tissue, islets of Langerhans, which secrete hormones into the 
bloodstream. The α- and β-cells regulate the use of glucose through the production of 
glucagon and insulin, respectively. Pancreatic polypeptide and somatostatin, that are 
produced in the PP and δ-cells, regulate the secretory properties of the other pancreatic cell 
types (Bardeesy and DePinho, 2002). 
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Figure 1. Anatomy of pancreas. (Adapted from Bardeesy and DePinho, 2002). 
1.1.3. Histopathology and molecular pathology of Pancreatic Cancer  
1.1.3.1. Histopathology of PDAC 
PDAC evolves through a stepwise progression from well-defined and non-invasive 
precursor lesions that, in the context of their genetic features, define the genetic progression 
model of pancreatic carcinogenesis (Hruban et al., 2000).  
Early disease histology manifests as several distinct types of precursor lesions. Most 
carcinomas arise from microscopic pancreatic intraepithelial neoplasia (PanIN) (Maitra and 
Hruban, 2008). PanIN lesions are classified into three grades according to the extent of 
cytological and architectural atypia: PanIN1A and PanIN1B (micropapillary type) show low-
grade dysplasia; PanIN2 exhibits additional loss of polarity, nuclear crowding, cell 
enlargement, and hyperchromasia with frequent papillary formation; and PanIN3 (also known 
as in situ carcinoma) are advanced lesions with severe nuclear atypia, luminal necrosis, and 
manifest epithelial cell budding into the ductal lumen (Hruban et al., 2004; Sipos et al., 2009).   
PanIN lesions are frequently associated with atrophy of acinar parenchyma followed by 
a reprogramming process known as acinar-to-ductal metaplasia (ADM). These structures have 
been proposed to be the precursors of PanIN lesions (Brune et al., 2006). Molecular analyses 
have demonstrated that PanIN harbors many of the same genetic alterations found in 
infiltrating PDAC (Hruban et al., 2007). These include activating point mutations in K-RAS, and 
inactivation of the CDKN2A, TP53 and SMAD4 genes (Hruban et al., 2007; Wilentz et al., 1998). 
Mutations in K-RAS and CDKN2A are early events, while TP53 and SMAD4 gene mutations are 
found in high grade lesions (PanIN3) (Figure 2) (Hruban et al., 2007; Yoshizawa et al., 2002). 
Interestingly, recently developed GEMMs in which a mutant K-Ras is expressed in the 
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pancreas (see section 1.1.9), develop PanIN lesions histologically identical to those found in 
humans, that eventually progress to invasive PDAC (Guerra et al., 2007; Hingorani et al., 2003). 
 
Figure 2. Histological, molecular and genetic hallmarks of human PDAC. Schematic diagram of the 
preneoplastic lesions and molecular changes that precede the development of PDAC (adapted from 
Morris et al., 2010a). 
Some pancreatic ductal adenocarcinomas arise from other types of preneoplastic 
lesions: Intraductal Papillary Mucinous Neoplasms (IPMNs) and Mucinous Cystic Neoplasms 
(MCNs). IPMNs are grossly visible, non-invasive mucin-producing epithelial neoplasms, which 
usually form long finger-like papillae that are more than 1 cm in size. By definition, IPMNs, 
involve the main pancreatic duct or one of its branches and they arise, more frequently, in the 
head of the pancreas than in the tail (Hruban et al., 2007). A variety of molecular alterations 
have been reported in IPMNs. The frequency of K-RAS gene mutations raises with increasing 
degrees of dysplasia (Yoshizawa et al., 2002). The frequency of TP53 and CDKN2A gene 
inactivation is more variable. However, SMAD4 gene mutations are relatively uncommon 
(Hruban et al., 2007). In contrast, LKB1 which is a gene associated with the Peutz-Jeghers 
syndrome, is biallelically inactivated in 25%, and the Phosphatidylinositol-4,5-Bisphosphate 3-
Kinase Catalytic Subunit Alpha (PIK3CA) gene is mutated in 10% of IPMNs (Schönleben et al., 
2006; Su et al., 1999). MCNs are far less common than IPMNs. They occur almost exclusively 
in women and they are much more frequent in the body and tail of the pancreas. Unlike IPMNs, 
MCNs do not involve the pancreatic duct system. The mucinous epithelium in MCNs is 
accompanied by an underlying ovarian-type stroma, a diagnostic requirement for MCNs and a 
key feature that distinguishes them from IPMNs. At the molecular level, activating point 
mutations in the K-RAS gene are early events in the development of MCNs, while TP53 and 
SMAD4 gene mutations represent late changes (Fukushima and Fukayama, 2007; Yoshizawa 
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et al., 2002). Aberrant methylation of the CDKN2A gene occurs in a minority of MCNs (Hruban 
et al., 2007).  
1.1.3.2. Molecular PDAC subtypes  
In 2016, Bailey et al. defined 4 molecular subtypes of PDAC based on integrated 
genomic analysis of 456 PDAC tumors: squamous, pancreatic progenitor, aberrantly 
differentiated endocrine exocrine (ADEX) and immunogenic tumors. Genomic and epigenetic 
features that characterize each subtype conclude in different mechanisms of molecular 
evolution (Bailey et al., 2016).  
Squamous tumors are associated with mutations in TP53 and Lysine-specific 
demethylase 6A (KDM6A) genes, an upregulated TP63ΔN transcriptional network, activated 
EGF signaling and downregulation of genes involved in pancreatic endodermal cell fate 
determination like Pancreatic and Duodenal Homeobox 1 (PDX1), GATA6, etc., leading to loss 
of endodermal identity. Squamous subtype is associated with poor prognosis (Bailey et al., 
2016).  
Pancreatic progenitor tumors express genes involved in early pancreatic development 
like FOXA2, FOXA 3 and PDX1 among others (Bailey et al., 2016). Especially, PDX1 is critical 
for pancreas development considering that ductal, exocrine and endocrine cells derived from a 
progenitor that expresses PDX1 (Hale et al., 2005).  
ADEX tumors show deregulation of transcriptional pathways involved in late stages of 
pancreatic development and differentiation. These tumors contain highly expressed genes 
involved in K-RAS activation and upregulation of transcriptional networks associated with 
acinar and endocrine differentiation (Bailey et al., 2016).  
Immunogenic tumors share many of the features of the pancreatic progenitor subtype, 
but with a significant increase in immune infiltrates. Thus, these tumors contained upregulation 
of immune networks pathways including B cell signaling pathways, antigen presentation, CD4+ 
T cell, CD8+ T cell and Toll-like receptor signaling (Bailey et al., 2016).  
1.1.4. Molecular genetics of pancreatic adenocarcinoma 
Exome sequencing of PDACs have identified, on average, more than 60 miscoding 
mutations per tumor (Jones et al., 2008). Moreover, all tumors examined had mutations in 
components of at least 12 different signaling pathways including Notch, Sonic Hedgehog (Shh) 
and Wnt pathways (Jones et al., 2008). More recent studies using whole-genome sequencing 
and copy number variation analysis have revealed frequent chromosomal rearrangements that 
harbor focal gene amplifications (Waddell et al., 2015). These findings make it very difficult to 
design rational and viable therapeutic strategies to treat advanced PDAC and may explain why 
most clinical trials carried out during the last two decades have made very limited 
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contributions to the treatment of this disease (Hidalgo, 2010).  
1.1.5. Frequent mutations in oncogenes and tumor suppressor genes.  
Although some (2–10%) PDACs are associated with hereditary factors (Habbe et al., 
2006), most are related with high-frequency somatic mutations in a subset of genes, including 
the K-RAS oncogene, and the tumor suppressors CKDN2A, TP53 (Ruggeri et al., 1992; Scarpa 
et al., 1993) and SMAD4 (Hahn et al., 1996), thus modifying different signaling pathways.  
K-RAS, which encodes a small GTPase that mediates downstream signaling from 
growth factor receptors, is the most frequently mutated oncogene in pancreatic cancer. 
Somatic mutations in K-RAS are nearly universal (>90%) in human PDAC (Jones et al., 2008; 
Wood and Hruban, 2012). K-RAS mutations found in PDAC cluster in specific hotspots (most 
commonly in codon 12) (Smit et al., 1988). The result is a constitutively active protein, unable 
to hydrolyze Guanosine Triphosphate (GTP), thus promoting persistent signaling to 
downstream effectors and controlling cell proliferation, survival and many other aspects of cell 
behavior (Downward, 2003). K-RAS mutations are present in most low-grade PanIN, 
suggesting that this event is one of the earliest alterations in pancreatic tumorigenesis (Kanda 
et al., 2012).  
Additionally, rare somatic mutations have been reported in other members of this 
signaling pathway, such as B-RAF (Calhoun et al., 2003). B-RAFV600E mutation is found in 3% 
of human PDAC. Moreover, B-RAF mutations are mutually exclusive with K-RAS mutations, 
and are present in 30% of the K-RAS wild type PDAC cases (Witkiewicz et al., 2015). 
Interestingly, GEMMs have illustrated that expression of B-RafV600E in the pancreas is sufficient 
to lead PanIN development (Collisson et al., 2012).  
CDKN2A, which encodes an essential cell-cycle regulator, is the most frequently altered 
tumor suppressor gene, with loss of function in more than 90% of ductal adenocarcinomas 
(Wood and Hruban, 2012). This loss is mediated by several mechanisms, including intragenic 
mutation coupled with loss of the second allele, homozygous deletion, and promoter 
methylation (Maitra et al., 2006). Alterations in CDKN2A are also early events, with loss of 
p16INK4A expression in a subset of low-grade PanINs (Maitra et al., 2003).  
Somatic mutations in the TP53 tumor suppressor gene are present in 50-70% of PDACs. 
Changes in TP53 are late events, occurring in high grade PanINs and invasive carcinoma. 
TP53 inactivation occurs first through small intragenic mutation followed by loss of the wild 
type allele (Jones et al., 2008; Scarpa et al., 1993). The protein encoded by TP53 plays a key 
role in the cellular stress response and is mutated in a wide range of tumor types (Griffin et al., 
1995). 
The tumor suppressor gene SMAD4 mediates signaling downstream of the Transforming 
Growth Factor β (TGFβ) receptor. It is inactivated in about 55% of PDAC tumors, through 
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homozygous deletion or intragenic mutation followed by loss of the wild type allele. In this 
case, mutations also appear in late stages of tumor progression (Hahn et al., 1996). These 
alterations are associated with poor prognosis in pancreatic adenocarcinoma (Vogelstein and 
Kinzler, 2004). 
1.1.6. Telomere shortening 
PDAC is characterized by genomic complexity and instability. Approximately 90% of 
PanIN1A lesions exhibit telomere shortening, which is one of the most common early events in 
pancreatic tumorigenesis. As a consequence, critical shortening of telomere length in PanINs 
may favor these non-invasive lesions to accumulate chromosomal abnormalities and to 
develop into an invasive carcinoma (van Heek et al., 2002).  In most cases, cells with 
chromosome instability are eliminated by TP53 activation. These alterations persist in those 
cells with TP53 mutations (such in high-grade PanIN lesions) promoting rapid accumulation of 
genomic alterations (Meeker and De Marzo, 2004).  
1.1.7. Sonic hedgehog, Notch and Wnt–β-catenin signaling in PDAC 
Embryonic signaling pathways are typically present during fetal development, but are 
also frequently reactivated in cancers enhancing tumor progression and mediating resistance 
to chemotherapy. PDAC is characterized by frequent de-regulation of these type of pathways, 
including Shh, Notch and Wnt–β-catenin signaling (Morris et al., 2010a).  
Paracrine signaling of Shh is not only important in gut and pancreas development, it also 
has a role in adult tissue homeostasis and it is an important mediator in human pancreatic 
carcinoma (Taipale and Beachy, 2001). Aberrant Shh ligand expression is observed at high 
frequency in human PDAC (~75%) and it is abnormally expressed in PanINs. There is also a 
high expression of Gli (transcription factor of Shh signaling pathway) in PanINs (Thayer et al., 
2003). Shh ligands secreted by cancer cells act on fibroblasts promoting desmoplasia and cell 
motility (Bailey et al., 2008). Inhibition of Shh signaling by cyclopamine (IPI-926) in combination 
with gemcitabine can deplete the pancreatic stroma in GEMMs of PDAC, leading to transient 
stabilization of the disease (Olive et al., 2009).  
Wnt–β-catenin signaling is frequently activated in PDAC and contributes to tumor cell 
proliferation and biology. Enhanced activation of Wnt signaling is found in 65% of PDAC 
(Wang et al., 2009). Shh and SMAD4 pathways induce Wnt signaling (Romero et al., 2008), 
thus Wnt should be considered as a combined therapeutic strategy. Wnt-β-catenin signaling in 
PDAC might also be involved in chemoresistance and metastasis (Cui et al., 2012), therefore 
representing a promising therapeutic approach.  
One of the main functions of Notch signaling seems to be maintenance of pancreatic 
progenitor cells in an undifferentiated state by promoting their survival and self-renewal 
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(Apelqvist et al., 1999). Notch signaling pathway appears to be activated in human pancreatic 
cancer, promoting initiation, progression and maintenance of PDAC (Miyamoto et al., 2003), 
suggesting inhibition of Notch signaling as a promising therapeutic strategy in this malignancy. 
However, recent studies utilizing mouse models have revealed both oncogenic and tumor 
suppressor roles for Notch signaling in PDAC development (Avila and Kissil, 2013).  
1.1.8. Stroma and extracellular matrix 
A hallmark of PDAC is the extensive peritumoral stroma and desmoplasia, consisting of 
a complex array of cellular components such as Cancer Associated Fibroblasts (CAFs) and 
inflammatory cells, surrounded by extracellular matrix (Neesse et al., 2011). The stroma 
represents up to 90% of the tumor volume. Stroma has been recognized as a barrier 
surrounding tumor cells (Neesse et al., 2011) and was hypothesized to contribute to inefficient 
drug delivery and chemoresistance in PDAC (Olive et al., 2009), and more importantly to 
exclude cytotoxic T cells from reaching the tumor cells, a phenomenon called “immune 
privilege” (Fearon, 2014). Furthermore, the stroma promotes tumor growth and metastasis (Xu 
et al., 2012). Thus, ablation of this stromal barrier may represent a major advance in the 
treatment of this deadly disease. Nevertheless, recent studies have raised doubts about the 
role of the stroma in cancer progression since its depletion resulted in aggressive PDAC 
(Özdemir et al., 2014; Rhim et al., 2014). In this regard, instead of ablation of the stroma, 
forthcoming therapeutic strategies should focus on stromal reprogramming (Whatcott et al., 
2015). In fact, transcriptional remodeling through suppression of Shh pathway (Olive et al., 
2009), Connective Tissue Growth Factor (CTGF) (Neesse et al., 2011) and CXCL12 chemokine 
(Feig et al., 2013), as well as activation of vitamin D receptor (Sherman et al., 2014), broadly 
halted the capacity of CAFs to support tumor growth. Therefore, transcriptional reprogramming 
of PDAC stroma with tumor-directed cytotoxic and/or immunologic drugs could be a promising 
PDAC therapeutic strategy. 
1.1.9. Use of mouse models for the study of pancreatic cancer 
Mouse models provide controllable genetic systems to analyze the complexities of 
cancers in a physiological context. Genetic engineering has allowed us to generate mouse 
strains that faithfully reproduce the natural history of pancreatic human tumors, in order to 
understand PDAC biology and to design and test new therapeutic approaches (Guerra and 
Barbacid, 2013). 
Due to its high frequency in PDAC, mutation of K-RAS was proposed as an initiating 
genetic event in this disease. However, initial efforts to assess the sufficiency of mutant K-Ras 
to initiate PDAC progression in mice failed because of the limitations of transgenic 
approaches. Expression of a transgene encoding mutant K-RasG12D under a ductal promoter 
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(Cytokeratine-19) resulted in periductal inflammation and failed to generate PDAC and even 
PanIN lesions (Brembeck et al., 2003).  
The ability of mutant K-Ras to drive PDAC was not successful until the development of a 
Cre-inducible conditional allele Lox-stop-Lox K-RasG12D (K-RasLSLG12D) targeted to the 
endogenous K-Ras locus (Hingorani et al., 2003), thus allowing expression of constitutively 
active K-Ras under temporal and spatial control. Initially, mice expressing the K-RasLSLG12D 
allele were crossed with mice expressing the bacterial Cre-recombinase under the control of 
pancreatic progenitor genes promoters: Pdx1 and p48 (also known as Ptf1a), therefore 
targeting mutant K-Ras to most cells in the developing pancreas. A small number of Pdx1-Cre; 
K-RasLSLG12D and p48-Cre;K-RasLSLG12D mice developed PDAC over the course of 1 year. 
Furthermore, these strains develop, with complete penetrance, the full spectrum of PanIN 
lesions histologically indistinguishable from those present in human patients (Hingorani et al., 
2003). Addition of mutations in loci encoding tumor suppressor genes known to be mutated or 
inactivated in human PDAC such as p16Ink4a/p19Arf, p53, Lkb1 or Smad4 accelerates the 
progression of these PanIN lesions, leading to the formation of invasive tumors with complete 
penetrance (Aguirre et al., 2003; Bardeesy et al., 2006; Hingorani et al., 2005).  
There are remarkable similarities between PanIN and PDAC observed in these GEMMs 
(Pdx1-Cre; K-RasLSLG12D and p48-Cre;K-RasLSLG12D) with those detected in human patients. 
However, there are several differences to consider. PDAC is not a pediatric disease, and is 
likely to arise due to sporadic mutations in adult individuals. Moreover, K-RAS mutations 
appear in specific populations of cells, not in the entire pancreas. In 2007, our laboratory 
developed a PDAC mouse model in which a resident K-Ras oncogene is expressed in acinar 
cells (Guerra et al., 2007). This GEMM was generated by crossing a knockin K-RasLSLG12Vgeo 
with a double transgenic mouse that expresses the Cre-recombinase under the control of the 
Elastase promoter (Elas-tTa/tetO-Cre) following an inducible Tet-off strategy in which the 
expression of the enzyme is controlled by a tetracycline trans-activator (tTA). Thus, this 
complex model allows us to control temporally the expression of the K-Ras oncogene. These 
mice, if untreated (in absence of doxycycline), express the resident K-RasG12Vgeo in a limited 
percentage of acinar cells (20-30%) during late embryonic development (from E16.5 stage). 
Interestingly, they develop PanIN lesions with similar latencies and penetrance to mice 
expressing K-RasG12D in all pancreatic lineages (Guerra et al., 2007). Furthermore, a percentage 
of these mice develop PDAC by one year of age. Consequently suggesting that the cell of 
origin in PDAC tumors is likely to be an acinar cell or an acinar precursor rather than cells of 
ductal lineages. As indicated above, addition of mutations in p16Ink4a/p19Arf and p53 tumor 
suppressor genes increases PDAC penetrance to 100%, and significantly reduces tumor 
latency (6-8 months of age) (Guerra et al., 2011).  
The Elas-tTa/tetO-Cre;K-RasLSLG12Vgeo PDAC mouse model offers the possibility to turn 
on K-Ras oncogene expression during adulthood by simply providing doxycycline in the 
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drinking water until adult stages. Surprisingly, expression of constitutively active K-Ras in adult 
mice (≥ 60 days old) fails to induce pancreatic lesions (Guerra et al., 2007). Indeed, adult acinar 
cells are resistant to K-RasG12V transformation even in the presence of inactivated p53 or 
p16Ink4a/p19Arf tumor suppressors (Guerra et al., 2011). However, these mice develop PanINs 
and PDAC in the context of chronic, acute or even sporadic events of pancreatitis, induced by 
exposure to cholecystokinin analog, caerulein (Guerra et al., 2007, 2011). 
It is not clear how pancreatitis causes adult mice to overcome the resistance to 
induction of PanIN or PDAC by oncogenic K-Ras. Pancreatitis induces tissue damage that 
results in proliferation of acinar cells to repair the injured parenchyma. It is uncertain whether 
this proliferation is mediated by the recruitment of progenitor cells or by de-differentiation of 
mature acinar cells. These progenitors and/or the differentiated acinar cells become 
susceptible to transformation by the resident K-Ras oncogene leading to the acquisition of 
ductal-like properties as observed in the ADM and in low grade PanINs (Guerra and Barbacid, 
2013). It was reported that oncogenic K-Ras induced differentiation of the regenerating acinar 
cell compartment into ductal like structures by a mechanism that involved decreased 
expression of β-catenin (Morris et al., 2010b).  
Many GEMMs have been developed to evaluate different targets and pathways that are 
important for PDAC tumors, such as Egfr, Notch, Phosphoinositol-3-kinase (PI3K), etc. 
(Gopinathan et al., 2015; Guerra and Barbacid, 2013; Pérez-Mancera et al., 2012). For 
instance, two independent studies using PDAC GEMMs have illustrated that Egfr is essential 
for PDAC development (Ardito et al., 2012; Navas et al., 2012).  
At the time of diagnosis, human PDAC patients usually present a late-stage carcinoma. 
However, many of these genetic studies in GEMMs have been performed with germline 
knockouts or Cre-dependent alleles that are expressed or deleted simultaneously with the 
oncogenic events. Thus, these studies should be considered only preventive strategies more 
than therapeutic approaches. For this reason, it would be important to assess efficacy of the 
targets of interest in already established tumors. 
Recently, new generation models have been developed using dual recombinase system 
(DRS) technologies to separate temporally and physically tumor development from target 
deletion, using a combination of Flp-FRT and Cre-Lox systems (Schönleben et al., 2006). 
Schönhuber et al., used this DRS to first express K-Ras oncogene mutation, and after PanIN 
development, delete 3-phosphoinositide-dependent protein kinase 1 (Pdk1), an important 
downstream effector of PI3K, to demonstrate that deletion of this target blocks PanIN 
progression (Schönhuber et al., 2014).  
1.2. Epidermal Growth Factor Receptor 
Growth factors participate in different cellular responses by binding to cell surface 
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receptors. Most of these receptors are tyrosine kinase receptors (RTKs) with intrinsic kinase 
activity. Around 60 RTKs have been identified, and classified into more than 16 receptor 
families. Growth factors and RTKs interactions trigger different signaling pathways that alter 
gene expression and, if de-regulated, may result in alterations in the physiological state of the 
cell (Perona, 2006).  
Epidermal growth factor (EGF) was one of the first growth factors discovered in the early 
1960s. It was shown to stimulate epidermal and mesodermal cell growth and differentiation 
(Cohen, 1983). Subsequent studies identified the receptor and its intrinsic kinase activity. EGF 
was shown to bind with high affinity to a specific receptor located in the cell membrane and 
stimulate rapid activation of a protein kinase activity. Epidermal growth factor receptor type 1 
(EGFR) was purified and characterized as a 170KDa glycoprotein, bearing ligand-inducible 
kinase activity (Ullrich et al., 1984).  
1.2.1. ErbB family 
EGFR is a member of the ErbB family, constituted by four closely related tyrosine kinase 
receptors: EGFR (also known as ErbB1), ErbB2, ErbB3 and ErbB4, which are expressed 
ubiquitously in epithelial, mesenchymal, cardiac and neuronal cells. They are involved in a 
variety of cellular processes, including proliferation, survival, angiogenesis and metastasis in 
many cancer types (Appert-Collin et al., 2015). EGFR and ErbB2 are found mutated, activated 
or overexpressed in a wide variety of human cancers like breast and lung cancer. These 
alterations result in excessive signaling that cooperates in the development and malignancy of 
these tumors (Burgess, 2008). 
Moreover, this family of tyrosine kinase receptors is essential for embryo development.  
In mice, loss of signaling by any member of the ErbB family results in embryonic lethality with 
defects in organs, including lung, skin, heart, and brain (Table 1).  
 
  Table 1. Knockout mouse models for ErbB family receptors 
ErbB family member Discovery 
Egfr knockout 
(Miettinen et al., 1995; Sibilia and Wagner, 1995; Sibilia et al., 
1998; Threadgill et al., 1995)  
ErbB2 knockout (Lee et al., 1995) 
ErbB3 knockout (Erickson et al., 1997) 
ErbB4 knockout (Gassmann et al., 1995) 
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1.2.2. Structure of EGFR 
The structure of EGFR and the rest of the family members consists of a large 
extracellular domain, a single hydrophobic transmembrane segment, and an intracellular 
domain containing a juxtamembrane domain, a typical tyrosine protein kinase segment, and a 
tyrosine-rich carboxy-terminal tail (Ferguson, 2008). Upon receptor activation, these C-terminal 
tyrosines are phosphorylated. The intracellular tyrosine kinase domain of ErbB receptors is 
highly conserved, although the kinase domain of ErbB3 contains substitutions of critical amino 
acids and therefore lacks kinase activity (Guy et al., 1994). The extracellular domain is made of 
tandem repeat leucine-rich segments that participate in ligand binding, and cysteine-rich 
domains for homo- and hetero-dimer formation with ErbB family members. Extracellular 
domains are less conserved among the four receptors, suggesting that they have different 
specificity in ligand binding (Olayioye et al., 2000; Yarden and Sliwkowski, 2001).  
1.2.3. Activation of EGFR  
ErbB receptors are activated by binding to growth factors that are produced by the 
same cells that express ErbB receptors (autocrine secretion) or by surrounding cells (paracrine 
secretion) (Normanno et al., 2006).  
EGFR is regulated by at least seven different activating ligands in humans: EGF, 
transforming growth factor α (TGFα), betacellulin (BTC), heparin-binding EGF-like growth factor 
(HB-EGF), amphiregulin (ARG), epiregulin (EPR), and epigen (EGN). Each contains an EGF-like 
domain that is responsible for receptor binding and activation. EGFR ligands are all produced 
as membrane-bound precursor proteins and are cleaved by cell-surface proteases to yield the 
active growth factor species (Harris et al., 2003). ErbB3 and ErbB4 are regulated by 
neuregulins (NRGs). NRG1 and NRG2 bind both to ErbB3 and ErbB4, whereas NRG3 and 
NRG4 appear to be ErbB4 specific (Falls, 2003). Three of the EGFR ligands mentioned above 
(BTC, EPR, and HB-EGF) also bind and activate ErbB4. For ErbB2, no soluble ligand has been 
identified. This orphan receptor is generally assumed to be only regulated by hetero-
dimerization with other ErbB family receptors (Riese and Stern, 1998). 
Binding of ligands to the extracellular domain of ErbB receptors induces the formation of 
receptor homo- or heterodimers, and subsequent activation of the intrinsic tyrosine kinase 
domain (Olayioye et al., 2000). In particular, ErbB2, which does not have known direct 
activating ligand, and ErbB3, which does not have kinase activity, do not form homo-dimers 
and they signal only through hetero-dimerization (Olayioye et al., 2000; Yarden and Sliwkowski, 
2001). Dimerization leads to auto-phosphorylation of specific tyrosine residues in the carboxy-
terminal tail (Heldin, 1995). Phosphorylated ErbB receptors induce the recruitment of adaptor 
proteins which lead to activation of intracellular signaling pathways (Shoelson, 1997) (Figure 3). 
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Figure 3. ErbB receptor mammalian family and their ligands. Upon ligand binding (A) the receptors 
form homodimers and heterodimers. The receptors then become phosphorylated on specific cytoplasmic 
tyrosines residues initiating downstream signaling pathways (B) (Adapted from Hynes and MacDonald, 
2009).  
1.2.4. EGFR signaling pathways 
After ligand binding, the intracellular tyrosine kinase domain of the dimerized receptor is 
activated, leading to the phosphorylation of specific C-terminal tyrosine residues that serve as 
docking sites for adaptor proteins containing Src homology 2 (SH2) domains and 
phosphotyrosine binding (PTB) domains. Some of these adaptor proteins are Src Homology 2 
domain Containing protein (Shc), Growth Factor Receptor-bound protein 2 (Grb2), Growth 
Factor Receptor-bound protein 7 (Grb7), CT10 Regulator of Kinase (Crk), Non-Catalytic region 
of tyrosine Kinase adaptor protein (Nck), Phospholipase C gamma (PLCγ), intracellular kinases 
Src, PI3K, protein tyrosine phosphatases SHP1/2 and the Cbl E3 ubiquitin ligase, among 
others (Normanno et al., 2006). These adaptor proteins promote the activation of several 
intracellular signaling pathways including the PI3K/AKT, JAK/STAT, Protein Kinase C (PKC) 
and Ras/Mitogen-Activated Protein Kinase (MAPK) pathways, with functions such as growth, 
survival, proliferation, and differentiation (Oda et al., 2005).  
1.2.4.1. RAS/MAPK 
RAS/MAPK pathway is one of the most widely studied signaling cascades and one of 
the best described in cancer. It regulates several cellular responses, of which cell proliferation 
is probably one of the most relevant processes (Molina and Adjei, 2006). 
RAS proteins play a critical role in cell signaling both in normal cell growth and malignant 
transformation. They regulate proliferation, differentiation and survival in response to 
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extracellular stimuli (Malumbres and Barbacid, 2003). Importantly, RAS genes were found 
mutated in approximately 30% of all human tumors, thus making RAS the most frequently 
mutated oncogene in human cancer (Roberts and Der, 2007). In mammals there are three RAS 
genes that code for the four RAS isoforms: H-RAS, N-RAS and K-RAS4A and K-RAS4B (these 
last are splice variants of exons 4A and 4B). K-RAS4B is the principal isoform expressed in 
human cells (Cox and Der, 2010) and tumors (Stephen et al., 2014).   
All ErbB ligands and receptors induce activation of the RAS/MAPK pathway through 
either Grb2 or Shc adaptor proteins (Jorissen et al., 2003). Grb2 contains an SH2 domain that 
binds to the phosphotyrosine residues of the active receptor. When Grb2 binds to the guanine 
nucleotide exchange factor (GEF) SOS, recruits it to the plasma membrane where RAS is also 
localized because of farnesylation. Active SOS then allows the release of bound GDP and its 
exchange for GTP from a member of the RAS subfamily. RAS can then bind GTP and become 
active. RAS-GTP complex triggers activation of downstream effectors leading to proliferation, 
and cell survival (Egan et al., 1993). Active RAS-GTP is converted back into the inactive RAS-
GDP by GTP hydrolysis, a reaction accelerated by the interaction of RAS-GTP with GTPase-
activating proteins (GAPs) (Hennig et al., 2015) (Figure 4).  
Activated RAS binds to and stimulates a variety of effector proteins including: Rapidly 
accelerated fibrosarcoma (RAF) serine/threonine kinases, PI3K, guanine nucleotide exchanged 
factor for RAL (RalGEFs), and Phospolipase C epsilon (PLCε) among others (Downward, 2003). 
Some of these effectors are known to be involved in RAS driven oncogenesis, such as RAF 
serine/threonine kinases and PI3K (Davies et al., 2002; Karakas et al., 2006). The best-
characterized pathway activated by RAS is the RAF/MEK/ERK pathway. RAS-GTP binds to 
and activates the three closely related RAF proteins, A-RAF, C-RAF and B-RAF. This 
interaction causes RAF to be relocalized to the plasma membrane, which is crucial for its 
activation by serine/threonine phosphorylation (Marais et al., 1995). When RAF proteins are 
active, they have the capability to phosphorylate Mitogen Activating Protein (MAP) kinase 1 
and 2 (MEK1 and MEK2) which will phosphorylate and activate the Extracellular signal-
Regulated Kinases 1 and 2 (ERK1 and ERK2) (Matallanas et al., 2011). These last 
Serine/Threonine kinases can phosphorylate more tan 150 substrates in the cytosol as well as 
in the nucleus where they promote the transcription of a wide variety of factors, most of them 
implicated in cell proliferation and survival (Yoon and Seger, 2006) (Figure 4). 
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Figure 4. Ras signaling pathway 
1.2.4.2. PI3K pathway 
In addition to the MAPK pathway, RAS also stimulates several other effector pathways, 
including the PI3K and Ral guanine nucleotide dissociation stimulator (RalGDS) (Malumbres 
and Barbacid, 2003). As mentioned above, EGFR can also directly activate PI3K by recruitment 
of its p85 subunit to the activated receptors (Soltoff and Cantley, 1996).  
PI3K has a key role promoting cell survival. The activation of this lipid kinase leads to the 
phosphorylation of phosphatidylinositol-4,5-byphosphate (PIP2) to produce 
phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 attracts proteins with phosphoinositide-
binding domains to the plasma membrane, such as Rac-alpha serine/threonine-protein kinase 
(AKT) and 3-Phosphoinositide-Dependent Protein Kinase 1 (PDK1). AKT is recruited to the 
membrane and fully activated. Activated AKT mediates several cell responses such as growth, 
cell survival and resistance to apoptosis. It is know that the Phosphatase and Tensin homolog 
(PTEN) act as a phosphatase to dephosphorylate PIP3, acting as a tumor suppressor 
negatively regulating this pathway (Downward, 2003).  
Activation of the PI3K/AKT pathway is found in 59% of human PDAC cases and 
represents a negative prognostic factor (Yamamoto et al., 2004). Mutations in the catalytic 
subunit of PI3K (p110α, encoded by PI3KCA), in the regulatory PI3K subunit (p85α, encoded 
by PIK3R1) and amplification of AKT are commonly found in human pancreatic cancers 
(Witkiewicz et al., 2015; Ying et al., 2016). Furthermore, heterozygous or homozygous deletion 
of PTEN is found in 15% of human PDACs.  
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Although it was demonstrated that overexpression of a constitutively active Pik3caH1047R 
can induce PDAC development in GEMMs (Eser et al., 2013), PI3KCA mutations in human 
PDAC are almost always concurrent with oncogenic K-RAS mutations, suggesting that they 
both cooperate during pancreatic tumor development (Witkiewicz et al., 2015). Moreover, it 
has been demonstrated the role of PI3K pathway in K-Ras driven PDAC mouse models since 
the PI3K kinase subunit p110α, but not p110β, promotes PDAC growth (Baer et al., 2014) and 
the development of PanIN and PDAC is abolished upon deletion of Pdk1 (Eser et al., 2013). In 
addition, loss of Pten in K-Ras driven PDAC GEMMs dramatically promotes highly invasive and 
metastatic PDAC development by a mechanism that involves p16Ink4a/p19Arf locus 
inactivation (Ying et al., 2011). 
1.2.4.3. JAK/STAT 
Signal Transducer and Activator of Transcription (STAT) signaling pathway participates 
in a wide range of cell behaviors as cell proliferation, survival, motility, invasion, angiogenesis 
and inflammation (Li et al., 2011). STAT tyrosine phosphorylation is mediated by Janus Kinase 
(JAK) family, which is activated by cytokine and growth factors receptors, such as EGFR 
(Darnell et al., 1994). In mammals 7 STAT genes have been identified, STAT 1-4, 5a, 5b and 
STAT 6. Knocking out Stat3 in the developing exocrine pancreas results in significantly 
reduced PanIN development, especially in high-grade lesions, and consequently, mice had 
lower incidence of PDAC (Fukuda et al., 2011).  
1.2.4.4. PLCγ-PKC 
EGFR, when phosphorylated, can bind directly to PLCγ. PLCγ is a membrane-
associated enzyme that, when active, hydrolyzes PIP2 in two molecules: 1,2diacilglecerol 
(DAG) and inositol-1,4,5-triphosphate (IP3). These products are important second messengers 
that control different cellular processes, leading to PKC activation, which finally activates tumor 
promotion and c-Jun N-terminal kinases (JNK) (Wahl et al., 1990).  
1.2.5. EGFR-MAPK in cancer  
Deregulated expression and signaling of EGFR is a common feature of solid cancers. 
Several studies reported high expression of EGFR, ranging from 7% to 100% of human PDACs 
(Conradt et al., 2011). As mentioned above, one of the best-characterized EGFR effector 
pathways is the RAS-MAPK pathway and frequent mutations in RAS/RAF/MEK/ERK signaling 
are found in many human cancers.  
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1.2.5.1. Mechanisms leading to constitutive activation of EGFR  
EGFR amplifications and gene mutations are frequently observed in most solid human 
neoplasms, like ovarian, lung, breast and pancreas cancer (Normanno et al., 2006). In many 
cancer types, EGFR pathway becomes hyper-activated because of mechanisms involved in 
ligand or receptor over-expression, or constitutive activation of the receptors (Yarden and 
Sliwkowski, 2001). 
TGFα and EGF are commonly altered in different cancer types. Both ligands act 
regulating EGFR through an autocrine/paracrine secretion promoting tumor growth. Several 
studies in transgenic mice have shown that TGFα overexpression induces epithelial 
hyperplasia in liver, pancreas and gastrointestinal tract and the appearance of hepatocellular 
and breast carcinoma (Jhappan et al., 1990). Moreover TGFα and EGFR are co-expressed in 
several types of carcinomas, which correlates with poor prognosis (Salomon et al., 1995). A 
linkage between RAS/MAPK and EGFR receptor is mediated by the upregulation of expression 
of EGFR ligands by RAS signaling. One important gene target of RAS activation involves 
transcriptional activation of TGFα gene, which promotes persistent stimulation of EGFR. 
Monoclonal antibodies against EGFR, like cetuximab, were developed in order to impair 
ligand-receptor binding. These antibodies have an anti-proliferative effect in tumor cells 
expressing EGFR (Zandi et al., 2007).  
EGFR overexpression in PDAC tumors is associated with poor prognosis and disease 
progression (Ueda et al., 2004). There are different mechanisms by which the level of EGFR is 
increased in tumor cells. Gene amplification has been demonstrated to occur in different tumor 
types such as PDAC, breast carcinomas, Non-Small Cell Lung Cancer (NSCLC) and 
Glioblastoma Multiforme (GBM) (Zandi et al., 2007). EGFR might also be overexpressed 
because of increased activity of the EGFR promoter or de-regulation at translational and post-
translational levels. Wild type and mutant TP53 protein activates EGFR transcription by directly 
binding to specific sites in its promoter. As the level of mutant TP53 protein is usually high in 
tumor cells, it may lead to strong and continuous activation of EGFR promoter (Bykov et al., 
2003). Elevated EGFR levels can also be achieved by damaged post-translational recycling, 
meaning that a significant portion of EGFR is recycled back to the cell surface following EGF 
stimulation instead of being degraded (Zandi et al., 2007).   
 Increased receptor signaling can also be due to EGFR mutations giving rise to 
constitutively active variants. These mutations can affect the extra- or the intracellular domain. 
Extracellular mutations are particularly frequent in GBM. Most of them are deletions in exons 
encoding all or parts of the extracellular domain. These mutations give rise to truncated 
receptors that are constitutively active (Zandi et al., 2007). Intracellular mutations are usually 
deletions and/or duplications of exons codifying for the tyrosine kinase domain. They are 
frequent in GBM and NSCLC (Lynch et al., 2004). Of the seven exons that encode the tyrosine 
kinase domain (exons 18-24) these mutations are restricted to the first four (exons 18-21) 
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exons. According to COSMIC database most frequent mutations are small deletions in exon 
19, missense mutations (L858R en exon 21 and G719A/C in exon 18 and 3), and small 
duplications or insertions in exon 20.  These mutations prolong the activity of ligand-activated 
receptors (Sordella et al., 2004). GEMMs were developed to study the role of some of these 
EGFR mutations. Transgenic mice harboring in type II pneumocytes a deletion of Egfr in exon 
19 develop lung adenocarcinomas (Politi et al., 2006). Similar results were obtained with Egfr 
L858R mutant mice (Politi et al., 2006).  
Aberrant EGFR signaling due to defective receptor downregulation has also been linked 
to neoplastic transformation. EGFR downregulation is a mechanism by which EGFR signaling 
is attenuated involving the internalization and subsequent degradation of the activated 
receptor. It was described that EGFR downregulation can be affected by overexpression of 
ErbB2, which can shift the formation of EGFR homodimers towards the formation of 
EGFR/ErbB2 heterodimers (Huang et al., 1999; Wang et al., 1999; Zandi et al., 2007). 
Interestingly, EGFR/ErbB2 heterodimer appears to be the strongest and the most potent 
inducer of cellular transformation and mitogenic signaling compared to other ErbB homo- and 
heterodimers (Lenferink et al., 1998; Yarden and Sliwkowski, 2001). Thus, ErbB2 
overexpression is one of the mechanisms leading to potent EGFR activation (Haslekås et al., 
2005).  
There are other mechanisms that can induce EGFR activation through tyrosine 
phosphorylation and consequently stimulation of intracellular signaling pathways; this process 
is known as EGFR transactivation. For example, cytokines can directly activate EGFR through 
JAK2, which phosphorylates specific tyrosine residues in the cytoplasmic domain of EGFR and 
ErbB2 (Yamauchi et al., 1997, 2000). Similarly, the serine/threonine kinase PKC has also been 
frequently shown to be involved in EGFR signal transactivation (Fischer et al., 2003). EGFR 
transactivation has also been particularly well studied upon stimulation of G-protein coupled 
receptors (GPCR) that can have positive effects on receptor signaling through two 
mechanisms. First, GPCRs can stimulate matrix metalloproteinases, which induce cleavage of 
EGF-like ligands precursors, leading them to bind EGFR enhancing its signaling (Fischer et al., 
2003; Prenzel et al., 1999). Second, GPCRs can indirectly activate Src, which phosphorylates 
tyrosine residues in the intracellular domains of EGFR (Dikic et al., 1996; Luttrell et al., 1997).  
1.2.5.2. EGFR-MAPK inhibition 
Nowadays, gemcitabine is the standard care for metastatic pancreatic cancer. However, 
it only confers a modest survival improvement among treated patients (Burris III et al., 1997; Li 
et al., 2004). For this reason, understanding the nature of PDAC biology and molecular events 
will permit the inhibition of key specific pathways in pancreatic tumor development.  
EGFR signaling is highly upregulated in many tumor types, including PDAC. Higher 
EGFR expression in PDAC patients is related with metastasis and poor prognosis (Tobita et al., 
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2003). Thus, EGFR has been intensively studied as a therapeutic target and specific inhibitors 
against the receptor have been developed. There are two types of EGFR inhibition, monoclonal 
antibodies and tyrosine kinase inhibitors (TKIs).  
Monoclonal antibodies, like cetuximab and panitumumab, bind to the extracellular 
domain in order to inhibit ligand binding (Burgess et al., 2003). They interfere in receptor 
dimerization, phosphorylation and signal transduction, as well as they can cause receptor 
endocytosis (Roskoski, 2014). However, treatment of PDAC advanced patients with the 
combination of gemcitabine plus cetuximab did not improve the outcome compared with 
patients treated with gemcitabine alone (Philip et al., 2010) suggesting that combination of 
EGFR with alternative targets should be evaluated for new drug development.  
TKIs bind to EGFR intracellular tyrosine kinase domain impairing receptor auto-
phosphorylation and cell signaling (Seshacharyulu et al., 2012). Blocking EGFR with erlotinib 
decreases growth and metastasis of human pancreatic xenografts and improves the 
anticancer effect of gemcitabine (Ng et al., 2002). In 2007, a clinical trial in phase III showed 
that gemcitabine in combination with erlotinib significantly improved overall survival in 
advanced PDAC patients compared with patients only treated with gemcitabine (Moore et al., 
2007). Although the benefit of the combination was minimal, it was surprising since EGFR 
signals upstream of K-RAS, which is mutated in most of human PDAC cases.  Indeed, these 
results are in discrepancy with clinical data in NSCLC, in which oncogenic mutations in EGFR 
and K-RAS are mutually exclusive (Shigematsu et al., 2005). Similarly, oncogenic K-RAS 
mutations have shown to be detrimental in colorectal cancer patients treated with anti-EGFR 
therapy (Bardelli and Siena, 2010).  
Nevertheless, in 2012 our laboratory and others, demonstrated using K-Ras driven 
PDAC mouse models that Egfr is essential for PDAC initiation, unlike this is not happening in 
colon and lung tumors.  Indeed, ablation of Egfr in acinar cells prevents the development of 
preneoplastic PanIN lesions even in the context of chronic pancreatitis or in the absence of 
p16Inka/p19Arf tumor suppressors. Nevertheless, Egfr deletion is not sufficient to inhibit tumor 
development in the absence of p53, although tumors develop with significant longer latencies 
(Ardito et al., 2012; Navas et al., 2012). Tumorigenesis is a multi-step process involving several 
mutations that affect different pathways (Jones et al., 2008) which might explain why EGFR 
therapeutics has only be partially successful. Therefore, it is possible that the inhibition of 
EGFR in advanced PDAC tumors may not be enough because of the genetic complexity of 
these tumors, thus EGFR inhibition should be combined with drugs affecting other molecular 
pathways in order to induce conclusive responses in PDAC patients.  
K-RAS is mutated in 90% of human PDAC cases, however there are no selective drugs 
against these tumors and the design of K-RAS inhibitors is still challenging. Nevertheless, an 
inducible K-RasG12V model has been developed to allow the conditional and reversible 
expression of the oncogene in the pancreas by a Tet-on strategy to study the therapeutic 
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benefit of inhibiting the expression of K-Ras mutation in already established PDAC tumors 
(Collins et al., 2012a; Ying et al., 2012). These mice when combined with a p53-mutated allele 
develop PDAC, but these tumors and the metastasis rapidly disappear in the absence of the 
oncogene. Thus, these results illustrate that continuous K-RasG12V expression is required for 
tumor maintenance (Collins et al., 2012a, 2012b; Kapoor et al., 2014). However, PDAC tumor 
cells can acquire alternative mechanisms to survive and proliferate in the absence of K-Ras 
oncogene. Results obtained with this model have identified Yes-associated protein 1 (Yap-1) 
amplification, a transcriptional co-activator of the Hippo pathway that controls cell proliferation 
and apoptosis, as a potential bypass mechanism to overcome the dependence of PDAC on 
oncogenic K-Ras (Kapoor et al., 2014). Although this model is useful, it is important to take into 
account that the inducible K-Ras is encoded by a transgene, consequently generating an extra 
copy of K-Ras not drive by the endogenous promoter (Collins et al., 2012a; Ying et al., 2012). 
Target-based therapies are widely considered to be the key of cancer treatment. While 
K-RAS remains an undruggable molecule, several kinase inhibitors have been generated 
against upstream and downstream K-RAS effectors. Due to the frequent alterations in 
RAF/MEK/ERK downstream kinases, this pathway is at the drug discovery vanguard. 
Genetically, deletion of Mek1/2 or Erk1/2 completely prevented oncogenic K-Ras driven lung 
adenocarcinoma development (Blasco et al., 2011). Unfortunately, systemic ablation of these 
targets in adult mice led to extreme toxicities resulting in the rapid death of the animals. But in 
addition, there was identical tumor suppression with c-Raf deletion, without inducing 
significant toxicity (Blasco et al., 2011), suggesting that c-Raf is the most suitable target to 
block K-Ras-mediated activation of MAPK signaling. Recently, it has been demonstrated that 
c-Raf is critical for PanIN and PDAC initiation. Nevertheless, in the absence of p53, c-Raf 
ablation is not sufficient to block PDAC formation (unpublished results, see appendix 8.1).  
As previously mentioned, pancreatic tumors are highly heterogeneous containing 
multiple mutations that affect many different pathways (Jones et al., 2008). Additionally, the 
failure of single targeted therapies may be related to the extensive crosstalk between 
redundant signaling pathways in tumor cells (Huang et al., 2011), suggesting that concurrent 
inhibition of multiple effector pathways could be a promising therapeutic strategy. Importantly, 
it was recently determined that combined ablation of Egfr and c-Raf completely blocks PDAC 
initiation in a p53 deficient context (unpublished results, see appendix 8.2).  
 
Taking into account all these precedents, further research is required to identify new 
effective targets and combination of targets for treating PDAC. This is the main goal of this 
thesis. 
  
  
2. Objectives
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Pancreatic ductal adenocarcinoma is known to be one of the most lethal cancers, mainly 
because patients do not benefit from current available therapeutics. Therefore, there is a 
substantial and urgent demand to develop novel drugs to treat pancreas cancer. GEMMs can 
help to design and validate new therapeutic strategies affecting selective targets at different 
stages of tumor development. Indeed, studies using mouse models that recapitulate the 
human disease, demonstrated that Egfr is essential for PDAC initiation. Nevertheless, since 
protein elimination cannot be achieved in the clinic, it was important to elucidate whether 
tyrosine kinase inhibitors could be a suitable therapy for these pancreatic tumors. Moreover, 
Egfr and other validated targets can be used in combination to identify new strategies that 
would eventually pave the way for the design of more effective therapies that will benefit PDAC 
patients.  
 
Hence, the objectives of this thesis were as following: 
 
1. Generation of a kinase dead EgfrD839A allele and characterization of its constitutive 
expression during embryo development. 
 
2. Validation of the inhibition of Egfr kinase activity as a therapeutic strategy for K-Ras 
driven PDAC. 
 
3. Unveiling the role of Egfr and its tyrosine kinase activity in established pancreatic 
tumors.  
 
4. Studying the potential therapeutic benefit of targeting Egfr and c-Raf simultaneously in 
full-blown PDACs. In addition, identifying the possible side effects derived from the 
systemic deletion of Egfr and c-Raf. 
  
 
  
3. Materials and Methods
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3.1. Generation and maintenance of mouse lines 
3.1.1. Mouse lines used in this work 
The PDAC mouse model was generated by crossing the knockin K-Ras+/LSLG12Vgeo 
(Guerra et al., 2003) with the Elas-tTA/tetO-Cre bitransgenic strain. In these mice, the Elas-
tTA/tetO-Cre transgenes drive the expression of the bacterial Cre-recombinase from the 
Elastase promoter under the negative control of doxycycline (Tet-off system) (Guerra et al., 
2007). Elas-tTA and tetO-Cre were provided by Dr. Grippo (Northwestern University, Chicago, 
IL, USA) and Dr. J.I Gordon (Washington University, St. Louis, MO, USA) respectively. The 
p53Lox (Jonkers et al., 2001) and the p16Ink4a/p19ArfLox were generated (Krimpenfort et al., 
2001) in Anton Berns´ laboratory (The Netherlands Cancer Institute, Amsterdam, The 
Netherlands). The EIIa-CreT (Lakso et al., 1996) was generated in Heiner Westphal´s laboratory 
(National Institute of Child Health and Human Development, Bethesda, MD, USA).  The EgfrLox 
(Natarajan et al., 2007) was generated in Maria Sibilia´s laboratory (Institute for Cancer 
Research, Vienna, Austria). The c-RafLox (Jesenberger et al., 2001) was generated in Manuela 
Baccarini´s laboratory (Institute of Microbiology and Genetics, Vienna, Austria). The K-
RasFSFG12V (Drosten, unpublished) was generated in Mariano´s Barbacid Laboratory (Spanish 
National Cancer Centre, CNIO, Madrid, Spain). In collaboration with the CNIO Transgenic Mice 
Core Unit we generated the Elas-tTA/tetO-Flp bitransgenic strain. The p53FRT (Lee et al., 2012) 
was generated in David Kirsch´s laboratory (Duke University Medical Center, Durham, NC, 
USA). The Tg.hUBC-CreERT2T (Ruzankina et al., 2007) was generated in Eric. J. Brown´s 
laboratory (University of Pennsylvania, School of Medicine, Philadelphia, PA, USA).  
By crossing the different mouse strains we generated the final genotypes used in this 
work.  
3.1.2. Generation of EgfrLmLD839A/LmLD839A mutant mice 
For the generation of the murine EgfrLmLD839A allele, the genomic region encoding the 
murine Egfr gene was cloned from the BAC RP23-26C13. The D839A mutation and the LoxP-
cDNA-STOP-neo-LoxP cassette were inserted in the Egfr genomic locus by Red/ET (“triple 
recombination”) (performed by Genebridges, Heidelberg, Germany), and PCR analysis 
confirmed correct modification of the locus. The modified Egfr genomic locus from the BAC 
was subcloned into a high-copy plasmid backbone introducing NotI and SalI restriction 
recognition sites for convenient linearization of the targeting construct prior to introduction into 
Embryonic Stem (ES) cells.  
The linearized vector was electroporated into B6129SF17/J mouse ES cells. ES cell 
clones having undergone proper homozygous recombination with both arms of the targeting 
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vector were identified by southern blot as described below (see section 2.8). Single cell 
suspensions of two independent and positive ES cell clones (58 and 103) were microinjected 
into FVB donor blastocysts, which were then implanted into pseudopregnant C57BL/6J 
females. The Transgenic Mice Unit at the CNIO performed the electroporation and aggregation 
procedures. Two male founder chimera pups were backcrossed to C57BL/6J females for 
germline transmission of the targeted allele. 
3.1.3. Maintenance of mice 
All mice used in these projects were housed in the Animal Facility of the Spanish 
National Cancer Research (CNIO) in accordance with Federation of European Laboratory 
Animal Science Association (FELASA) recommendations and following European Union 
legislation. All experiments described in this thesis have been approved by the Bioethics and 
Animal Welfare Committee of the Institute for Health Care Carlos III. Mice were subjected to 
light and dark cycles of 12 hours each with temperature and humidity regulated. Animals were 
fed ad libitum with a standardized diet (28018S, Tekland).  
3.2. In vivo proceedings  
3.2.1. Doxycycline and caerulein treatments 
The Elas-tTA/tetO-Cre transgenes drive the expression of the bacterial Cre-recombinase 
from the Elastase promoter under the negative control of doxycycline (Tet-off system). In the 
absence of doxycycline, the expression of the Cre-recombinase starts at embryonic day 16.5 
(E16.5) (embryonic protocol henceforth). The enzyme recognizes the LoxP sites in the K-
RasLSLG12Vgeo locus and allows the expression of resident K-RasG12Vgeo oncogene in 20-30% of 
acinar cells (Guerra et al., 2007). To prevent the expression of the Elastase-driven Cre-
recombinase, doxycycline is provided and the enzyme is not expressed. At 2 months of age (or 
P60), doxycycline is removed and the expression of the Cre-recombinase allows for the 
expression of the K-RasG12Vgeo mutation in the adulthood (adult protocol henceforth) (Guerra et 
al., 2007) (Figure 5).   
Doxycycline (2mg/ml; Sigma) was provided in the drinking water as a sucrose solution 
(5% w/v) to pregnant mothers from the time of conception and to their offspring until the time 
of activated expression of the resident K-RasG12Vgeo oncogene (P60, at this time we considered 
that mice have reached adulthood). The doxycycline provided in the drinking water was 
changed every two days, being photolabile. In the adult protocol and for the appearance of 
tumors, chronic pancreatitis was needed. Pancreatitis was induced by caerulein (Sigma-
Aldrich), a cholecystokinin analog. Caerulein was administered as a 0.1ml single daily 
intraperitoneal injection of 125μg/Kg, 5 days per week for 3 months (from P90 to p180). 
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Figure 5. Schematic representation of protocols and treatments. (A) Schematic diagram of timing 
at which the resident knockin K-Ras oncogene is expressed during embryonic development. Mutated 
oncogene is expressed from embryonic day 16.5, animals were sacrificed and their pancreas analyzed at 
1 year of age. (B) Schematic diagram of the timing at which the K-RasG12Vgeo  is expressed in adult mice. 
In the Elas-tTA/tetO-Cre; K-RasLSLG12Vgeo strain, the mothers and their offspring were exposed to 
doxycycline in drinking water to prevent expression of the oncogene until the animals were 2 months old. 
These mice do not develop any lesions unless they underwent pancreatitis, thus pancreatitis was induced 
by caerulein treatment for 3 months. Mice were sacrificed and their pancreas analyzed at 14 months of 
age.  
3.2.2. Abdominal Ultrasound  
Imaging studies were done by the Molecular Imaging Core Unit at CNIO. Briefly, mice 
were anesthetized with 4% isoflurane (Braun Vetcare) in 100% oxygen at a rate of 1.5 liter/min. 
Hypothermia associated with anesthesia was avoided using a bed-heater. Abdominal hair was 
removed by depilation cream to prepare the examination area. Mice were screened for PDAC 
and tumors were measured with a micro-ultrasound system Vevo 770 (Visualsonics, Toronto, 
Canada) with an ultrasound transducer of 40 MHz (RMV704, Visualsonics, Toronto, Canada). 
PDAC size was calculated as LengthxWidth2 /2.  
3.2.3. Tamoxifen diet 
Tamoxifen diet was provided to induce the activity of the modified CreERT2-
recombinase (tamoxifen inducible Cre-Estrogen Receptor (ER) fusion protein expressed from 
the transgene Tg.hUC-CreERT2T). Tamoxifen allows for the CreERT2 enzyme to translocate 
into the nucleus to achieve target deletion or expression of floxed alleles. The standardized diet 
(28018S, Tekland) contains natural estrogens like genistein, a phytoestrogen that belongs to 
the category of the isoflavones. The genistein has been shown to interact with animal and 
human estrogen receptors. Hence, to avoid the competition between genistein and tamoxifen 
for the estrogen receptor, and to eliminate them from the organism, we used a transition diet 
(2919S Tekland) that lacks the main sources of these compounds in rodent diet (alfalfa or 
soybean) for a minimum of 10 days. Afterwards, mice were fed with Tekland CRD 
Tam400/CreER tamoxifen containing diet ad libitum. Tamoxifen is hydroxylated in the mouse 
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liver into 4-Hydroxytamoxifen (4-OHT), which is the active metabolite of tamoxifen. 
3.2.4. Standard necropsy 
Necropsies were performed in the dissection laboratory. Mice were euthanized in a CO2 
chamber and several tissue samples were collected either in 10% buffered formalin, 
embedded In Optimal Cutting Temperature compound (OCT) and/or frozen at -80ºC to be 
sectioned at a later time on a microtome-cryostat or directly frozen in dry ice for extraction of 
protein, DNA or RNA. The Comparative Pathology Core Unit at CNIO processed all the tissues 
samples fixed in formalin. Embryos were extracted from the uterus of the mother at different 
time points (E13.5 and E18.5), fixed in formalin and processed by the Comparative Pathology 
Core Unit at CNIO. 
3.3. Genotyping  
3.3.1. DNA extraction  
At weaning, a piece of the tail of the mouse was cut to extract genomic DNA for 
genotyping. Cells were cultured, harvested and collected in pellets. Tissues and cells were 
incubated with a lysis buffer (20mM Tris-HCl pH 8.0, 100mM NaCl, 0.5% SDS, 10mM EDTA 
pH 8.0 and milliq H2O) and 400μg/ml of proteinase K overnight at 55ºC. The next day, 300μl of 
saturated NaCl were added to the digested sample. After mixing vigorously by inversion, the 
mix was incubated on ice for 10 minutes. The samples were then centrifuged at 13,000 rpm for 
10 minutes at 4ºC.  The supernatant was transferred to a clean eppendorf, 800μl of 
isopropanol were added and the solution was mixed vigorously. Then, after incubating the mix 
for at least 5 minutes at room temperature to allow DNA precipitation, the samples were 
centrifuged at 13,000 rpm for 30 minutes at 4ºC. The supernatant was discarded and the 
pellets were washed twice with 500μl of 70% ethanol (EtOH). The samples were centrifuged 
again at 13,000 rpm for 10 minutes at 4ºC and the supernatant was discarded. Finally, the 
pellets were left to air dry. Dry pellets were resuspended in 100μl of Tris-EDTA buffer solution. 
3.3.2. Genotyping PCR 
Most of the mice were genotyped by Transnetyx (Cordoba, TN, USA). Nevertheless, 
occasionally for mice and always for cell lines, the genotyping was done as following.  
Isolated genomic DNA from mice tails were used for genotyping by Polymerase Chain 
Reaction (PCR). Each reaction contained: 1μl MgCl2 25mM, 2μl Taq-Polymerase Buffer 1X, 
0.25μl dNTPs 10mM, 0.2μl BSA 10 mg/ml, 0.1μl Taq-Polymerase (5U/μl EcoTaq, Ecogen), 
0.75μl of each of the primers (10μM, Sigma), 1μl of DNA and up to 20μl of milli-q H2O.  
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The oligonucleotides used for genotyping, and the expected bands were:  
 
K-RasLSLG12Vgeo 
K-Ras I0: 5´-CGTCCAGCGTGTCCTAGACTTTA-3´  
K-Ras 3’ex1: 5´-CTCAGTCATTTTCAGCAGGC-3´  
K-Ras STOP: 5´-TAGTGCCTTGACTAGAGATCA-3´ 
K-RasLSLG12Vgeo allele: 590bp (K-Ras STOP + K-Ras 3’ex1) 
K-Ras+ allele: 420bp (K-Ras I0 + K-Ras 3’ex1) 
K-RasG12Vgeo allele: 669bp (K-Ras I0 + K-Ras 3’ex1) 
 
p16Ink4a/p19Arf Lox 
p16/p19 forward: 5´-CCTGACTATGGTAGTAAAGTGG-3´   
p16/p19 reverse: 5´-ACGTGTATGCCACCCTGACC-3´    
p16Ink4a/p19ArfLox allele: 390bp 
p16Ink4a/p19Arf+ allele: 290bp 
 
p53Lox  
p53 forward: 5´-CACAAAAACAGGTTAAACCCAG-3´    
p53 reverse: 5´-GAAGACAGAAAAGGGGAGGG-3´    
p53Lox allele: 370bp  
p53+ allele: 288bp  
 
EgfrLmLD839A 
Egfr KD forward: 5´-ACCGCATCAAGCAAAG-3´ 
Egfr KD 2R reverse: 5´-CGATCTTCCAGGTAGTTCA-3´ 
EgfrLmLD839A allele: 246bp 
EgfrD839A allele: 282bp 
Egfr+ allele: 189bp 
 
K-RasFSFG12V 
K-Ras 3’ex1: 5´-CTCAGTCATTTTCAGCAGGC-3´  
K-Ras STOP: 5´-TAGTGCCTTGACTAGAGATCA-3´ 
K-Ras 2F_8B2: 5´-CCACAGGGTATAGCGTACTATGCAG-3´  
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K-RasFSFG12V allele: 507bp (K-Ras STOP + K-Ras 3’ex1) 
K-Ras+ allele: 358bp (K-Ras 2F_8B2 + K-Ras 3’ex1) 
K-RasG12V allele: 441bp (K-Ras 2F_8B2 + K-Ras 3’ex1) 
 
p53FRT  
p53 FRT forward: 5´- CAAGAGAACTGTGCCTAAGAG-3´    
p53 FRT reverse: 5´- CTTTCTAACAGCAAAGGCAAGC -3´    
p53 ∆ Rv: 5´-ACTCGTGGAACAGAAACAGGCAGA-3´    
p53FRT allele: 292bp (p53 FRT forward + p53 FRT reverse) 
p53∆ allele: 352bp (p53 FRT forward + p53 ∆ reverse) 
p53+ allele: 258bp (p53 FRT forward + p53 FRT reverse) 
 
EgfrLox 
Egfr forward 15C9: 5´-CTCTTGACTGCTGCCAACTTAG-3´ 
Egfr reverse 7B9:  5´-GAGATCTCCACACTTCCAGGTCA-3´ 
EgfrLox allele: 550bp  
Egfr+ allele: 350bp  
 
c-RafLox 
c-Raf forward 1F: 5´-CTGATTGCCCAACTGCCATAA-3´ 
c-Raf forward 3F: 5´-GAGTCAGCAAATGCACTGAAATG-3´ 
c-Raf reverse: 5´-ACTGATCTGGAGCACAGCAAT-3´ 
c-RafLox allele: 196bp (c-Raf 1F forward + c-Raf reverse) 
c-Raf ∆ allele: 270bp (c-Raf 3F forward + c-Raf reverse) 
c-Raf + allele: 143bp (c-Raf 1F forward + c-Raf reverse) 
 
The following PCR program was used: denaturation at 94°C for 1 minute, followed by 35 
cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds and extension 
at 72°C for 1 minute, and finally, followed by a long extension at 72°C for 10 minutes.  
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3.4. Processing of mouse tissues 
3.4.1. X-Gal staining on cryosections 
The K-RasLSLG12Vgeo allele carries an IRES-βgeo cassette within the 3´ non-translated 
sequences. The Internal Ribosomal Entry Site (IRES) allows for bicistronic translation of βgeo 
sequences from a transcript driven by the endogenous K-Ras promoter upon Cre-recombinase 
cleavage of the STOP transcriptional cassette (Guerra et al., 2003). βgeo is a bacterial gene 
that contains sequences from LacZ (the gene encoding β-galactosidase enzyme) and neoR 
(the gene that confers resistance to neomycin). This strategy allows identification of K-
RasG12Vgeo expressing cells by X-Gal staining.  
X-Gal staining provides a visual assay of β-galactosidase activity. As mentioned before, 
LacZ gene encodes the β-galactosidase enzyme that cleaves X-Gal into galactose and 5-
bromo-4-chloro-3-hydroxyindole. This second compound is then oxidized into 5,5-dibromo-
4,4-dichloro-indigo. Indicative of the name, this final product has a blue color. 
To detect β-galactosidase activity, pancreas and PDAC tumors were embedded in OCT 
and frozen at -80ºC. The samples were cut at a 10μm thickness using a microtome-cryostat 
(Vacutomer, Dako). Sections were stored at 4ºC overnight or 1 hour at room temperature (RT). 
For fixing, sections were incubated for 10 minutes at RT in a solution containing 0.2% 
glutaraldehyde (Sigma-Aldrich), 2mM MgCl2, 5mM EGTA and 0.1M phosphate buffer pH 7.2 for 
15 minutes at RT. After the fixation, sections were washed three times, 10 minutes each; with a 
washing solution that contains 2mM MgCl2, 0.1M phosphate buffer pH 7.2, 0.02% NP-40 and 
0.01% sodium deoxycholate (Sigma-Aldrich). After washes, sections were incubated in a 
staining solution containing 2mM MgCl2, 0.1M phosphate buffer pH 7.2, 0.02% NP-40, 0.01% 
sodium deoxycolate, 5mM K3Fe(CN)6 (Prolab), 5mM K4Fe(CN)6 (Prolab) and 1mg/ml X-Gal 
(Panreac) dissolved in Dimethyl Sulfoxide (DMSO) at 37ºC overnight. The following day or after 
48 hours, sections were washed 3 times with washing solution and counter-stained with 
Nuclear Fast Red (NFR). 
3.4.2. Nuclear Fast red Staining  
The NFR solution was prepared as follows: 25g aluminum sulphate (Sigma) and 0.5g 
NFR (Sigma) were boiled in 500ml milliq H2O and then filtered. For counter-staining, sections 
were washed once with distilled-water and then introduced in a coupling with NFR solution for 
30 seconds. The sections were rinsed with abundant distilled-water and dehydrated by 
incubating them twice for 2 minutes in 70% EtOH (Panreac), twice for 2 minutes with 100% 
EtOH and finally 1 minute in xylol (Merck). Finally, the sections were mounted with mounting 
media (Dako). 
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3.4.3. Histopathology and immunohistochemistry 
Specimens were fixed in 10% buffered formalin (Sigma-Aldrich) and embedded in 
paraffin. For histopathological analysis, pancreas were serially sectioned (3μm thick) and every 
ten sections stained with hematoxylin and eosin (H&E). Sections (3μm thick) of bone marrow, 
brain, heart, kidney, large intestine, liver, lung, pancreas, skin, small intestine, spleen, stomach 
and thymus were stained with H&E for histopathological examination. 
Antibodies used for immunohistochemistry included pre-diluted rat monoclonal anti-
Cytokeratin 19 (CK-19) (Monoclonal Antibodies Core Unit; CNIO) and rabbit polyclonal anti-
cleaved Caspase3 (1:750; Cell Signaling #9661). Toluidine blue staining was performed in skin 
paraffin slides in order to detect mast cells.  
3.4.4. Laser Capture Microdissection and PCR analysis 
Approximately 7,000-10,000 cells were obtained by Laser Capture Microdissection 
(LCM) using a PALM microbeam Zeiss Axio Observer (Carl Zeiss) from pancreas cryosections 
(10μm thick) stained with X-Gal to identify cells expressing (blue staining) and non expressing 
(not stained) K-RasG12V oncogene, as previously described (Guerra et al., 2003). Cells from 
PanIN lesions were also obtained by LCM from paraffin sections (3μm thick). The cap 
containing captured cells was mixed with 25μl NIDD buffer (50mM KCl, 10mM Tris-HCl pH 7.5, 
2mM MgCl2, 0.45% NP-40, 0.45% Tween-20) containing 400μg/ml proteinase K and incubated 
overnight at 55ºC with gentle shaking. Samples were boiled for 10 minutes to inactivate 
proteinase K and 5μl of the product was submitted to PCR amplification in the presence of 1μl 
MgCl2 25mM, 2μl Taq-Polymerase Buffer 1X, 0.25μl dNTPs 10mM, 0.2μl BSA 10mg/ml, 0.1μl 
Taq-Polymerase (5u/μl EcoTaq, Ecogen), 0.75μl of each of the primers (10μM, Sigma-Aldrich), 
and up to 25μl of milliq H2O.  
 
Primers used and the expected bands were the following: 
 
EgfrLmLD839A 
Egfr KD forward: 5´-ACCGCATCAAGCAAAG-3´ 
Egfr KD 2R reverse: 5´-CGATCTTCCAGGTAGTTCA-3´ 
EgfrLmLD839A allele: 246bp 
EgfrD839A allele: 282bp 
Egfr+ allele: 189bp 
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c-RafLox 
c-Raf forward 1F: 5´-CTGATTGCCCAACTGCCATAA-3´ 
c-Raf forward 3F: 5´-GAGTCAGCAAATGCACTGAAATG-3´ 
c-Raf reverse: 5´-ACTGATCTGGAGCACAGCAAT-3´ 
c-RafLox allele: 196bp (c-Raf 1F Forward + c-Raf Reverse) 
c-Raf ∆ allele: 270bp (c-Raf 3F Forward + c-Raf Reverse) 
c-Raf + allele: 143bp (c-Raf 1F Forward + c-Raf Reverse) 
 
The following PCR program was used: denaturation at 94°C for 1 minute, followed by 35 
cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds and extension 
at 72°C for 30s, and finally, followed by a long extension at 72°C for 10 minutes. 
3.5. Tissue Culture 
3.5.1. Tissue culture conditions 
Cells were maintained in an incubator at 37ºC with 16% O2 and 5% CO2. Mouse PDAC 
cell explants, Mouse Embryonic Fibroblasts (MEFs) and HEK293T cells (ATCC® Number CRL-
11268TM) were cultured in Dulbecco´s Modified Eagle´s Medium (DMEM; Gibco) with 10% 
(vol/vol) of Fetal Bovine Serum (FBS; Gibco) and 1% Penicillin/Streptomycin (Gibco). When 
specified, 10% Calf Bovine Serum  (CBS; Gibco) replaced FBS.  
3.5.2. PDAC cell explants 
To generate mouse PDAC explants, freshly isolated tumors were minced with sterile 
razor blades, digested with collagenase P (1.5μg/ml) in Hank´s Balanced Salt Solution (HBSS; 
Gibco) for 30 minutes at 37ºC, and cultured in DMEM with 10% FBS and 1% 
Penicillin/Streptomycin. After 48 hours, media was supplemented with G418 (75μg/ml; Sigma-
Aldrich), an analog of neomycin sulfate, to select K-RasG12Vgeo mutant cells, due to the 
presence of the neomycin resistance cassette (geo; section 3.4.1) in cells expressing the 
oncogene.  
All studies were done on cells maintained in culture for less than 10 passages. Their 
corresponding genotypes were verified by PCR analysis.  
3.5.3. Derivation of MEFs from mouse strains 
Timed pregnancies were set up and MEFs were isolated from E13.5 embryos 13 days 
after the appearance of the copulation plug. Embryos were separated by slicing through the 
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uterus in the regions between each embryo. The yolk sac was gently pulled off with forceps. 
Embryos were washed by immersion in three consecutive 10 cm tissue culture plate with PBS 
with 1% Penicillin/Streptomycin. The head, separated from the body using forceps, was used 
for genotyping. After tearing out the red tissue (heart and liver), the rest of the embryo was 
placed in a 6 cm tissue culture plate and dissected manually with a blade to mince the tissue 
into pieces of 1-2mm and incubated 10 minutes with 4ml 0.25% trypsin-EDTA. The dish was 
removed from the incubator and cells pipetted up and down several times with a 10ml pipet, 
and then placed in a 37°C tissue culture incubator for another 5 minutes. The cell suspension 
was then transferred to a 10cm tissue culture plate with 16ml of DMEM supplemented with 
10% FBS and 1% Penicillin/Streptomycin. When cells were confluent, usually after 48 hours, 
they were harvested by trypsinization, spun down, and the cell pellet resuspended in freezing 
medium (DMEM with 20% fetal bovine serum and 10% DMSO). The MEFs were aliquoted into 
cryovials and frozen using standard methods for mammalian cell cryopreservation. 
3.5.4. Immortalization of MEFs 
To immortalize cells, primary MEFs we continuously plated 1.0 x 106 cells in a 10cm 
tissue culture plate with DMEM, 10% FBS and 1% Penicillin/Streptomycin every 3 days for 15-
20 passages (also known as 3T3 protocol). Cells tend to enter a crisis stage around passage 5-
6, where they would not actively proliferate between passages. Once the crisis stage had 
passed and cells continuously proliferate to more than double the seeded density they were 
considered immortal and frozen down. Same protocol was followed with DMEM 10% Calf 
Bovine Serum (CBS; Gibco), although in this case, the crisis stage was longer. 
3.5.5. Proliferation MTT assay  
Cells were cultured in DMEM containing either CBS or FBS. Cells were seeded in 96 well 
plates at a density of 1,000 cells/well and incubated in DMEM supplemented with 10% FBS or 
10% CBS and 1% Penicillin/Streptomycin. Proliferation assays were done for 8 days and 
proliferation rate was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay (Roche). The resulting absorbance was measured with a microplate 
reader at 590 nm (EnVision 2104 Multilabel Reader, Perkin Elmer, Walthman, MA). Results 
represent the average of six independent experiments in which all samples were assayed in 
triplicate. 
3.5.6. Egfr Phosphorylation Assay 
MEFs were serum starved for 16 hours before ligand stimulation. Ligand stimulation was 
performed using 150ng/ml EGF (Sigma Aldrich) at 37ºC for 5 minutes. Cells were lysed and 
Egfr was immunoprecipitated from protein extracts using anti-Egfr monoclonal antibody (1:50; 
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Rabbit monoclonal; Abcam ab52894) bound to protein A sepharose (GE Healthcare). Proteins 
were separated on SDS/PAGE gel and transferred to a nitrocellulose membrane for 
immunoblotting with anti-Egfr antibody (1:100; Rabbit monoclonal; Abcam ab52894) and anti-
Phosphotyrosine 4G10 HRP-conjugated (1:10,000; Mouse monoclonal; Millipore 16-316). For 
time-course and EGF-stimulation assays, 1x106 MEFs or tumor cells, respectively, were 
seeded in p10 plates. The next day cells were rinsed twice with PBS and serum starved for 16 
hours. They were stimulated with EGF (150ng/ml) during the indicated time periods and 
collected for Western blot.   
3.5.7. Acinar to ductal metaplasia assay 
Cell explants of normal adult mouse pancreas were established by modification of 
previously published protocols (Githens et al., 1994; De Lisle and Logsdon, 1990; Wagner et 
al., 2002). Whole pancreas was harvested and digested in 0.2mg/ml collagenase-P (Roche) at 
37ºC. Following multiple washes with HBSS supplemented with 5% FBS, collagenase-P 
(Roche) digested pancreatic tissue was sequentially filtered through 100μm polypropylene 
mesh (Spectrum Laboratories). The filtrate was passed through a 30% FBS cushion at 1,000 
rpm. The cellular pellet was resuspended in RPMI 1640 (Lonza) supplemented with 1% 
Penicillin/Streptomycin and 10% FBS. An equal volume of neutralized Rat-Tail Collagen type I 
(RTC; Discovery Labware Inc.) was added to the cellular suspension. The cellular/RTC 
suspension was supplemented with 0.1mg/ml soybean trypsin inhibitor (Sigma-Aldrich) and 
1μg/ml dexamethasone (Sigma-Aldrich). Cellular/RTC suspension (500μl) was pipetted into 
each well of a 24 well plate pre-coated with 200μl of RTC. After solidification of the RTC, media 
supplemented with Penicillin/Streptomycin and FBS (at above mentioned concentrations) was 
added. Cultures were maintained at 37ºC in a 5% CO2 incubator for 5 days with medium 
replaced on days 1 and 3. The first day G418 was added to the media at a final concentration 
of 75μg/ml to select those cells expressing the resident K-RasG12V oncogene (about 30% of all 
acinar cells). Cell explants were maintained in the presence or absence of recombinant human 
TGFα 50ng/ml (PrePro Tech, 100-16A) and/or EGF 50ng/ml (Sigma-Aldrich, E4127).  
3.5.8. Infection of cells with Adenoviruses 
Mouse PDAC cell explants were seeded at equal densities and were infected at 100 MOI 
(Multiplicity Of Infection) with Adeno-CreGFP (Adenovirus expressing Cre-recombinase and 
Green Fluorescent Protein) particles. Five days post-infection cells were screened for GFP and 
then seeded to assess their colony formation ability.   
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3.5.9. Colony formation assay 
Cells were seeded in 10 cm tissue culture dishes at equal densities (2,000 and 5,000 
cells). They were allowed to form colonies for approximately 2 weeks. Fresh media was added 
to the tissue culture plates twice a week. After 10-14 days colonies were stained with crystal 
violet. 
3.5.10. Crystal violet staining of colonies 
 First, the media was removed from the plates and they were washed with PBS. Cells 
were fixed for 5-10 minutes with 7ml of glutaraldehyde 0.1%. Then they were rinsed with PBS 
and stained with crystal violet 0.5% for one hour. Afterwards the plates were washed with 
water several times, to remove excess dye and dried at RT overnight. 
3.5.11. Production of lentivirus and infection of cells 
Lentiviral supernatants were produced in HEK293T cells (70%-80% confluence). 
Packaging plasmids pLP1 (1.9μg), pLP2 (1.3μg), pLP/VSVG (1.64μg) (Invitrogen) and the 
lentiviral construct (5μg) were mixed and added to 40μl of Polyethylenimine (1mg/ml) and 500μl 
serum free DMEM. The mixture was vortexed for 5 seconds and incubated at RT for 15 
minutes. HEK293T cells were transfected by addition of this transfection mix dropwise. 
Transfected cells were incubated at 37ºC overnight followed by a 24 hours incubation at 32ºC. 
Lentiviral supernatant was collected and filtered with 0.45μm pore size filters. Cells were 
infected with this filtered solution and Polybrene added at a concentration of 8μg/ml. 
Alternatively, filtered lentiviral supernatant could be stored at -80ºC for later use. After infection 
cells were selected with 2μg/ml puromycin for 48h. 
Knockdown of ErbB2 was mediated with lentiviral Mission short hairpin RNA (shRNA) 
plasmid (Sigma TRCN0000234103). Non-target shRNA control vector was used as a negative 
control.  
3.6. Western blot 
3.6.1. Protein Extraction  
Protein extraction, either from tissues or cultured cells, was performed in NP-40 lysis 
buffer: 50mM Tris-HCl pH 7.4, 150mM NaCl, 0.5% NP40, and a cocktail of proteases and 
phosphatases inhibitors (cOmplete Mini, Roche; Phosphatase Inhibitor Cocktail 2 and 3, 
Sigma-Aldrich). For tissue protein extraction, we used a homogenizer to mechanically 
breakdown the tissue samples and maximize the efficiency of lysis. Five zirconium beads were 
added to a 1.5ml screw capped tube together with the sample and four volumes of lysis buffer. 
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The samples were incubated on ice for 30 minutes. The extracts were centrifuged for 10 
minutes at 13,000 rpm and 4ºC to remove the undigested membranes/DNA and the 
supernatant was transferred to a new tube. To quantify the amount of protein obtained, we 
used the Bradford method (Bio-Rad) (1μl of the protein extract was added to 1ml of 1X 
Bradford reagent and the absorbance was read on a spectrophotometer at 595nm). Bovine 
Serum Albumin (BSA) was used to generate a standard curve. 
3.6.2. Protein electrophoresis  
Tissue/cell extracts (25/50μg) were prepared for loading in the gel by adding 4X loading 
buffer and 10X reducing agent (Thermo Fisher Scientific). Samples were boiled for 5 minutes at 
95ºC, spun down and loaded in Nupage Bis-Tris Midi gels (Thermo Fisher Scientific). MOPS 1X 
(Thermo Fisher Scientific) running buffer was used for separating large- to medium-sized 
proteins. In addition, we loaded 10μl of Spectra Multicolor Broad Range Protein Ladder 
(Thermo Fisher Scientific) for molecular weight reference. 
3.6.3. Transferring the denatured proteins to a membrane 
A piece of nitrocellulose transfer membrane (GE Healthcare) and Whatman 3MM (Sigma-
Aldrich) paper were sized to gel and prewet in transfer buffer (Tris-Glycine 1X, Lonza; MeOH 
20%, Panreac). A “transfer sandwich” was assembled in the following order: cathode, 4x 
Whatman paper, gel, nitrocellulose membrane 4x Whatman paper, anode. Generally wet 
transfers were performed, as it is recommended specially for proteins with a large molecular 
weight. The gel was transferred for 70 minutes at a constant current of 0.40A and maximum 
power. Afterwards, staining with Ponceau S solution (Sigma) was performed to check the 
efficiency of protein transfer.  
3.6.4. Blocking and antibodies 
Membranes were blocked by incubation with 5% BSA in TBST (1X Tris-Buffered Saline 
(TBS) solution; 0.1% of Tween-20) for phosphorylated proteins, and 5% non-fat milk in TBST 
buffer for the rest of the proteins, for 45 minutes at RT. Incubation with primary antibodies 
diluted in the blocking solution was performed overnight on a rotating platform at 4ºC. The 
next day, the membranes were washed three times with 1X TBST buffer for 10 minutes on a 
shaking platform at RT. Afterwards, blots were incubated for 1h with the appropriate 
secondary antibodies HRP (1:2000, Dako) or fluorescence (1:5000, Life Technologies) labeled. 
For HRP secondary antibodies, protein visualization was carried out with and enhanced 
chemiluminiscent system (ECL Plus; Amersham Biosciences) using different exposure times 
depending on the antibody. For the fluorescent secondary antibodies, the LICOR scanner was 
used. 
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Membranes were blotted with antibodies raised against Egfr (1:100; Rabbit monoclonal; 
Abcam ab52894), phospho-Egfr Tyr1068 (1:1,000; Rabbit monoclonal; Cell Signaling #3777), 
ErbB2 (1:500; Rabbit monoclonal; Cell Signaling #3250), Akt (1:500; Rabbit polyclonal; Cell 
Signaling #9272), phospho-Akt Ser473 (1:250; Rabbit polyclonal; Cell Signaling #9271), Erk1/2 
(Erk1, 1:2,000 Mouse monoclonal BD Biosciences 554100; Erk2 1:1,000 Mouse monoclonal 
BD Biosciences 610103), phospho-Erk1/2 Thr202/Tyr204 (1:500; Rabbit polyclonal; Cell 
Signaling #9101), Phospho-tyrosine 4G10 HRP-conjugated (1:10,000; Mouse monoclonal; 
Millipore 16-316) and Gapdh (1:10,000; Mouse monoclonal; Sigma-Aldrich G8795) for loading 
control.  
3.7. Quantitative Real Time PCR 
3.7.1. RNA extraction  
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). Briefly, cells 
were washed with cold PBS and scrapped with RLT lysis buffer. Lysates were transferred to a 
QIAshredder column in order to shred tissue finely. After centrifuging at maximum speed for 2 
minutes at 4ºC, one volume of 70% EtOH was added to the flow-through and mixed by 
pipetting. Then, up to 700μl was transferred to an RNeasy spin column. Columns were 
centrifuged for 30 seconds at 1,000 rpm and flow-through was discarded. Following 350μl of 
RW1 buffer were added to the column and again centrifuged. Residual genomic DNA was 
removed from the samples by digestion with 10μl of DNAse in 70μl RDD buffer per column. 
Digestion was performed on column, during incubation at RT for 15 minutes.  To stop the 
digestion, 350μl of RW1 buffer were added to the column followed by centrifugation. Flow-
through was discarded and 500μl of RPE buffer were added to wash the column, it was 
discarded after centrifuging for 2 minutes at 10,000 rpm. Residual alcohol was removed by 
doing a dry spin at maximum speed for 1 min. RNA was then eluted in 30-50μl of RNase free 
H2O. Finally, RNA was quantified using a Nanodrop spectrophotometer.  
3.7.2. cDNA synthesis: Reverse Transcription PCR (RT-PCR)  
cDNA synthesis was performed using SuperScript II Reverse Transcription kit (Thermo 
Fisher Scientific) following manufacture´s protocol. For each sample 1μg of RNA in 6μl of H2O 
was incubated for 2 minutes at 65ºC followed by 2 minutes on ice. Afterwards, the following 
mix was added: 4μl of 5X buffer, 2μl of 0.1M DTT, 2μl of 10mM dNTPs, 0.5μl of RNAse inhibitor 
(400U/μl), 5μl of random primers (previously diluted 1:30) and 0.5μl of the SII polymerase 
(200U/μl). The mixture was incubated for 10 minutes at RT and then 1 hour at 42ºC. The 
reaction was stopped by heating at 98ºC for 5 minutes. Finally, 80μl of H2O were added to the 
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reaction and samples were frozen at -20ºC.  
3.7.3. Real Time PCR 
Designed primers had a melting temperature between 58ºC-61ºC, length of 100-200bp, 
and when possible cover an exon-exon junction (to avoid the problem of possible residual 
genomic DNA contamination). Primers were ordered to Sigma-Aldrich with standard desalting 
purification.  
 
Primers used were the following:  
 
Egfr 
Egfr forward: 5´-GCCATCTGGGCCAAAGATACC- 3´ 
Egfr reverse: 5´-GTCTTCGCATGAATAGGCCAAT- 3´ 
 
Gapdh 
Gapdh forward: 5´-CCCACTAACATCAAATGGGG- 3´ 
Gapdh reverse: 5´-CCTTCCACAATGCCAAAGTT- 3´ 
 
Quantitative RT-PCR assays were performed with the AB 7900 Fast Real Time PCR 
System using Power SYBR Green PCR Master Mix (Applied Biosystems). For each sample the 
following mix was added: 10μl SYBR Green Mix (Roche), 0.5μl of 10μM primer forward, 0.5μl of 
10μM primer reverse, 1μl of cDNA template and 8μl of H2O. Samples were prepared in a 96-
well plate, sealed with optical adhesive film.   
3.7.4. Data analysis 
The relative mRNA expression was calculated using the comparative cycle threshold (Ct) 
method:  
 ΔΔCt = ΔCt sample – ΔCt reference  
 ΔCt sample is the Ct value for any sample normalized to the endogenous 
housekeeping gene and ΔCt reference is the Ct value for the calibrator also normalized to the 
endogenous housekeeping gene (Gapdh). 
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3.8. Southern blot 
3.8.1. DNA extraction  
A phenol-chloroform protocol was followed in order to obtain DNA pure enough for 
southern application. Cells were lysed overnight at 55ºC in lysis buffer (20mM Tris-HCl pH 8.0, 
100mM NaCl, 0.5% SDS, 10mM EDTA pH 8.0 and milli-q H2O) with 400μg/ml of proteinase K. 
The next day, 500µl of phenol were added and mixed vigorously by vortexing to create an 
emulsion. The mix was centrifuged for 5 minutes at 13,000 rpm at 4ºC. The upper aqueous 
phase was transferred to a new 1.5ml tube. 500µl of phenol-chloroform were added and mixed 
vigorously by vortexing to create an emulsion. The mix was centrifuged for 5 minutes at 13,000 
rpm and 4ºC. The upper aqueous phase was transferred to a new 1.5ml tube. 500 µl of 
chloroform were added and mixed vigorously by vortexing to create an emulsion. The mix was 
centrifuged for 5 minutes at 13000 rpm and 4ºC. The upper aqueous phase was transferred to 
a new 1.5ml tube. 700µl of isopropanol were added and mixed by inverting the tube 15 times. 
To allow for precipitation the mix was incubated 10 minutes at RT. The mix was centrifuged for 
15 minutes at 13,000rpm and 4ºC. The supernatant was discarded avoiding disruption of the 
pellet. The pellet was cleaned with 1ml of 70% ethanol. The mix was centrifuged for 5 minutes 
at 13,000rpm and 4ºC. Again, the supernatant was discarded avoiding disruption of the pellet. 
The pellet was dried and finally dissolved in Tris-EDTA buffer solution.  
3.8.2. DNA digestion with restriction enzymes 
DNA (30-50μg) was prepared in a 26μl volume. To perform digestion the following was 
added to each DNA sample: 3μl of restriction enzyme of interest, 1μl RNase DNase-free, 4μl of 
spermidine, 4μl of 10X restriction enzyme buffer and 2μl of 100X BSA. The final mix of 40μl was 
mixed well and incubated at 37°C overnight. The digested genomic DNA was resolved in a 
0.8% agarose gel to obtain enough separation of the expected bands. The gel was washed 
with distilled H2O and incubated with 0.25N HCl for 15 minutes in gentle agitation to depurinate 
DNA fragments, break the DNA into smaller pieces that will be easily transferred from the gel to 
the membrane. Then, it was rinsed with distilled H2O and incubated with denaturing solution 
(0.5 M NaOH, 1.5 M NaCl) for 20 minutes with gentle agitation to denature the double-stranded 
DNA. Afterwards, the gel was transferred to the neutralizing solution (0.5 M Tris-HCl pH 8.0, 
1.5 M NaCl) for 30 minutes with gentle agitation. Finally, the gel was equilibrated with transfer 
buffer 10X Saline Sodium Citrate (SSC) for at least 10 minutes. Then, the DNA was transferred 
to a nylon membrane by capillarity with 10X SSC buffer. To this end, a “transfer sandwich” was 
prepared. First, 3mm Whatman blotting paper was placed on a facedown plastic gel mold 
within a pyrex tray filled with 10X SSC buffer. The following components were piled up in this 
order: the gel facing down, one nylon Hybond N+ membrane (Amersham), two pieces of 
Whatman paper (cut to size of gel and membrane), and finally on top a stack of paper towels. 
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The entire transfer was wrapped in plastic wrap to avoid evaporation of buffer. The DNA was 
allowed to transfer overnight. The next day, the membrane was exposed to 1.2x105μJ of 
ultraviolet radiation using a UV Stratalinker 1800 (Stratagene) to permanently attach the DNA to 
the membrane by covalent crosslinking. Following which, the membrane was incubated with 
10ml of pre-Hybridization buffer (5mM Polyvinylpyrrolidone, 2mM Ficoll, 0.1M Dextran Sulfate, 
25mM Na2HPO4, 0.9M NaCl, 35mM SDS, 2.5M EDTA pH 8, 10mg/ml of salmon sperm DNA, 
13M formamide) to reduce non-specific bindings, for at least 4 hours in a glass tube (with the 
DNA side facing inwards) in a rotating oven at 42°C. 
3.8.3. Labeling the DNA probe and Hybridization 
 1μl of the probe (25-100ng) was added to 45μl of H2O and the mix was boiled in water 
for 3 minutes to produce denaturation of the DNA. Right after that, it was put on ice during 3 
minutes to avoid renaturation and thereafter added to an eppendorf of the kit Rediprime II 
Random Prime Labelling system (Amersham). Then 5μl of α32P-dCTP was added and 
everything was mixed by pipetting. The mix was incubated in a shaking thermoblock for 10 
minutes at 37 °C to allow labeling of the probe. During this period, the pre-hybridation buffer in 
the glass tube with the membrane was replaced with new 10ml. The labeled probe was 
purified with a column from the G-50 Microcolums Radiolabeled Probe Purification Kit 
(Amersham). 1μl of a labeled probe against the lambda-HindIII DNA ladder was added to the 
recently labeled probe and 5μl of NaOH 5N was also added to induce chemical denaturation of 
the probes. The membrane was incubated with the labeled probes overnight at 42ºC in the 
rotating oven. The following day the membrane was washed in the glass tube in three steps of 
20 minutes each: 2X SSC, 0.1% SDS; 1X SSC, 0.1% SDS and 0.1X SSC, 0.1% SDS at 42ºC. 
The membrane was placed in a plastic sleeve and exposed to a phosphoimager screen for at 
least 4 hours. The screen was then developed using the phosphoimager and its software 
(Molecular Dynamics). 
3.9. Statistical Analyses 
All statistical analyses were performed using unpaired Student t-test. P-value <0.05 was 
considered to be statistically significant (*p<0.05; **p<0.01; ***p<0.001). All the calculations 
were performed with the Excel software (Microsoft). 
  
  
  
4. Results
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4.1. Study of Egfr tyrosine kinase inhibition in PDAC initiation 
Egfr deletion has been reported to impair PDAC initiation (Ardito et al., 2012; Navas et 
al., 2012). However, elimination of the protein cannot be achieved in the clinic and most of the 
current EGFR inhibitors are small molecules that inhibit EGFR tyrosine kinase activity. Because 
of this, it was important to investigate whether the therapeutic benefit observed upon ablation 
of Egfr in PDAC mouse models relied on Egfr catalytic activity and or on kinase independent 
functions.   
We decided to generate a conditional knock-in allele that upon Cre-mediated 
recombination expresses a kinase dead Egfr protein to mimic the effect of selective and 
efficient EGFR inhibitors for PDAC treatment. These approaches should provide relevant 
information for the design of future clinical trials that will benefit cancer patients.  
4.1.1. Generation of an inducible Egfr kinase dead allele: EgfrD839A 
We therefore designed an inducible Egfr kinase dead knock-in allele that expresses a 
catalytic inactive Egfr protein under its own regulatory elements upon Cre-mediated 
recombination. With this purpose and in order to ensure proper expression of both Egfr wild 
type and catalytic inactive proteins, we designed a targeting vector (Figure 6A) with the 
following elements in the specified order:  
- A mouse Egfr cDNA encoding exons 21 to 28 (indicated as “minigene”) 
- A transcriptional Stop sequence 
- The PGK-Neomycin resistance gene cassette, in reverse orientation.  
- LoxP sites flanking the aforementioned elements to allow their excision upon Cre-
recombinase activity   
- The exon 21 containing the point mutation, resulting in the substitution of the Aspartic 
acid D839 for an Alanine (D839A) in an essential conserved triad of amino acids constituting 
the HRD motif. This highly conserved Aspartic acid plays a critical role during catalysis as it 
serves as a catalytic base to accept the proton from the hydroxyl group of the substrate (Jura 
et al., 2011; Zhang et al., 2015b). Therefore, this mutation confers a kinase dead property to 
this protein, thus kinase dead mutants cannot stimulate cell signaling.  
This allele will be referred to as EgfrLmLD839A where LmL accounts for LoxP-minigene-
LoxP. EgfrLmLD839A mice express the wild type Egfr protein during embryonic and postnatal 
development because of the floxed minigene. When these sequences are removed by the Cre-
recombinase, the kinase dead isoform is expressed from the targeted endogenous locus. This 
strategy has been successfully used earlier to express isoforms of other genes (Dankort et al., 
2007).  
 RESULTS 
 
80 
Briefly, for the generation of the EgfrLmLD839A allele, ES cells were electroporated with the 
targeting vector and homologous recombination events were identified by Southern blot (figure 
6B). Mice were generated from clones (58 and 103), with the help of the Transgenic Mice Core 
Unit at the CNIO, and a breeding colony was established in a mixed B6;129Sf17/J 
background. 
 
 
Figure 6. Schematic representation of Egfr+, EgfrLmLD839A and EgfrD839A alleles. (A) The mouse 
genomic Egfr wild type locus (Egfr+), the inducible (EgfrLmLD839A) and the catalytic inactive (EgfrD839A) 
knock-in alleles are represented. External 5´ and 3´ Southern blot probes (5´SP and 3´SP, respectively) 
and the size of restriction fragments are indicated. Exons (boxes), LoxP sites (triangles), Minigene (cDNA 
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from exon 21 to 28), Neomycin resistance cassette gene (Neo) and transcriptional Stop cassette (STOP) 
are depicted. The modified exon 21 encoding the D839A mutation is indicated (*). (B) Southern blot 
analysis for both homology arms was performed with DNA isolated from ES cell clones electroporated 
with the targeting vector and selected with G418. DNA was digested with BamHI (for the 5´SP) and 
EcoRV (for the 3´SP). Diagnostic bands for each allele are indicated. ES homologous recombinant clones 
are indicated in bold.  
4.1.2. Egfr kinase activity is essential for mouse embryo development 
All members of the ErbB family are essential for embryo development since loss of 
signaling of any of them is associated with early lethality in mice. ErbB2 null mice die at mid-
gestation due to neural crest and motor nerve defects and trabecular malformation in the heart, 
similar to ErbB4 deficient mice (Gassmann et al., 1995; Lee et al., 1995). ErbB3 knockout 
embryos die at later stages because they lack the Schwann cell precursors, which result in the 
death of motor and sensory neurons (Erickson et al., 1997). Egfr is normally required for 
embryo implantation, development and appropriate maturation of central nervous system. Egfr 
knockout mice (Egfr−/−) die at different stages of development depending on the genetic 
background: CF1 background results in peri-implantation death, 129/Sv mice reach mid-
gestation, C57Bl/6J mice die just after birth and MF1 and CD1 mice can live for up to 20 days 
after birth (Miettinen et al., 1995; Sibilia and Wagner, 1995; Sibilia et al., 1998; Threadgill et al., 
1995). Suggesting that this signaling cascade is differently regulated in various mouse strains 
and that there are other pathways capable of partially compensate Egfr signaling in the 
embryo. All surviving Egfr knockout mice suffer from neurodegeneration and defects in skin, 
liver, kidney and lung (Sibilia et al., 1998). Additionally, two Egfr mutant alleles with reduced 
receptor signaling have been described in mice. Egfrwa2 mutation alters the kinase domain 
reducing by 80-95% the activity of the receptor (Luetteke et al., 1994). Homozygous Egfrwa2 
mice are viable but they develop impaired maternal lactation (Fowler et al., 1995).  Egfrwa5  allele 
encodes an entire  kinase dead receptor that results from an Aspartate to a Glycine change 
that alters the DFG domain of the Egfr catalytic domain. Egfrwa5 homozygotes mice die 
perinatally and display placental defects identical to those observed in Egfr knockout mice (Du 
et al., 2004; Lee et al., 2004).  
To address the effect of the constitutive expression of the EgfrD839A catalytic inactive 
receptor, we crossed Egfr+/LmLD839A mice with a transgenic mouse strain expressing the Cre-
recombinase under the control of the EIIa promoter. This strain carries a Cre-transgene under 
the control of the adenovirus EIIa promoter that targets expression of the Cre-recombinase in 
the early mouse embryo, driving recombination prior to implantation in the uterine wall (Lakso 
et al., 1996). Cre-mediated recombination occurs in a wide range of tissues, including germ 
cells that transmit EgfrD839A mutation to the progeny. Indeed, genotyping of the pups confirmed 
that the EgfrD839A allele was transmitted. Egfr+/D839A mice were crossed with C57BL/6J mice to 
eliminate the EIIa-Cre transgene. Finally, crosses between Egfr+/D839A mice were set up. 
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Egfr+/D839A mice reached adulthood without any apparent defect, whereas homozygous 
EgfrD839A/D839A mice died during embryonic development. Few EgfrD839A/D839A embryos survive 
until E13.5 and E18.5 (Table 2). At E18.5 mutant embryos were slightly reduced in size and 
weight compared to their wild type littermates. They showed open eyelids, immature lungs 
with poorly inflated regions and increased amount of cells in the alveolar area, and skin 
abnormalities with almost absent keratinization of the epidermis and poor differentiated hair 
follicles (Figure 7). Death in-utero probably resulted from a defect in the spongiotrophoblast 
layer of the placenta (the part of the placenta where maternal and fetal tissues come in closest 
contact); it was reduced in size, with only a thin layer of cells (Figure 7B). These results 
recapitulate the defects observed in Egfr−/− and Egfrwa5/wa5 mice (Du et al., 2004; Lee et al., 
2004; Sibilia and Wagner, 1995) 
As was previously described (Sibilia and Wagner, 1995; Threadgill et al., 1995), genetic 
background plays an important role in regulating Egfr signaling. For this reason, we 
backcrossed the EgfrD839A allele to the C57BL/6J genetic background for 7 generations to 
reproduce previous results (Sibilia and Wagner, 1995). However, in contrast to Egfr−/− mice that 
died just after birth, EgfrD839A/D839A embryos died during gestation (Table 3).  
In conclusion, Egfr catalytic activity is required for embryonic development since 
expression of the EgfrD839A/D839A alleles resulted in embryonic lethality in both mixed and 
C57BL/6J pure genetic backgrounds likely due to placental defects.  
 
Table 2. Offspring from matings between Egfr+/D839A mice (mixed background).  
Stage n Egfr+/+ Egfr+/D839A EgfrD839A/D839A 
E13.5 69 18 (26%) 42 (61%) 9 (13%) 
E.18.5 102 25 (24.5%) 73 (71.6%) 4 (3.9%) 
P0 130 46 (35%) 84 (65%) 0 (0%) 
  
 
Table 3. Offspring from matings between Egfr+/D839A mice in C57BL/6J genetic background.  
Stage n Egfr+/+ Egfr+/D839A EgfrD839A/D839A 
E13.5 38 14 (36.9%) 20 (52.6%) 4 (10.5%) 
E.18.5 68 30 (44.1.%) 38 (55.9%) 0 (0%) 
P0 92 30 (32.6%) 62 (67.4%) 0 (0%) 
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Figure 7. Constitutive expression of EgfrD839A leads to embryonic lethality. (A) Representative 
images of wild type and EgfrD839A/D839A embryos at E18.5. EgfrD839A/D839A embryos were smaller than their 
wild type littermates and showed open eyelids. Scale bar represents 1cm. (B) Lung, skin and placenta 
H&E staining obtained from Egfr+/+ and EgfrD839A/D839A embryos at E18.5. Sp: Spongiotrophoblast. L: 
Labyrinth. Scale bar represents 100µm (lung and skin) and 500µm (placenta).  
4.1.3. EgfrD839A protein has impaired kinase activity 
4.1.3.1. EgfrD839A shows impaired ligand-dependent phosphorylation  
In order to study the role of EgfrD839A in vitro, crosses between Egfr+/D839A mice were set 
up and MEFs were extracted at embryonic day E13.5. As previously mentioned, EgfrD839A/D839A 
embryos were not obtained at Mendelian ratios (Tables 2 and 3).  
Firstly, the expression of the catalytic inactive receptor was verified by Quantitative Real 
time PCR (qRT-PCR) and Western blot. As expected, there were no significant differences 
comparing Egfr expression levels between Egfr+/+, EgfrLmLD839A/LmLD839A and EgfrD839A/D839A 
alleles, indicating that the genetic modifications of the allele were neither affecting the 
expression nor the stability of the protein in primary MEFs (Figure 8A, B). 
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Figure 8. Analysis of the expression of the Egfr catalytic inactive receptor in MEFs. (A) qRT-PCR 
analysis of the relative expression levels of Egfr in Egfr+/+, EgfrLmLD839A/LmLD839A and EgfrD839A/D839A MEFs 
(n=3). Gapdh expression levels were used for normalization. Data are represented as mean ± SD. (B) 
Western blot analysis of Egfr expression in whole cells extracts obtained from Egfr+/+, 
EgfrLmLD839A/LmLD839A and EgfrD839A/D839A MEFs. Gapdh expression served as loading control. Migration of 
the indicated proteins is shown by arrowheads.  
Ligand binding leads to the formation of EGFR homo- and/or heterodimers with other 
ErbB family members. Subsequently, the EGFR intracellular C-terminal region is 
phosphorylated and the catalytic domain is activated. Active EGFR recruits and 
phosphorylates signaling proteins, such as Grb2, which links cell surface receptors to the 
RAS/MAPK signaling cascade (Jorissen et al., 2003).  
To evaluate Egfr catalytic activity, phosphorylation status of the receptor was assessed 
in response to EGF stimulation in MEFs. After Egfr immunoprecipitation we could observe that 
EGF-dependent phosphorylation was markedly reduced in EgfrD839A/D839A MEFs and 
consequently EgfrD839A protein has impaired catalytic activity (Figure 9A).  
In addition, to evaluate the contribution of Egfr on ligand-induced signal transduction, 
phosphorylation levels of the main downstream targets were assessed at different time points 
in response to EGF stimulation. We analyzed by Western blot the phosphorylation status of 
Erk1/2 (as a readout of the MAPK pathway) and Akt (as a readout of the PI3K pathway). 
EgfrD839A/D839A mutant MEFs failed to trigger MAPK and PI3K signaling and both pathways were 
downregulated compared to wild type MEFs (Figure 9B). Furthermore, phosphorylation of Egfr 
(Tyr 1068) in EgfrD839A/D839A mutant MEFs was absent, which is in accordance with the 
immunoprecipitation results. 
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Figure 9. EgfrD839A protein has impaired kinase activity. (A) Egfr+/+ and EgfrD839A/D839A MEFs were 
serum starved for 16 hours and then stimulated with EGF (150ng/ml). Following EGF stimulation (5 min), 
whole-cell extracts were prepared and Egfr proteins were immunoprecipitated. The presence of 
phosphorylated Egfr was detected by Western blotting with the anti-phosphotyrosine antibody. Lanes 
WCE: whole-cell extract at a 1:10 dilution before immunoprecipitation (IP), M: mock immunoprecipitate. 
(B) Egfr+/+ and EgfrD839A/D839A MEFs were serum starved for 16 hours and then stimulated with EGF 
(150ng/ml). Whole-cell extracts were prepared at the indicated times following EGF stimulation. Western 
blot analysis of Egfr, Erk1/2 and Akt phosphorylated proteins. Gapdh expression served as loading 
control. Arrowheads show migration of the indicated proteins. Lanes +: whole-cell extract from Egfr+/+ 
MEFs. Lanes D839A: whole-cell extract from EgfrD839A/D839A MEFs. 
4.1.3.2. Characterization of Egfr kinase dead MEFs 
We next determined the impact of Egfr kinase dead mutation on spontaneous 
immortalization of MEFs following a 3T3 protocol (Figure 10A, B). In standard media conditions 
(10% FBS) there were no detectable differences between mutant homozygous and wild type 
MEFs. In contrast, under restricted growth factor conditions (10% CBS), mutant MEFs did not 
overcome the crisis stage even after 40 passages, thus indicating, that under these 
circumstances, EgfrD839A has an impact on immortalization process (Figure 10B). We also found 
significant differences between the proliferation rates of EgfrD839A/D839A MEFs and wild type 
MEFs over 12 days in culture either in media containing FBS or CBS. Consequently, EgfrD839A 
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mutation has an inhibitory effect in proliferation and EgfrD839A/D839A MEFs display a significant 
limited proliferation capability (Figure 10C, D). 
 
 
Figure 10. Egfr kinase activity is required for MEFs immortalization and proliferation in vitro. (A, B) 
Immortalization of primary Egfr+/+ (n=3) and EgfrD839A/D839A (n=3) MEFs following a 3T3 protocol. Cells 
were cultivated in DMEM supplemented with 10% FBS (A) or alternatively 10% CBS (B). Error bars 
indicate mean ± SD. (C, D) Proliferation curves of primary Egfr+/+ (n=6) and EgfrD839A/D839A (n=6) MEFs 
cultivated in DMEM supplemented with 10% FBS (C) or 10% CBS (D). Proliferation was determined by 
MTT. Error bars indicate mean ± SD. P-values at day 8 **p<0.01, ***p<0.001.  
4.1.4. EgfrD839A impairs PDAC tumor initiation 
As previously mentioned, our PDAC mouse model was generated by crossing a knock-in 
K-RasLSLG12Vgeo allele with a double transgenic mice Elas-tTA;tetO-Cre (from now on ElasK-
RasG12Vgeo) allowing the expression of the K-RasG12Vgeo in acinar cells, following an inducible 
Tet-Off strategy in which the expression of the Cre-recombinase is under the control of the 
Elastase promoter (Guerra et al., 2007).  
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One of the main objectives of this thesis was to investigate whether the elimination of 
Egfr catalytic activity was able to recapitulate the results obtained with the elimination of Egfr 
protein in PDAC initiation. To this end, we carried out the same studies performed earlier 
(Navas et al., 2012).  
We generated the ElasK-RasG12Vgeo;EgfrLmLD839A/LmLD839A mouse strain. Since K-
RasLSLG12Vgeo and EgfrLmLD839A/LmLD839A inducible knock-in alleles are based on the Cre-mediated 
recombination system, expression of the K-RasG12Vgeo oncogene and the EgfrD839A kinase dead 
form was concomitant in acinar cells 
4.1.4.1. Egfr catalytic activity is essential for K-Ras oncogene-driven ADM in 
vitro 
Acinar to ductal metaplasia (ADM) is the described precursor of PanIN lesions (Brune et 
al., 2006; Parsa et al., 1985). Lineage tracing experiments in PDAC mouse models 
demonstrated that PanIN lesions are mainly derived from acinar cells undergoing acinar to 
ductal metaplasia (Kopp et al., 2012), suggesting that ADM might be an early event that 
promotes K-Ras driven tumorigenesis. Moreover, it was previously shown that generation of 
ductal-like structures in vitro from wild type acinar cells is largely dependent on activation of 
Egfr by EGF (Means et al., 2005). Acinar cells isolated from ElasK-RasG12Vgeo mice efficiently 
transdifferentiated in vitro into metaplastic ductal-like cells and this process was largely 
dependent on activation of Egfr considering that ADM was highly reduced in the absence of 
this receptor (Navas et al., 2012). The very same approach was done in ElasK-
RasG12Vgeo;EgfrLmL839A/LmLD839A isolated acinar cells. Inhibition of Egfr catalytic activity 
significantly reduced the capability of acinar cells to generate ductal-like structures, but did not 
block completely the competence of acinar cell explants to generate metaplastic structures 
(Figure 11). These observations suggest that ADM requires Egfr signaling in the presence of a 
mutant K-Ras oncogene but also that EGF and TGFα may contribute to ADM by activating 
additional signaling pathways, at least in vitro. 
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Figure 11. Acinar cells expressing the endogenous K-Ras oncogene require Egfr catalytic activity 
to undergo metaplasia in vitro. Acinar cell explants were isolated from pancreas of dox-untreated (in 
absence of doxycycline) 6 to 8 weeks-old ElasK-RasG12Vgeo;Egfr+/+ (solid bars, n=3) mice and ElasK-
RasG12Vgeo;EgfrLmLD839A/LmLD839A  (open bars, n=3) mice. Acinar cells were incubated in the absence (-) or 
presence of the indicated growth factors at a final concentration of 50ng/ml. G418 (75µg/ml) was added 
to the culture media to select K-RasG12Vgeo expressing cells. The number of metaplasias was determined 
after five days in culture. Data shown represent mean ± SD, *p<0.05,  **p<0.01.  
4.1.4.2. Egfr catalytic activity is essential for K-Ras oncogene-driven PanIN 
lesions  
We performed histological examination of the pancreas in mice not exposed to 
doxycycline to allow expression of the Elastase-driven Cre-recombinase from late embryonic 
development (E16.5) (embryonic protocol). One-year-old control ElasK-RasG12Vgeo;Egfr+/+ mice 
(n=12) exhibited abundant low- and high-grade PanIN lesions (average of 6.4 and 2.5 per 
pancreas, respectively) (Figure 12A). In contrast, analysis of serial sections of pancreas from 
one-year-old ElasK-RasG12Vgeo;EgfrLmLD839A/LmLD839A mice (n=14) only revealed the presence of a 
limited number of PanIN lesions in three of the mice. Importantly, analysis of all these lesions 
disclosed incomplete recombination of the EgfrLmLD839A allele (Figure 12B).  These observations 
indicate that Egfr catalytic activity is essential for the induction of PanIN lesions by K-Ras 
oncogene.  
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Figure 12. Induction of PanIN lesions by an endogenous K-Ras oncogene requires Egfr catalytic 
activity. (A) Number of low- and high-grade PanIN lesions and PDAC per mouse in the embryonic 
protocol carrying the indicated alleles. ElasK-RasG12Vgeo;Egfr+/+ (solid circles, n=12) and ElasK-
RasG12Vgeo;EgfrLmLD839A/LmLD839A (open circles, n=14). Horizontal bars indicate the average number of 
lesions per mouse for each genotype. (B) PCR analysis of Egfr alleles from PanIN lesions obtained by 
LCM. Lanes 1, 2 and 3: Egfr+/+ (wt), EgfrLmLD839A/LmLD839A and EgfrD839A/D839A controls, respectively. Lane 
4: DNA extracted from PanIN lesions of ElasK-RasG12Vgeo;EgfrLmLD839A/LmLD839A  mice revealed the 
presence of the unrecombined EgfrLmLD839A allele. Lane 5: blank. Lane M: DNA ladder. Expected 
fragments for each allele are depicted.  
The absence of PanIN lesions in ElasK-RasG12Vgeo;EgfrLmLD839A/LmLD839A  mice could be due 
to a reduction in the number of cells expressing the K-Ras oncogene. However, X-Gal staining 
of pancreatic cryosections of ElasK-RasG12Vgeo;EgfrLmLD839A/LmLD839A mice  demonstrated β-
galactosidase activity (blue staining) in 20-30% of the acinar cells, the same percentage as in 
ElasK-RasG12Vgeo;Egfr+/+ pancreatic sections (Figure 13A). Furthermore, PCR analysis from DNA 
of X-Gal positive cells isolated by LCM, demonstrated complete recombination of EgfrLmLD839A 
allele in acinar cells expressing the K-RasG12Vgeo oncogene (Figure 13B). 
 
 
Figure 13. Acinar cells expressing the K-RasG12Vgeo, identified by β-galactosidase activity, exhibit 
complete recombination of the EgfrLmLD839A allele. (A) Identification of K-RasG12Vgeo expressing acinar 
cells by X-Gal staining (blue spots) in cryosections from pancreas of ElasK-
RasG12Vgeo;EgfrLmLD839A/LmLD839A mice. Scale bar represents 100µm. (B) PCR analysis of Egfr alleles from 
X-Gal positive acinar cells. Lane 1, 2 and 3: Egfr+/+ (wt), EgfrLmLD839A/LmLD839A and EgfrD839A/D839A controls, 
respectively. Lane 4: DNA extracted from X-Gal positive acinar cells of ElasK-
RasG12Vgeo;EgfrLmLD839A/LmLD839A  mice revealed complete recombination of the EgfrLmLD839A allele. Lane 5: 
blank. Lane M: DNA ladder. Expected fragments for each allele are depicted.  
4.1.4.3. Adult mice also require Egfr catalytic activity for PanIN formation 
We exposed ElasK-RasG12Vgeo;Egfr+/+  and ElasK-RasG12Vgeo;EgfrLmLD839A/LmLD839A littermates 
to doxycycline from conception until adulthood (P60) to prevent expression of the Cre-
recombinase. As previously reported (Guerra et al., 2007), in the adult protocol it is necessary 
the cooperation of the pancreatitis for PanIN and PDAC induction. Hence, mice were treated 
with caerulein for 3 months (P90-P180) and pancreas were analyzed at 14 month of age (1 year 
after turning on the expression of the resident K-Ras oncogene). ElasK-
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RasG12Vgeo;EgfrLmLD839A/LmLD839A mice (n=10) revealed complete absence of low- and high grade 
PanIN lesions and PDAC (Figure 14). Only four mice carried PanIN lesions, all of which still 
retained the expression of the Egfr wild type protein (data not shown). As expected, ElasK-
RasG12Vgeo;Egfr+/+  control littermates exhibited multiple lesions (Guerra et al., 2011; Navas et al., 
2012). Egfr wild type mice (n=13) developed low grade PanINs (average of 17 per pancreas) 
and more than 90% (12 out of 13) of displayed high-grade PanINs (average of 13 per 
pancreas), only one mouse developed PDAC.  
The expression of a catalytic inactive form of Egfr blocked tumor initiation in the adult 
and in the embryonic protocol. Therefore, the inhibition of Egfr tyrosine kinase activity 
recapitulates the results of the Egfr conditional knockout (Navas et al., 2012). 
 
Figure 14. Induction of PanIN lesions by an endogenous K-RasG12Vgeo oncogene requires Egfr 
catalytic activity in the adult protocol. Number of low- and high-grade PanIN lesions and PDAC per 
mouse in 14-month-old ElasK-RasG12Vgeo mice carrying the indicated alleles. ElasK-RasG12Vgeo;Egfr+/+ 
(solid circles, n=13) and ElasK-RasG12Vgeo;EgfrLmLD839A/LmLD839A (open circles, n=10). These mice were 
exposed to doxycycline from conception until P60. At that time, Cre-recombinase leads the concomitant 
expression of the resident K-RasG12Vgeo oncogene and the catalytic inactive form of Egfr in acinar cells. 
Mice were treated with caerulein from P90 to P180. Horizontal bars indicate the average number of 
lesions per mouse for each genotype.  
4.1.5. Lack of Egfr kinase activity blocks PDAC tumor initiation in a 
p16Ink4a/p19Arf deficient background 
In addition to K-RAS mutations, most human PanINs and PDAC display inactivation of 
the p16INK4a/p14ARF locus (Wood and Hruban, 2012). In mice, it has been described that 
loss of p16Ink4a/p19Arf in combination with the expression of the mutated K-Ras oncogene 
results in an earlier appearance of PanIN lesions that rapidly progress to highly invasive and 
metastatic PDAC (Aguirre et al., 2003; Guerra et al., 2011). These studies indicate that loss of 
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p16Ink4a/p19Arf contributes to pancreatic cancer in mice.  
Conditional floxed p16Ink4a/p19Arf alleles were introduced into ElasK-RasG12Vgeo mice 
carrying either wild type or Egfr LmLD839A alleles. Mice were allowed to age and were sacrificed 
at humane end point or at 1 year of age. These mice were not exposed to doxycycline to allow 
for the expression of the resident K-RasG12Vgeo oncogene during late embryonic development 
(E16.5, embryonic protocol). Littermates carrying wild type Egfr alleles in homozygosis (n=7) or 
heterozygosis (n=10) succumbed to the disease (Figure 15A). All mice displayed PDAC, which 
occasionally metastasized to several organs. In contrast, ElasKRasG12Vgeo;EgfrLmLD839A/LmLD839A 
mice (n=7) were alive at 1 year of age, time at which they were sacrificed and their pancreas 
analyzed. Interestingly, the few PanIN lesions detected still expressed the wild type receptor 
from the EgfrLmLD839A allele (Figure 15B). These observations indicate that upon inactivation of 
p16Ink4a/p19Arf alleles, K-Ras mutant acinar cells still need Egfr catalytic activity for PDAC 
initiation, similar to the results obtained with the Egfr conditional knockout (Navas et al., 2012). 
 
 
 
Figure 15. Loss of p16Ink4a/p19Arf tumor suppressors does not abrogate the need of Egfr 
catalytic activity for PanIN/PDAC initiation. (A) Survival curve of dox-untreated ElasK-RasG12Vgeo; 
p16Ink4a/p19ArfLox/Lox;Egfr+/+ (solid circles, n=7) mice, ElasK-RasG12Vgeo; p16Ink4a/p19ArfLox/Lox; 
Egfr+/LmLD839A mice (grey circles, n=10) and ElasK-RasG12Vgeo; p16Ink4a/p19ArfLox/Lox;EgfrLmLD839A/LmLD839A 
mice (open circles, n=7). (B) PCR analysis of Egfr alleles from PanIN lesions isolated by LCM. Lanes 1, 2 
and 3: Egfr+/+ (wt), EgfrLmLD839A/LmLD839A and EgfrD839A/D839A controls, respectively. Lane 4: DNA extracted 
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from PanIN lesions of ElasK-RasG12Vgeo;p16Ink4a/p19ArfLox/Lox;EgfrLmLD839A/LmLD839A  mice revealed the 
presence of the unrecombined floxed allele. Lane 5: blank. Lane M: DNA ladder. Expected fragments for 
each allele are depicted.  
4.1.6. Lack of Egfr kinase activity does not impair tumor initiation in a p53 deficient 
background. 
Most PDAC tumors are associated with mutations in tumor suppressor genes including 
CKDN2A, TP53 (Ruggeri et al., 1992; Scarpa et al., 1993) and SMAD4 (Hahn et al., 1996). 
Mutations in TP53 and SMAD4 are often associated with progression of PanIN-3 lesions to 
invasive PDAC tumors (Guerra and Barbacid, 2013). In GEMMs, addition of mutations in p53 
accelerates the progression of PanIN lesions towards invasive PDAC that results in reduced 
survival (Guerra et al., 2007; Hingorani et al., 2005).  
In order to study the effect of inhibiting Egfr kinase activity in the absence of p53, we 
introduced the p53Lox/Lox   alleles in the ElasK-RasG12Vgeo strain in the presence of the wild type 
or the inactive form of Egfr.  
Ten weeks-old dox-untreated mice (before mice show signs of over tumor development) 
carrying Egfr+/+ alleles (n=10) displayed abundant low- and high-grade PanIN lesions and PDAC 
(average of 9 high-grade PanINs and 4 PDAC per mouse). Interestingly, mice carrying 
conditional Egfr kinase dead alleles (n=9) also displayed neoplastic lesions but with 
significantly reduced incidence (average of 2 high-grade lesions and 0.2 PDAC per mouse) 
(Figure 16A). This observed difference in tumor development affected survival. When we 
allowed these mice to age, animals carrying Egfr+/+ alleles (n=7) displayed an average survival 
of 17 weeks of age, similar to heterozygous mice (n=10). Nonetheless, mice carrying 
conditional EgfrLmLD839A/LmLD839A alleles (n=7) display an average survival of 24 weeks of age. 
Thus, impaired Egfr catalytic activity promotes a significant 41% increase in survival (17 versus 
24 weeks) (Figure 16B). Tumor development was not due to incomplete recombination of 
EgfrLmLD839A alleles, since all tumors analyzed by PCR expressed the inactive form of Egfr 
(Figure 16C). Similar results were previously described with the Egfr conditional knockout, 
although the increase of median survival was slightly higher (Navas et al., 2012). 
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Figure 16. Inhibition of Egfr catalytic activity delays but does not prevent PanIN and PDAC 
initiation in the absence of p53 tumor suppressor gene during the embryonic protocol.  (A) Number of 
low- and high-grade PanIN lesions and PDACs per mouse in dox-untreated 10 weeks–old ElasK-
RasG12Vgeo;p53Lox/Lox;Egfr+/+ (solid circles, n=10) mice, and ElasK-
RasG12Vgeo;p53Lox/Lox;EgfrLmLD839A/LmLD839A (open circles, n=9) mice. In these mice, expression of the Cre-
recombinase in pancreatic acinar cells during late embryonic development results in the concomitant 
expression of the endogenous K-RasG12Vgeo and the inactive form of Egfr, together with the ablation of 
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p53 conditional alleles. Horizontal bars indicate the average number of lesions per mouse for each 
genotype. *p<0.05, **p<0.01 are indicated. (B) Survival of dox-untreated ElasK-
RasG12Vgeo;p53Lox/Lox;Egfr+/+ (solid circles, n=7) mice, ElasK-RasG12Vgeo;p53Lox/Lox;Egfr+/LmLD839A (grey 
circles, n=10) mice and ElasK-RasG12Vgeo;p53Lox/Lox;EgfrLmLD839A/LmLD839A   (open circles, n=7) mice. 
*p<0.05 is indicated. (C) PCR analysis of Egfr alleles from PDAC-derived cell explants. Lanes 1, 2 and 3: 
Egfr+/+ (wt), EgfrLmLD839A/LmLD839A and EgfrD839A/D839A controls respectively. Lanes 4, 5, 6: DNA extracted 
from three different PDAC-derived cell explants obtained from ElasK-
RasG12Vgeo;p53Lox/Lox;EgfrLmLD839A/LmLD839A  mice revealed complete recombination of the EgfrLmLD839A 
allele. Lane 7: blank. Lane M: DNA ladder. Expected fragments for each allele are depicted.  
A similar approach was followed with mice expressing the resident K-RasG12Vgeo 
oncogene during adulthood. These mice were treated with doxycycline and later treated with 
caerulein for 3 months. Whereas in the embryonic protocol there is a significant increase in 
survival in mice expressing Egfr kinase dead alleles, in the adult protocol, ElasK-
RasG12Vgeo;p53Lox/Lox; EgfrLmLD839A/LmLD839A   (open circles, n=14) mice died with a median survival 
of 40 weeks, and control ElasK-RasG12Vgeo;p53Lox/Lox;Egfr+/+ (solid circles, n=7) mice died with a 
median survival of 36 weeks. As illustrated in the survival curve in figure 17, lack of Egfr kinase 
activity neither impaired nor delayed tumor development. Mice died after 45 to 50 weeks 
irrespective of the Egfr genotype. In contrast, ablation of Egfr resulted in an increased survival 
time of 40% (Navas et al., 2012). As previously observed in the embryonic protocol, tumors 
expressed the inactive form of Egfr when analyzed by PCR (data not shown). Consequently, 
inhibition of the Egfr catalytic activity did not impair or delay PDAC formation during adulthood 
in p53 deficient tumors.   
Together, these results indicate that loss of p53 triggers oncogenic pathways that 
bypass the requirement of Egfr signaling for tumor initiation. 
 
Figure 17. Inhibition of Egfr catalytic activity during adulthood did not impair PDAC tumor 
formation in the absence of p53. Survival of ElasK-RasG12Vgeo;p53Lox/Lox;Egfr+/+ (solid circles, n=7) mice, 
ElasK-RasG12Vgeo;p53Lox/Lox;Egfr+/LmLD839A (grey circles, n=9) mice and ElasK-RasG12Vgeo; 
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p53Lox/Lox;EgfrLmLD839A/LmLD839A   (open circles, n=14) mice. Mice were exposed to doxycycline from 
conception until P60. At that time, Cre-recombinase leads the concomitant expression of the resident K-
RasG12Vgeo oncogene, the catalytic inactive form of Egfr and the ablation of p53 conditional alleles. Mice 
were treated with caerulein from P90 to P180. There are not statistically significant differences. 
4.1.6.1. ErbB2 is responsible of EgfrD839A phosphorylation and MAPK signaling 
activation in a p53 deficient background 
Egfr is responsible for the activation of some of the pathways that have been shown to 
be important in pancreas tumorigenesis, including PI3K and MAPK. Unexpectedly, ElasK-
RasG12Vgeo;p53−/−;EgfrD839A/D839A PDAC cell explants exhibited phosphorylation of the inactive 
receptor and consequently, activation of downstream signaling cascades (Figure 18A). To 
asses whether other members of the ErbB family were compensating the lack of Egfr tyrosine 
kinase activity, we knocked down ErbB2 with a specific shRNA in ElasK-
RasG12Vgeo;p53−/−;Egfr+/+  and ElasK-RasG12Vgeo;p53−/−;EgfrD839A/D839A PDAC cell explants. As 
illustrated in figure 18B, knockdown of ErbB2 led to substantial inhibition of EgfrD839A 
phosphorylation together with inhibition of MAPK signaling pathway (as shown by reduced 
levels of Erk1/2 phosphorylation), whereas these effects were not observed in cells expressing 
the wild type form of Egfr. However, the effect of ErbB2 knockdown in the PI3K pathway was 
inconclusive, since phosphorylation of Akt was only reduced in two out of three cell explants 
analyzed.  
 
 
Figure 18. ErbB2 triggers Egfr kinase dead phosphorylation and activation of downstream 
signaling pathways. (A) Western blot analysis of Egfr, Erk1/2 and Akt phosphorylated proteins in ElasK-
RasG12Vgeo;p53−/−;Egfr+/+ (n=3) and ElasK-RasG12Vgeo;p53−/−;EgfrD839A/D839A (n=3) PDAC-derived cell 
explants. Gapdh expression served as loading control. Arrowheads show migration of the indicated 
proteins. (B) ElasK-RasG12Vgeo;p53−/−;Egfr+/+ (n=3, representative Western blot from one explant is shown) 
and ElasK-RasG12Vgeo;p53−/−;EgfrD839A/D839A PDAC cell explants (n=3) were infected with lentiviral particles 
expressing either a shRNA against ErbB2 (+) or a control shRNA (–). Phosphorylation levels of Egfr, 
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Erk1/2 and Akt proteins and total ErbB2 expression were analyzed by Western blot. Gapdh expression 
served as loading control. Arrowheads show migration of the indicated proteins.  
4.2. Analyzing the potential therapeutic benefit of targeting Egfr and c-Raf in 
established PDAC 
It is known that EGFR, and all ErbB family members, are capable of activating the 
RAS/MAPK and PI3K pathways (Jorissen et al., 2003), which are essential in cell cycle 
regulation, differentiation and proliferation and are commonly deregulated in cancer 
(Malumbres and Barbacid, 2003). However, as previously shown in this thesis, Egfr inhibition is 
not sufficient to block PDAC tumorigenesis and it should be used in cooperation with targets 
affecting other signaling pathways to induce better responses.  
Moreover, these and previous results were obtained using our initiation PDAC mouse 
model, in which ablation or inhibition of the target of interest was concomitant with K-RasG12V 
expression and p53 deletion. Consequently, these results only disclose the effects of selected 
targets during the first stages of tumorigenesis, thus they should be considered as only 
preventative strategies rather than therapeutic. For this reason, we decided to develop a new 
PDAC mouse model to assess the therapeutic value of Egfr and its combination with c-Raf in 
already established PDAC. 
4.2.1. Generation of the PDAC therapeutic strain 
To address the therapeutic value of the Egfr deletion/inhibition and its combination with 
other targets of interest in full-blown tumors, we developed a PDAC mouse model in which we 
can separate, spatially and temporally, tumor induction from target ablation/inactivation using 
two independent recombinases. Development of PDAC was initiated by the Flp/Frt 
recombinase system, whereas the Cre/LoxP system was used to ablate the potential 
therapeutic targets to be validated.  
In collaboration with the Transgenic Mice Core Unit at CNIO we generated the tetO-Flp 
transgenic strain, which in combination with the Elas-tTA strain (Elas-tTA/tetO-Flp), allows the 
expression of the yeast Flp-recombinase in cells expressing the Elastase promoter under the 
negative control of doxycycline (Tet-off system). Additionally, we took advantage of the K-
Ras+/FSFG12V mice (Drosten et al., unpublished) and p53Frt/Frt mice (Lee et al., 2012), in which the 
expression of the K-Ras mutation and the deletion of p53 takes place upon Flp-mediated 
recombination of Frt sites. By crossing the K-RasFSFG12V;p53Frt/Frt strain with the Elas-tTA/tetO-
Flp we allowed for concomitant expression of the K-RasG12V oncogene and p53 deletion in 
acinar cells during late embryonic development (E16.5). The resulting strain, Elas-tTA/tetO-
Flp;K-RasFSFG12V;p53Frt/Frt developed PDAC tumors with complete penetrance and similar 
latencies to those observed in Elas-tTA/tetO-Cre;K-RasLSLG12Vgeo;p53Lox/Lox mice (data not 
shown).  
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Besides, the modified Cre-recombinase (CreERT2) was introduced as a transgene 
(Tg.hUBC-CreERT2+/T) together with floxed target alleles. The CreERT2 recombinase is 
ubiquitously expressed under the human Ubiquitin C promoter (Ruzankina et al., 2007). 
Exposure of the resulting tumor-bearing mice (as determined by non-invasive ultrasound 
techniques) to a tamoxifen-containing diet resulted in the translocation of the CreERT2 enzyme 
into the nucleus and in the systemic deletion/inactivation of floxed alleles. This approach 
allowed us to assess both the therapeutic efficacy of ablation/inactivation of target genes in 
already established PDAC tumors, and the systemic toxicity associated to the lack or inhibition 
of studied proteins in the whole body (Figure 19). 
 
Figure 19. Timeline for the therapeutic approach. The expression of the resident K-RasG12V and the 
ablation of the p53 tumor suppressor started at E16.5 by the Flp-recombinase in the absence of 
doxycycline (Tet-off system). The screening by ultrasound techniques started at 12 weeks of age. Positive 
PDAC animals were exposed to a tamoxifen-containing diet, which resulted in the ubiquitous activation of 
the Cre-recombinase and as a result, deletion/inactivation of floxed targets genes. Once the tumor was 
detected, tumor size was assessed by ultrasound weekly.  
4.2.2. Egfr elimination or inactivation does not affect PDAC progression in vivo 
With the purpose of investigating the role of Egfr in tumor progression, we introduced 
EgfrLox (to eliminate Egfr) and EgfrLmLD839A  (to inhibit Egfr tyrosine kinase activity) alleles in our 
PDAC therapeutic strain.  
Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;Tg.hUBC-CreERT2+/T control mice (10 
mice/15 tumors), Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;Tg.hUBC-CreERT2+/T mice 
(6 mice/8 tumors) and Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLmLD839A/LmLD839A; Tg.hUBC-
CreERT2+/T mice (8 mice/22 tumors) were monitored by ultrasound in order to detect 
established pancreatic tumors. Mice with established and comparable PDAC were subjected 
to tamoxifen treatment and tumor progression was monitored weekly. Unfortunately, neither 
deletion nor inhibition of Egfr affects tumor growth or survival. As a consequence, tumor 
volume fold change did not decrease in tumors lacking Egfr or its kinase activity in comparison 
with control tumors (Figure 20A, B). 
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Figure 20. Egfr elimination or inhibition of its catalytic activity does not impair PDAC progression. 
Tumor volume fold change of tumors from Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;Tg.hUBC-
CreERT2+/T mice (10 mice/15 tumors, solid circles), Elas-tTA/tetO-Flp;K-
RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;Tg.hUBC-CreERT2+/T mice (6 mice/8 tumors, open squares) and Elas-
tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLmLD839A/LmLD839A;Tg.hUBC-CreERT2+/T mice (8 mice/22 tumors, 
open triangles). Changes in tumor volume were calculated for each individual tumor based on ultrasound 
scans performed at the beginning and at the end of tamoxifen treatment. Horizontal bars indicate the 
average tumor fold change. There are not statistically significant differences.  
4.2.3. Combined deletion of Egfr and c-Raf as a multi-targeted therapy against 
PDAC  
Our laboratory has previously shown that c-Raf is essential for initiation (Blasco et al., 
2011) and progression (unpublished data) of K-RasG12V driven lung adenocarcinoma. Moreover, 
we determined that c-Raf was also essential for PanIN and PDAC initiation in a p53 proficient 
background (unpublished results, see appendix 8.1). 
Unfortunately, in a p53 deficient background, ablation of either Egfr (Navas et al., 2012) 
or c-Raf (unpublished results, see appendix 8.1), as well as expression of an Egfr kinase dead 
isoform, delays but does not prevent tumor appearance in PDAC mouse models. These 
already validated targets can be used in combination leading to the identification of therapeutic 
strategies that could be uncovered for future clinical trials. Accordingly to these observations, 
our laboratory demonstrated that, in the absence of p53, concomitant ablation of Egfr and c-
Raf target genes completely blocked PDAC initiation (unpublished results, see appendix 8.2).  
These results obtained by simultaneous deletion of Egfr and c-Raf in our initiation PDAC 
mouse model were surprising and promising. However, Egfr and c-Raf were deleted at the 
initiation stages and not in already established tumors. Consequently, this approach interferes 
in the first stages of tumorigenesis and do not reveal the therapeutic value of a genetic target. 
For this reason, we decided to assess the efficacy of Egfr and c-Raf deletion in already 
established PDAC tumors. Hence, we introduced EgfrLox together with c-RafLox alleles in our 
PDAC therapeutic strain, generating the Elas-tTA/tetO-Flp;K-RasFSFG12V; p53Frt/Frt;EgfrLox/Lox;c-
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RafLox/Lox;Tg.hUBC-CreERT2+/T final genotype.  
4.2.3.1. Combined elimination of Egfr and c-Raf affects proliferation of PDAC 
cell explants in vitro 
We took advantage of PDAC cell explants derived from Elas-tTA/tetO-Flp;K-RasFSFG12V; 
p53Frt/Frt;Egfr+/+;c-Raf+/+ mice (n=3) and Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-
RafLox/Lox mice (n=3) which were subjected to a colony formation assay. Clones were seeded at 
equal densities and infected with adenovirus particles expressing GFP-Cre at a MOI of 100. 
Cells were seeded 5 days post-infection to assess their colony formation capability.  
Simultaneous elimination of Egfr and c-Raf target genes induced arrest in proliferation, 
as illustrated by a decrease in the number of established colonies, in two out of three studied 
cell lines. Importantly, there was one cell line that continued growing after the genetic ablation 
of the targets (Figure 21A, B). Of note, expression of both Egfr and c-Raf was undetectable by 
Western blot, confirming complete recombination of floxed alleles since expression of both 
Egfr and c-Raf was undetectable by Western blot (Figure 21C). Characterization of these 
resistant PDAC cell explants is currently ongoing. We are performing RNA-seq analysis, 
phospho-receptor tyrosine kinase arrays and drug screenings in order to identify signaling 
pathways involved in this response. 
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Figure 21. Elimination of Egfr and c-Raf causes changes in proliferation of PDAC-derived cell lines. 
(A) Representative plates from colony formation assays. Elas-tTA/tetO-Flp;K-RasFSFG12V; 
p53Frt/Frt;Egfr+/+;c-Raf+/+ PDAC-derived cell lines (used as controls; numbers 1, 2 and 3) and Elas-
tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox PDAC-derived cell lines (numbers 4, 5 and 6)  
were infected with Adeno-CreGFP particles. After 5 days, they were seeded at equal densities and 
allowed to form colonies for 12 days. Cells were fixed with glutaraldehyde and stained with crystal violet. 
(B) Quantification of the number of colonies that grew 12 days after the Adeno-CreGFP infection. (C) 
Western blot analysis of Egfr and c-Raf protein expression in whole cell extracts obtained from colonies 
that grew after Adeno-CreGFP infection. All colonies growing from Elas-tTA/tetO-Flp;K-
RasG12V;p53−/−;Egfr−/−;c-Raf−/− did not express the targets of interest. Gapdh expression served as a 
loading control. Arrowheads show migration of the indicated proteins.  
4.2.3.2. In vivo concomitant deletion of Egfr and c-Raf alleles results in a 
positive outcome in established pancreatic tumors  
In order to investigate Egfr and c-Raf genes as potential therapeutic targets we decided 
to delete simultaneously both alleles in already established tumors. With this aim, we 
generated Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T and 
Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T strains. We 
monitored PDAC formation by high-resolution ultrasound starting at 12 weeks of age. Mice 
with established tumors of comparable size (tumor larger than 2 mm in diameter) were enrolled 
and fed ad libitum with a tamoxifen-containing diet activating the Cre-recombinase and 
therefore deleting systemically Egfr and c-Raf floxed alleles. To investigate whether tamoxifen 
or activation of CreERT2 itself affects PDAC growth, control (Elas-tTA/tetO-Flp;K-RasFSFG12V; 
p53Frt/Frt;Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T) mice were also subjected to tamoxifen 
treatment.   
Deletion of floxed Egfr and c-Raf alleles was efficient. In fact, we confirmed by Western 
blot that Egfr and c-Raf proteins were not expressed in several tissues of Elas-tTA/tetO-Flp;K-
RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice after 3 weeks of tamoxifen 
treatment (Figure 22). 
 
Figure 22. Systemic ablation of Egfr and c-Raf alleles is effective in mice exposed to a tamoxifen 
diet. Representative Western blot analysis of Egfr and c-Raf protein levels in tissues obtained from Elas-
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tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T and Elas-tTA/tetO-Flp;K-
RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice treated with tamoxifen for 3 weeks. 
Gapdh expression served as a loading control. Arrowheads show migration of the indicated proteins.  
Combined ablation of Egfr and c-Raf in established pancreatic tumors impaired tumor 
growth as revealed by significant differences in tumor volume fold change at time of necropsy. 
Tumor volume fold change was 4.99 in Egfr and c-Raf deleted tumors (9 mice/10 tumors) 
whereas in wild type tumors corresponded to 24.09 (10 mice/15 tumors) (Figure 23A). Tumors 
in Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T control mice (10 
mice/15 tumors) increased in size during the period under tamoxifen treatment (Figure 23A, B, 
C, D). In contrast, about 60% of tumors in Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-
RafLox/Lox;Tg.hUBC-CreERT2+/T mice (9 mice/10 tumors) either partially regressed (1 out of 10) 
or completely disappeared (5 out of 10) (Figure 23A, B, C, F). Furthermore, the majority of the 
tumors that progressed (4 out of 10) grew less than the control cohort (Figure 23A, C, E). 
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Figure 23. Egfr and c-Raf are essential for PDAC progression. (A) Tumor volume fold change of 
tumors from Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T mice (10 
mice/15 tumors, solid circles) and from Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-
RafLox/Lox;Tg.hUBC-CreERT2+/T mice (9 mice/10 tumors, open circles). Changes in tumor volume were 
calculated for each individual tumor based on ultrasound scans performed at the beginning and at the 
time of necropsy. *p<0.05 is indicated. (B) Tumor growth was monitored by high-resolution ultrasound in 
Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T and in Elas-
tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T control mice. Pictures show 
tumor growth at day 0 and 3 weeks after treatment with tamoxifen (+TAM). Visible lesions are outlined in 
white. Tumor volumes are indicated. (C) Waterfall plot representing the percentage of change in tumor 
volume of individual PDACs detected by ultrasound in Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;c-
Raf+/+;Tg.hUBC-CreERT2+/T mice (10 mice/15 tumors, solid bars) and Elas-tTA/tetO-Flp;K-
RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice (9 mice/10 tumors, open bars). 
Changes in tumor volume were calculated for each individual tumor based on ultrasound scans 
performed at the beginning and at the time of necropsy. (D) Quantification of tumor volume in tamoxifen-
treated Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T control mice (n=10 
mice, n=15 tumors). Each color represents a different mouse. (E) Quantification of tumor volume in 
tamoxifen-treated Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T 
mice (n= 4 mice, n=4 tumors) which harbored tumors that progressed upon target ablation. Each color 
represents a different mouse.  (F) Quantification of tumor volume in tamoxifen-treated Elas-tTA/tetO-
Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice (n= 5 mice, n=6 tumors) that 
responded to target elimination. We could appreciate how tumors regressed or even disappeared. Each 
color represents a different mouse. T1-T8 represents different tumors.  
As illustrated in Figure 24A, expression of both Egfr and c-Raf proteins were completely 
absent in tumor tissue after tamoxifen treatment. Remarkably, those tumors that progressed 
upon target elimination retained normal levels of phospho-Erk1/2 and phospho-Akt, 
suggesting that other signaling pathways compensated the absence of Egfr and c-Raf to 
sustain proliferation during tumor progression (Figure 24A, tumors T4, T5 and T6). Moreover, 
the histopathological analysis revealed that these tumors (T4, T5), as well as tumors that 
regressed (T7, T8), still expressed PDAC markers, such as the ductal marker CK19 (Figure 
24B). 
These facts suggest that targeting Egfr and c-Raf simultaneously impairs progression in 
about 60% of established PDACs. Nevertheless, there are tumors that can progress upon 
target elimination, suggesting the presence of tumor heterogeneity and the contribution of 
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alternative signaling pathways. It remains to be determined which other cascades are relevant 
for the maintenance of these tumor cells.  
 
 
 
Figure 24. Tumors lacking Egfr and c-Raf expression still show CK-19 positive cells and active 
downstream signaling pathways. (A) Western blot analysis of Egfr and c-Raf expression in PDAC lysates 
derived from Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T control mice 
(n=3, T1, T2 and T3) and Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-
CreERT2+/T (n=3, T4, T5 and T6) mice treated with tamoxifen. Phosphorylation levels of Erk1/2 and Akt 
were analyzed. Gapdh expression served as a loading control. Arrowheads show migration of the 
indicated proteins. (B) H&E and CK19 staining of PDAC sections from tumors of the indicated genotypes 
sacrificed at humane end point. Scale bar represents 100µm. T1-T8 represents different tumors (see 
figure XD, XE, XF).  
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4.2.3.3. Toxicity and side effects derived from systemic ablation of Egfr and c-
Raf  
One of the greatest challenges in oncology is to develop therapeutic strategies that 
diminish oncogenic signaling without affecting normal homeostasis. Importantly, due to the 
fact that human Ubiquitin C promoter led to the ubiquitous expression of the Cre-recombinase, 
Egfr and c-Raf were deleted systemically. Therefore, this approach also allowed us to evaluate 
the possible side effects associated with the combined treatment of Egfr and c-Raf inhibitors. 
However, observations derived from these genetic approaches need to be taken into 
consideration when targeting Egfr and c-Raf in the clinic, since pharmacologic therapeutic 
strategies are unlikely to result in irreversible loss of Egfr and c-Raf expression.  
In order to study the possible side effects of combined elimination of the targets, 
Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T and EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice were 
continuously fed with a tamoxifen-containing diet starting at 12 weeks of age. As illustrated in 
Figure XA, mice carrying Egfr and c-Raf floxed alleles lost weight at the beginning of the 
treatment to thereafter maintain it constant or almost recover it. A similar effect was observed 
in control mice (Figure 25A). However, EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice 
developed skin alterations (mostly associated with loss of Egfr expression, given that the same 
defects were observed in mice only lacking Egfr protein whereas these alterations were not 
present in mice with deletion of c-Raf). Mice exhibited hyperplasia and disorganization in the 
epidermis, hyperkeratosis, folliculitis, and inflammation with an increased number in mast cells 
(confirmed with toluidine-blue staining), apart from ulcers and scabs (Figure 25B, C).  
Approximately 50-100% patients treated with EGFR inhibitors develop acneiform rash 
and folliculitis (Owczarczyk-Saczonek et al., 2013), indicating that the defects observed in mice 
could be comparable with those observed in treated patients. Tamoxifen-treated mice also 
showed slight disorganization in the crypts of the small intestine with an increased number of 
apoptotic cells (confirmed by cleaved Caspase-3 immunohistoquemistry), but despite these 
alterations, the intestine maintained its architecture and functionality (Figure 25D). Apart from 
these alterations, mice survived without major health problems for several months. 
Nevertheless, mainly due to the described skin alterations, the first Elas-tTA/tetO-Flp;K-
RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice enrolled in the therapeutic 
studies were prematurely sacrificed. No defects incompatible with life were observed after 
histopathological examination. In fact, we have maintained mice for at least 17-18 weeks under 
tamoxifen treatment. We are currently trying to increase the number of mice and to prolong 
their time under tamoxifen treatment to deeply investigate tumor behavior. 
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Figure 25. Body weight, skin and intestinal defects associated with concomitant Egfr and c-Raf 
deletion. (A) Representation of the percentage of change in body weight in Egfr+/+;c-Raf+/+;Tg.hUBC-
CreERT2+/T (n=4) and EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice (n=4) exposed to tamoxifen. Body 
weight was weekly recorded. (B) Aspect of EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T mice and 
macroscopic skin defects that have been observed after 18 weeks of treatment with tamoxifen diet. (C) 
Representative H&E and Toluidine-blue staining in skin sections of Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T 
and EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T tamoxifen-treated mice. Scale bar represents 100µm 
(H&E) and 50µm (toluidine-blue). (D) Representative H&E and cleaved Caspase-3 staining in intestine 
sections of Egfr+/+;c-Raf+/+;Tg.hUBC-CreERT2+/T and EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T 
tamoxifen-treated mice. Scale bar represents 100µm. 
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Despite its low incidence, PDAC is one of the deadliest carcinomas due to the lack of 
effective treatments available. Furthermore, the first stages of tumor development are 
asymptomatic and diagnosis almost always occurs at late stages with a high incidence of 
metastasis. The development of GEMMs that closely recapitulate the natural history of human 
disease could help scientists design and validate newer and better therapeutic strategies.  
The most frequent genetic alteration in PDAC is an activating mutation in the K-RAS 
oncogene (Almoguera et al., 1988; Biankin et al., 2012). Several strategies to target K-RAS 
directly have been developed. However, these targeted therapies have been inefficient, in part 
because K-RAS itself has remained difficult to inhibit with small molecules. Hence, attempts to 
target this oncogene in the clinic have focused on the inhibition of upstream and downstream 
molecules of RAS signaling pathway.  
PDAC GEMMs that recapitulate the human disease have been developed to evaluate the 
therapeutic value of different targets and pathways. Using PDAC mouse models it was shown 
that Egfr has a key role in pancreas tumorigenesis impairing tumor initiation (Ardito et al., 2012; 
Navas et al., 2012). Nevertheless, genetic ablation cannot be achieved in the clinic and this 
could explain why EGFR therapeutics have only been partially successful (Moore et al., 2007). 
Moreover, pancreatic tumorigenesis involves several mutations affecting different pathways 
(Jones et al., 2008), thus EGFR inhibition in advanced PDAC patients will not be sufficient and 
it should be combined with drugs targeting different pathways with an important role in PDAC 
progression and maintenance.  
Along with this, it was recently demonstrated that the RAF/MEK/ERK pathway has a key 
role in K-Ras driven NSCLC and PDAC. Previous studies from our laboratory have illustrated 
that c-Raf is essential for lung (Blasco et al., 2011) and pancreas tumor initiation (unpublished, 
see appendix 8.1) without affecting normal homeostasis, suggesting that it is a suitable target 
to block the MAPK pathway. Interestingly, combined elimination of Egfr and c-Raf entirely 
blocks PDAC initiation in a p53 deficient context (unpublished, see appendix 8.2). 
Considering these results, the main aim of the current thesis was to investigate the 
potential therapeutic benefit of inhibiting Egfr and its combination with c-Raf as a multi-
targeted therapy in the context of K-Ras driven PDAC.  
5.1. Validation of Egfr tyrosine kinase inhibition in K-Ras driven PDAC 
5.1.1. Generation of a conditional Egfr kinase dead allele 
 In order to study the inhibition of Egfr tyrosine kinase activity in pancreatic 
tumorigenesis and to elucidate whether the benefit previously described (Ardito et al., 2012; 
Navas et al., 2012) relied on Egfr catalytic activity, we designed a mouse model that expressed 
a catalytic inactive form of the receptor (EgfrD839A) to mimic the effect of efficient and selective 
Egfr inhibitors.  
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As previously reported in this thesis, there are two Egfr mutant alleles that result in 
reduced signaling of the receptor, the recessive hypomorphic Egfrwa2 (Fowler et al., 1995; 
Luetteke et al., 1994) and the dominant antimorphic Egfrwa5  (Du et al., 2004; Lee et al., 2004). 
The Egfrwa2 allele is a spontaneously arising point mutation causing a V743G substitution in the 
ATP binding motif of the tyrosine kinase domain, presumably altering the structure of the active 
site. The mutated receptor has an 80-95% reduction in Egfr activity (Luetteke et al., 1994). 
Homozygous Egfrwa2 mice are viable and healthy, however females develop impaired maternal 
lactation (Fowler et al., 1995).  The Egfrwa5 strain was developed using N-Ethyl-N-Nitrosourea 
(ENU) mutagenesis. The ENU treatment induced an adenine to guanine transition leading to an 
amino acid change from Aspartic acid to Glycine (D833G). This mutation results in an alteration 
in the DFG domain of the Egfr catalytic loop, which plays a role in chelating Mg2+ and 
stabilizing ATP binding, encoding a completely inactive form of the receptor since no 
phosphorylation of Egfrwa5 is detected following stimulation with ligands. Egfrwa5 homozygous 
mice die during gestation with phenotypes indistinguishable to those observed in Egfr 
knockout mice (Du et al., 2004; Lee et al., 2004).  
In our EgfrD839A mice, an Alanine replaces the Aspartic acid of the HRD domain (D839A), 
which acts as a proton acceptor that is critical for catalysis. Constitutive homozygous 
expression of EgfrD839A resulted in embryonic lethality, reproducing the defects developed by 
the Egfr knockout and Egfrwa5 homozygous mice, illustrating that Egfr catalytic activity is 
essential for mouse embryo development. EgfrD839A protein stability was verified by Western 
blot and the phosphorylation assay revealed that EgfrD839A catalytic activity was impaired. 
Therefore, we can affirm that EgfrD839A protein lacked kinase activity without being affected in 
terms of protein expression or stability. Moreover, EgfrD839A MEFs showed impaired 
proliferation and they could not stimulate MAPK and PI3K signaling pathways in the presence 
of its ligands. Both cascades are essential for cell proliferation, survival and migration and 
consequently for mouse development.  
We generated an EgfrLmLD839A conditional allele that encodes an inducible catalytic 
inactive receptor upon Cre-mediated recombination. Using this conditional knockin approach 
we avoided the embryonic lethality associated with this mutation and we were able of 
exploring its role in tumor initiation and progression.    
5.1.2. Egfr kinase activity in K-RasG12V driven PDAC initiation 
5.1.2.1. Egfr catalytic activity is essential for PDAC initiation  
As previously reported, Egfr is expressed in pancreatic lesions and tumors, in mouse 
and human samples (Navas et al., 2012). Additionally, the presence of Egfr is essential for ADM 
in vitro and for PDAC development in vivo (Ardito et al., 2012; Navas et al., 2012). In order to 
investigate whether the therapeutic benefit observed upon Egfr ablation in K-RasG12V driven 
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PDAC relied on Egfr catalytic activity or on its kinase independent functions, we introduced the 
EgfrLmLD839A conditional strain in our PDAC initiation mouse model.   
In the embryonic protocol, the absence of pancreatic lesions in ElasK-
RasG12Vgeo;EgfrLmLD839A/LmLD839A mice suggests that the inhibition of Egfr catalytic activity 
concomitantly with K-RasG12Vgeo expression is impairing pancreatic tumorigenesis. 
Furthermore, we confirmed that upon K-RasG12Vgeo expression, Egfr signaling plays an 
important role in ADM, a key event for PanIN and PDAC initiation. It was previously shown that 
ADM is largely dependent on activation of Egfr considering that addition of its ligands, such as 
EGF and TGFα, highly increased the number of metaplasias (Means et al., 2005). As 
consequence, this process was significantly reduced in the absence of Egfr (Navas et al., 
2012). Upon expression of a catalytic inactive Egfr, ADM was significantly reduced but not 
completely blocked, suggesting that the generation of ductal-like structures requires Egfr 
signaling in the presence of K-RasG12V, but also that EGF and TGFα may contribute to ADM by 
activating additional signaling pathways, at least in vitro.  
Nevertheless, since PDAC is not a pediatric disease we studied the role of Egfr kinase 
activity during the adulthood. In the adult protocol, K-RasG12Vgeo expression started at 2 months 
of age and mice were treated with caerulein for three months to induce chronic pancreatitis. 
Control mice showed low- and high-grade lesions (more than 90% of mice displayed high-
grade PanIN lesions); however none of them were found in mice expressing the kinase inactive 
receptor. Thus, Egfr tyrosine kinase activity and its signaling are essential for K-RasG12V driven 
PanIN and PDAC initiation both in the embryonic and in the adult protocol.  
Although these studies have been done in our tumor initiation PDAC model, they 
suggest that EGFR tyrosine kinase inhibitors could be useful in the clinical scenario, especially 
for patients carrying the wild type form of TP53. Hence, the use of GEMMs could provide 
essential information for patient stratification that could be translated into a meaningful 
contribution for patient benefit.  
5.1.2.2. Egfr catalytic activity is essential for PDAC initiation in the absence of 
p16Ink4/p19Arf tumor suppressor genes, but loss of p53 triggers 
activation of other signaling pathways. 
Somatic mutations in tumor suppressor genes are highly associated with PDAC.  Loss of 
p16INK4A/p14ARF appears during early stages (PanIN1-2) affecting more than 90% of 
pancreatic tumors (Wood and Hruban, 2012) whereas mutations in TP53 are late events 
(PanIN-3) present in 50-70% of PDAC cases (Scarpa et al., 1993).  
GEMMs have allowed the study of cooperation between K-Ras and loss of a wide range 
of tumor suppressor genes such as p53, p16Ink4a/p19Arf, Smad4, Pten, among others, which 
significantly resulted in rapid tumor development, leading in some cases to the acquisition of a 
metastatic phenotype (Gopinathan et al., 2015).  
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In the embryonic protocol, ElasK-RasG12V;p16Ink4a/p19ArfLox/Lox;EgfrLmLD839A/LmLD839A mice 
at 1 year of age did not show any PanIN lesion nor PDAC. On the contrary, control mice 
developed PDAC tumors that implied their sacrifice at humane end point. These results 
indicate that in the absence of p16Ink4a/p19Arf tumor suppressor genes, Egfr signaling is 
essential for PDAC initiation. Patients with these types of genetic alterations could benefit from 
drugs inhibiting EGFR tyrosine kinase activity. Nevertheless, as previously pointed out, caution 
should be taken, considering that our PDAC model is useful to genetically investigate the role 
of different targets at initiation stages but not in established pancreatic tumors.  
During the embryonic protocol, in a p53 deficient context, loss of Egfr catalytic activity 
did not block the appearance of pancreatic tumors, although mice increased their lifespan by 
41% with respect to their wild type littermates. Whilst elimination of Egfr in the adult protocol 
delayed tumor formation in the absence of p53 (Navas et al., 2012), inhibition of its kinase 
activity did not show any survival benefit.  This observation is the only difference between the 
expression of an Egfr kinase dead receptor and the complete elimination of the protein in the 
K-RasG12V driven PDAC model, which may be related with the poor response in PDAC patients 
treated with the combination of erlotinib plus gemcitabine (Moore et al., 2007).  
All together, these results indicate that in the absence of p53 other signaling pathways 
are involved in tumor growth conferring resistance to Egfr inhibition. Notably, analysis of PDAC 
cell lines derived from ElasK-RasG12V;p53−/−;EgfrD839A/D839A pancreatic tumors revealed EgfrD839A 
tyrosine phosphorylation and activation. These observations suggest that there are other 
molecules regulating Egfr phosphorylation and consequently, persistent activation of MAPK 
and PI3K signaling in the absence of p53. 
It is important to note that ligand binding induces formation of receptor homo- and 
heterodimers, and subsequent activation of the intrinsic tyrosine domain. All possible homo- 
and heterodimeric receptor complexes between members of the ErbB family have been 
identified in different systems (Normanno et al., 2006). ErbB2 represents the preferred 
dimerization partner among all other ErbB receptors (Olayioye et al., 2000). Heterodimerization 
of EGFR with ErbB2 inhibits downregulation of EGFR, and thereby, prolongs growth factor 
signaling (Huang et al., 1999; Wang et al., 1999; Zandi et al., 2007). Remarkably, defective 
downregulation of ErbB2-EGFR heterodimers results in a more potent signaling than EGFR 
homodimers (Lenferink et al., 1998; Yarden and Sliwkowski, 2001). This raises the possibility 
that ErbB2 represents a mechanism for the increase of EGFR levels on the cell surface and 
prolongation of growth factor signaling (Hendriks et al., 2003).  
Besides dimerization with other ErbB family members, several other Egfr-related 
heterodimerizations could be important for therapeutic resistance. For instance, using lung 
cancer cell lines, it was shown that acquired resistance to TKIs was mediated by dimerization 
between Met (hepatocyte growth factor receptor) and ErbB3, driving activation of PI3K and Src 
and completely replacing signals from the inhibited Egfr (Engelman et al., 2007).  
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In an effort to elucidate whether other members of the ErbB family were compensating 
the loss of Egfr catalytic activity, we systematically knocked down ErbB2 with a specific 
shRNA in ElasK-RasG12Vgeo;p53−/−;Egfr+/+  and ElasK-RasG12Vgeo;p53−/−;EgfrD839A/D839A  PDAC-
derived cell explants. We found that ErbB2 was responsible for EgfrD839A phosphorylation and 
that Egfr/ErbB2 heterodimers were sustaining, at least in part, MAPK activation. Consequently, 
ErbB2 could be maintaining Egfr signaling and promoting PDAC development in the absence 
of p53.  
Interestingly, the first dual-specificity inhibitor, lapatinib, which targets both EGFR and 
ErbB2, was approved for the treatment of ErbB2 overexpressing breast cancer (Geyer et al., 
2006). During the last few years several other dual-specificity inhibitors, as afatinib have been 
developed (Li et al., 2008). Afatinib is a selective, potent and irreversible ErbB family blocker. 
Unlike erlotinib, afatinib covalently binds to and irreversibly blocks signaling from all homo- and 
heterodimers formed by the ErbB family members (Li et al., 2008). This drug received the Food 
and Drug Administration (FDA) approval in 2013 for treating EGFR-mutated NSCLC (Soria et 
al., 2015). Based on preclinical evidences in PDAC cell lines (Huguet et al., 2016; Ioannou et 
al., 2011), afatinib, is under current evaluation in an ongoing phase II trial in combination with 
gemcitabine (NCT01728818), and in a phase I trial, in combination with gemcitabine and nab-
paclitaxel (NCT02975141) to treat PDAC patients. In order to investigate the role of Egfr/ErbB2 
inhibition in PDAC GEMMs, we are also currently performing afatinib treatment in tumor-
bearing mice.  
It is important to highlight that the in effect on PI3K/Akt pathway activation after ErbB2 
knockdown in three different PDAC-derived cell lines was inconclusive. This may reflect tumor 
heterogeneity and extensive genetic diversity that needs further analysis. Likewise, tumor 
explants lacking p53 and Egfr displayed Akt phosphorylation that could explain for Egfr-
independent mechanism, that in the absence of p53, promote PanIN and PDAC initiation 
(Navas et al., 2012). Moreover, these tumor explants are sensitive to the combined inhibition of 
PI3K and STAT3 (Navas et al., 2012). Thus, successful treatment of advanced human 
pancreatic tumors may require inhibition of distinct signaling cascades.  
5.2. Targeting Egfr and c-Raf in K-Ras driven PDAC progression 
5.2.1. Generation of the therapeutic PDAC mouse model 
Our group and others have identified several candidate genes involved in K-Ras 
signaling with potential therapeutic value. For instance, Egfr and c-Raf are essential for PanIN 
and PDAC initiation. Similarly, targets of the PI3K pathway such as Pdk1 and p110α (Baer et 
al., 2014; Eser et al., 2013; Wu et al., 2014) were shown to be indispensable for pancreas 
tumorigenesis. Inhibition of NF-κB pathway by genetic ablation of IKKβ or the loss of non-
canonical IκB-related kinase (IKBKE) reduced the development of PanIN and PDAC (Ling et al., 
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2012; Rajurkar et al., 2017). However, all these studies were carried out in PDAC GEMMs in 
which the alleles of interest were deleted at the same time when the initiating oncogenic events 
were expressed. Consequently, this approach does not allow to genetically validate targets in 
established PDACs, nor genetic investigation of resistance mechanisms or manipulation of 
tumor microenvironment.   
Therefore, to mimic a clinical scenario in which the therapeutic intervention occurs after 
diagnosis of PDAC, we have developed a novel PDAC model based in a dual recombinase 
system (DRS) that enables sequential manipulation of PDAC. This new model combines the 
Flp-FRT recombination system for tumor development with the Cre-LoxP system for a second 
genetic manipulation. PDAC development is induced by concomitant expression of the 
oncogenic K-RasG12V mutation and p53 deletion with the Elas-tTA/tetO-Flp system. Target 
ablation or inactivation in established tumors (detected by ultrasound) is achieved by a 
CreERT2 system. Importantly, when CreERT2 is ubiquitously expressed, leads to systemic 
ablation of the target, allowing evaluation of possible side effects associated with target 
elimination or inhibition.  
Another recently described PDAC model has made use of the DRS (Schönhuber et al., 
2014). This Pdx1-Flp;FSF-K-RasG12D/+;FSF-Rosa26CAG-CreERT2/+ strain was used to eliminate 
Pdk1 upon tamoxifen treatment of mice at three months of age. Interestingly, Pdk1 ablation in 
PanINs blocked tumor progression almost completely (Schönhuber et al., 2014). Nevertheless, 
this study was performed in a p53 proficient background and Pdk1 ablation was not done in 
full-blown tumors. Additionally, in this model, the Cre-recombinase is only expressed in cells 
that have undergone Flp-recombination (in cells expressing the K-Ras oncogene) and not 
systemically, thus they could not study the possible related side effects derived from Pdk1 
ablation.  
This new genetic strategy has allowed us to study the therapeutic value of eliminating 
(conditional knockout alleles) or inhibiting (conditional knockin kinase dead alleles) Egfr as an 
individual target, or in combination with c-Raf as a multi-targeted therapy. Furthermore, we 
have evaluated the toxic side effects of systemic target ablation or inhibition.  
5.2.2. Deletion or inhibition of Egfr in full-blown tumors do not impair PDAC 
progression       
Aforementioned results obtained in this thesis demonstrated that, in aggressive p53-null 
adenocarcinomas, Egfr signaling inhibition is dispensable for PDAC initiation. Nevertheless, in 
order to determine the potential therapeutic benefit of Egfr in already established PDAC, we 
introduced EgfrLox alleles as well as EgfrLmLD839A alleles (to mimic the effect of efficient Egfr 
inhibitors) in our PDAC therapeutic strain (Elas-tTA/tetO-Flp;K-RasFSFG12V;p53Frt/Frt;Tg.hUBC-
CreERT2+/T ). Unfortunately, neither Egfr ablation nor inhibition of its kinase activity, exhibited a 
significant beneficial effect in PDAC progression. Tumors progressed, independently of Egfr 
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status without a significant difference in tumor fold change, likely due to activation of 
alternative pathways upon p53 deletion that still need to be elucidated. The molecular analysis 
and the histopathological characterization of these tumors are currently ongoing.  
These results in mice are in accordance to the observations derived from PDAC patients 
treated with erlotinib in combination with gemcitabine (Moore et al., 2007). The failure of Egfr 
targeted therapy may be related to the extensive crosstalk between redundant proliferation 
signaling pathways in tumor cells (Huang et al., 2011), which results in cancer cell survival even 
though some pathways are blocked by targeted therapy. This suggests, that dual pathway 
inhibition could be a promising therapeutic strategy. In addition, related intratumor 
heterogeneity could be an added complication that needs to be addressed (Burrell et al., 
2013). 
5.2.3. Combined elimination of Egfr and c-Raf in established K-Ras driven PDAC  
It has been recently shown that c-Raf is essential for K-Ras induced NSCLC (Blasco et 
al., 2011; Karreth et al., 2011) and PDAC (unpublished results). Ablation of c-Raf in acinar cells 
of ElasK-RasG12Vgeo mice completely prevented PanIN formation both in the embryonic and in 
the adult protocol. However, elimination of this target in a p53 deficient background did not 
block PDAC initiation (unpublished results, see appendix 8.1).   
Unfortunately, in a p53 deficient background, ablation of either Egfr (Navas et al., 2012) 
or c-Raf (unpublished results) as well as expression of an Egfr kinase dead receptor, delays but 
does not prevent development of PDAC. Importantly, loss of p53 can sustain proliferation in 
the absence of Ras proteins via Ras-independent activation of the MAPK signaling pathway 
(Drosten et al., 2014). The mechanism is still unknown, but it raises the possibility of the MAPK 
activation by a Ras independent mechanism when p53 is mutated. These observations may 
have an important implication in cancer treatment because mutations in Ras oncogenes and 
p53 are frequent events in human tumors (Griffin et al., 1995; Roberts and Der, 2007). In this 
scenario, loss of p53 would emphasize activation of the MAPK pathway by mutant Ras, which 
may cause stronger MAPK activation and increased tumor cell proliferation.  
Furthermore, human pancreatic tumors contain multiple mutations affecting different 
signaling pathways (Jones et al., 2008). Thus, it is presumably, that complete inhibition of 
tumor development requires inactivation of two or even more signaling cascade to induce 
better responses. Indeed, our previous results have demonstrated that simultaneous genetic 
ablation of Egfr and c-Raf results in complete inhibition of PDAC initiation (unpublished results, 
see appendix 8.2). These observations suggest that, in the absence of p53, both targets are 
critical during initial steps of PDAC formation such as ADM. Although these results look 
promising, it is important to note that they were obtained using GEMMs in which both Egfr and 
c-Raf were ablated during the first stages of tumorigenesis and not in full-blown tumors. 
Nevertheless, these observations suggest a promising value for this therapeutic combination. 
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Thus, to fully validate these findings we introduced Egfr and c-Raf floxed alleles in the PDAC 
therapeutic strain to investigate the combination of these targets in established PDACs.   
5.2.3.1. Combined deletion of Egfr and c-Raf in established PDACs results in a 
significant therapeutic effect  
Conventional chemotherapy has limited effect in pancreatic cancer and several signaling 
pathways, including MAPK and PI3K, represent exciting new targets for a possible therapeutic 
intervention, especially because known inhibitors are already clinical available.  
The crosstalk between redundant proliferation pathways, such as MAPK and PI3K 
cascades, in tumor cells appears to be particularly important clinically. Indeed, several 
preclinical studies have revealed that dual pathway inhibition shows promising effects. The 
combined inhibition of MEK and PI3K has been shown to be effective in K-Ras driven NSCLC 
(Engelman et al., 2008) as well as in other Ras mutant cancers (Roberts et al., 2012). 
Nevertheless, although combined targeting of MEK and PI3K provided clinically significant 
responses in a mouse model of PDAC, the treatment did not produce a durable response 
(Alagesan et al., 2015), indicating differences in the requirements of different types of tumors, 
and suggesting that alternative therapeutic strategies will be required. Combined FGFR1 and 
MEK inhibition (Manchado et al., 2016) and inhibition of DDR1 together with Notch signaling 
(Ambrogio et al., 2016) also shown a significant effect in a model of K-Ras driven lung 
adenocarcinoma. The first clinical studies to evaluate the efficacy of dual pathway inhibition in 
patients also showed promising effects in tumor growth targeting PI3K/AKT and MAPK 
pathways. However, multi-targeted inhibition was significantly more toxic than single-agent 
therapy (Shimizu et al., 2012). 
Most of these studies were done using different combinations of MEK inhibitors, but it is 
important to take into consideration that Mek and Erk genetic ablation caused multi-organ 
failure leading to the rapid death of the animals (Blasco et al., 2011). Furthermore, the use of 
MEK inhibitors is very limited in the clinic due to the associated toxicities. Fortunately, c-Raf 
elimination does not affect tissue homeostasis (Blasco et al., 2011).  
Simultaneous genetic ablation of Egfr and c-Raf in full-blown PDAC (Elas-tTA/tetO-
Flp;K-RasFSFG12V;p53Frt/Frt;EgfrLox/Lox;c-RafLox/Lox;Tg.hUBC-CreERT2+/T) results in a significant 
therapeutic effect. About 60% of PDACs displayed partial or even complete regression. 
However, there are still tumors that can progress upon target elimination. Moreover, in these 
tumors, lack of Egfr and c-Raf does not affect Erk1/2 and Akt phosphorylation, suggesting that 
resistant mechanisms lead to cell signaling activation compensating the deficiency of these 
proteins. Paraffin sections of pancreas from mice that responded to target ablation, presented 
few PanIN lesions (undetectable by ultrasound). It remains to be determined whereas these 
PanINs retain both Egfr and c-Raf expression (we are currently performing LCM to analyze 
them by PCR). Pancreatic tumors are extremely heterogeneous exhibiting a wide range of 
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mutations (Jones et al., 2008), which could explain different responses upon target elimination. 
In order to identify differentially expressed genes and the transcription programs involved in 
different tumor responses we will consequently perform DNA- and RNA-seq analysis.  
These results underscore the value of this therapeutic combination. Therefore, to 
validate our findings in a relevant preclinical setting we are using cell lines derived from PDAC 
patient-derived xenografts (PDX) that harbor K-RAS and TP53 mutations. With the help of 
CRISPR/Cas9 editing technology we are trying to concomitant ablate Egfr and c-Raf genes. 
Moreover, specific shRNAs against both targets are being used to promote simultaneous Egfr 
and c-Raf knockdown. PDX cell lines will be subcutaneously and/or orthotopically implanted in 
the pancreas of immunocompromised mice to monitor tumor growth in the presence or 
absence of the targets of interest.  
The use of drug combinations to target Egfr and c-Raf in GEMMs and PDX tumor 
models will be helpful to determine tumor behavior. As previously reported there are several 
specific EGFR inhibitors, but unfortunately, there are no specific drugs against C-RAF. One of 
the first-generation RAF inhibitors, sorafenib, was developed as a C-RAF inhibitor to treat RAS 
mutant cancers (Lyons et al., 2001). Although it was approved by the FDA for a variety of 
cancers, its efficacy remains unknown due to its multi-kinase inhibitory effects. Vemurafenib 
and dabrafenib are small molecules that were shown to potently inhibit B-RAFV600E (Gibney and 
Zager, 2013; Tsai et al., 2008). In PDAC, B-RAF mutations are mutually exclusive with K-RAS 
mutations and are present in 30% of K-RAS wild type PDAC cases (Witkiewicz et al., 2015). In 
mice, mutant B-Raf is sufficient to induce PDAC development (Collisson et al., 2012) 
implicating the utility of B-RAF inhibitors in PDAC. However, it should be stressed that any 
clinical trial with RAF inhibitors should be restricted to patients with confirmed B-RAF 
mutation, since targeting wild type B-RAF with RAF inhibitors can lead to paradoxical 
activation of ERK signaling through transactivation of C-RAF, triggering an accelerating tumor 
growth (Heidorn et al., 2010; Poulikakos et al., 2010). This observation led to the development 
of a second-generation of RAF inhibitors (also known as “paradox breakers”), which do not 
activate MAPK in the presence of RAS mutations. They are pan-RAF dimer inhibitors; they bind 
all RAF members with similar affinity inhibiting their kinase activity without activating MAPK in 
the presence of RAS mutations, indicating that the activity of the dimers was effectively 
blocked (Peng et al., 2015; Zhang et al., 2015a).  
As available RAF inhibitors are not selective against C-RAF, we are generating a new c-
Raf conditional kinase dead allele to introduce it into the therapeutic PDAC strain. We will 
finally combine it with the already described EgfrLmLD839A to genetically model the outcome of 
Egfr and c-Raf selective inhibitors in PDAC. For the pharmacological validation in vivo, either in 
GEMMs or in PDX models, trametinib (Mek inhibitor) and afatinib will be used to inhibit the 
MAPK and Egfr signaling pathway, respectively.   
As already described, combined ablation of Egfr and c-Raf results in a significant 
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therapeutic response. Nonetheless, there are few tumors that can progress upon target 
elimination, suggesting that Egfr and c-Raf may not be sufficient to provide optimal therapeutic 
benefit and they will have to be combined with other therapies. It was described that c-Raf can 
phosphorylate other proteins apart from Mek. Among them, Retinoblastoma protein (Rb) is 
phosphorylated and inactivated by c-Raf in the nucleus, which is necessary for cell cycle entry 
(Wang et al., 1998). Rb phosphorylation correlates with poor overall survival in PDAC (Trevino 
et al., 2013). Moreover, inhibitors of the complex c-Raf-Rb have been reported to inhibit 
proliferation, migration and invasion of pancreatic cell lines, including metastatic cells that are 
resistant to gemcitabine. The same effect was observed in preventing in vivo growth and 
metastasis of pancreatic cancer cells introduced in immunocompromised mice (Trevino et al., 
2013). Additionally, the absence of the Cyclin-dependent kinase 4 (Cdk4) protein, a well-known 
cell cycle regulator, has been reported to impair lung tumor initiation and progression in K-Ras 
driven lung adenocarcinoma (Puyol et al., 2010). Whereas Rb phosphorylation by c-Raf is 
considered as a preparing step for cell cycle entry (Wang et al., 1998), Rb mediated 
phosphorylation by Cdk4 promotes G1-S transition in cell division (Kato et al., 1993). Thus, 
concomitant genetic elimination of c-Raf and Cdk4 together with Egfr would be an interesting 
therapeutic strategy to assess whether this multi-targeted therapy could have a synergistic 
effect in K-Ras driven PDAC.  
5.2.3.2. Side effects associated with the systemic elimination of Egfr and c-Raf  
Loss of Egfr expression in adult mice is associated with skin side effects. Mice 
presented rashes together with ulcers, inflammation, hyperkeratosis and hyperplasia, similar to 
those alterations observed in patients treated with EGFR inhibitors (Owczarczyk-Saczonek et 
al., 2013). Germline loss of Egfr causes lung and neuronal defects (Sibilia and Wagner, 1995; 
Sibilia et al., 1998). Nevertheless, upon detailed examination none of these alterations were 
found in adult mice lacking the receptor.   
In human patients, acneiform rash is the most common side effect of EGFR inhibitors 
treatments. It is a follicular papulopustular eruption that affects skin areas with a high density 
of sebaceous glands, such as the face, scalp, chest and upper back (Fabbrocini et al., 2015).  
Likewise, adult mice lacking Egfr protein show primary symptoms around the snout, face, ears, 
scalp and upper back. Inhibition of EGFR in keratinocytes induces apoptosis, cell arrest, 
reduced cell migration and increased cell adhesively and differentiation. All these processes 
induce keratinocytes to release inflammatory chemokines promoting inflammatory cell 
infiltration (Paul et al., 2014). In mice, we have observed an increased amount of mast cells, 
which secrete numerous vasoactive and pro-inflammatory mediators (Theoharides et al., 2012) 
that could be related with the observed inflammatory processes in patients.  
It is known that monoclonal antibodies like cetuximab more frequently trigger acneiform 
rash than tyrosine kinase inhibitors like erlotinib (Thomas and Grandis, 2004). In accordance 
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with these observations, adult mice expressing EgfrD839A (the tyrosine kinase inactive form of 
Egfr) do not seem to develop skin alterations as severe as when the receptor is absent. This 
could be due to the fact that using tyrosine kinase inhibitors, EGFR signaling could be 
compensated by EGFR/ErbB2 heterodimers (Huang et al., 1999; Wang et al., 1999; Zandi et 
al., 2007), whereas monoclonal antibodies inhibit EGFR ligand binding and induce receptor 
endocytosis and degradation (Roskoski, 2014), probably blocking EGFR heterodimerization 
and consequently its signaling.   
Egfr and c-Raf combined ablation (apart from skin problems) resulted in increased 
apoptosis in intestinal crypts that did not compromise intestinal structure and/or functionality. 
We did not observe a significant weight loss or other obvious defects upon detailed 
examination of relevant tissues.  
All these observations need to be taken into consideration when targeting Egfr and c-Raf 
in the clinic, although clinical treatments do not result in irreversible loss of target expression.  
Unfortunately, most of the mice enrolled in our therapeutic studies were sacrificed due 
to ethical recommendations because of their aspect due to the dermatitis. In spite of this, mice 
under tamoxifen treatment can survive several months and we are currently maintaining them 
for longer periods of time to better understand tumor behavior. 
 
 
Together, these observations underscore the complexity of oncogenic K-Ras signaling 
and the need for an in-depth genetic analysis of the role and requirement of RAF/MEK/MAPK 
and other signaling pathway components in K-Ras driven PDAC progression and maintenance.
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The conclusions obtained in this thesis were the following:  
 
1. Egfr catalytic activity is indispensable for mouse development. Germline expression of 
a catalytic inactive Egfr mutant is associated with skin, lung and placental defects 
leading to perinatal lethality.  
 
2. Elimination of Egfr kinase activity impairs PanIN and PDAC development even in the 
context of chronic pancreatitis or in the absence of the p16Ink4/p19Arf tumor 
suppressor genes.  
 
3. Inhibition of Egfr catalytic activity is not sufficient to inhibit tumor development in the 
absence of p53. In this context, ErbB2 is important triggering Egfr phosphorylation and 
MAPK signaling activation.  
 
4. Elimination or inhibition of Egfr results in limited therapeutic effect in K-RasG12V PDAC 
maintenance and progression.  
 
5. Simultaneous deletion of Egfr and c-Raf in full-blown PDAC results in a significant 
therapeutic effect in approximately 60% of the tumors, with very low associated 
toxicity.  
 
6. Nevertheless, there are tumors that can progress upon target elimination, suggesting 
the existence of tumor heterogeneity and the contribution of alternative signaling 
pathways. Therefore, Egfr and c-Raf may not be sufficient to provide optimal 
therapeutic benefit and further research is required to identify effective therapeutic 
strategies.  
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Las conclusiones obtenidas en esta tesis son las siguientes:  
 
1. La actividad catalítica de Egfr es indispensable para el desarrollo del ratón. La 
expresión constitutiva de un mutante de Egfr catalíticamente inactivo está asociada 
con defectos en la piel, pulmones y placenta, que conllevan a una letalidad perinatal.  
 
2. La eliminación de la actividad quinasa de Egfr impide el desarrollo de PanIN y PDAC 
incluso en el contexto de pancreatitis crónica y en ausencia de los genes supresores 
de tumores p16Ink4/p19Arf.  
 
3. La inhibición de las actividad catalítica de Egfr no es suficiente para impedir el 
desarrollo tumoral en ausencia de p53. En este contexto, ErbB2 juega un papel 
importante en la fosforilación de Egfr y en la activación de la vía de señalización 
MAPK.  
 
4. La eliminación o inhibición de Egfr tiene un efecto terapéutico limitado en el 
mantenimiento y progresión de tumores de páncreas inducidos por el oncogén K-
RasG12V.  
 
5. La deleción simultánea de Egfr y c-Raf en tumores avanzados resulta en un efecto 
terapéutico significativo en aproximadamente el 60% de los tumores, con una 
toxicidad asociada baja.  
 
6. Sin embargo, hay tumores que pueden progresar tras la eliminación de las dianas, lo 
que sugiere la existencia de heterogeneidad tumoral y la contribución de otras vías de 
señalización. Por lo tanto, Egfr y c-Raf pueden no ser suficientes para proporcionar un 
efecto terapéutico óptimo y se requiere más investigación para identificar estrategias 
más eficaces.  
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8.1. Elimination of c-Raf blocks and delays K-Ras driven PanIN and PDAC 
formation 
To investigate the contribution of c-Raf in pancreatic tumorigenesis conditional floxed c-
Raf alleles were introduced in our PDAC mouse model. Ablation of c-Raf in acinar cells of 
ElasK-RasG12Vgeo  mice prevented the development of preneoplastic PanIN lesions even in the 
context of chronic pancreatitis (data not shown). However, deletion of c-Raf is not sufficient to 
inhibit PDAC tumor development in the absence of p53 in the embryonic protocol (Figure 26A). 
Interestingly, c-Raf deletion prolonged survival of ElasK-RasG12Vgeo;p53Lox/Lox mice in the adult 
protocol (Figure 26B). Efficient deletion of c-Raf alleles was verified by PCR of PDAC cells 
isolated from tumor specimens, ruling out the possibility that tumors developed due to 
incomplete c-Raf deletion (Figure 26C). 
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Figure 26. Deletion of c-Raf does not prevent PDAC development in a p53 deficient background. 
(A) Survival of dox-untreated ElasK-RasG12Vgeo;p53Lox/Lox;c-Raf+/+ (solid circles, n=20) mice and ElasK-
RasG12Vgeo;p53Lox/Lox;c-RafLox/Lox (open circles, n=13) mice. (B) Survival of ElasK-RasG12Vgeo;p53Lox/Lox;c-
Raf+/+; (solid circles, n=10) and ElasK-RasG12Vgeo;p53Lox/Lox;c-RafLox/Lox  (open circles, n=24) mice in the 
adult protocol. Mice were exposed to doxycycline from conception until P60. At that time, Cre-
recombinase leads to the concomitant expression of the resident K-RasG12Vgeo oncogene and the 
ablation of p53 and c-Raf conditional alleles. Mice were treated with caerulein from P90 to P180.  (C) PCR 
analysis of c-Raf alleles from tumor derived cell explants. Lanes 1, 2 and 3: c-Raf +/+ (wt), c-RafLox/Lox and 
c-Raf−/− controls, respectively. Lanes 4, 5, 6, 7, 8: DNA extracted from five different cell explants obtained 
from ElasK-RasG12Vgeo;p53Lox/Lox;c-RafLox/Lox PDACs revealing complete deletion of c-Raf alleles. Lane 9: 
blank. Lane M: DNA ladder. Expected fragments for each allele are depicted.   
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8.2. Concomitant ablation of Egfr and c-Raf completely blocks PDAC initiation 
Egfr and c-Raf floxed alleles were introduced in the ElasK-RasG12Vgeo;p53Lox/Lox PDAC 
mouse model to produce simultaneous ablation of both targets concomitantly with K-
RasG12Vgeo expression in acinar cells. Interestingly, the resultant strain ElasK-
RasG12Vgeo;p53Lox/Lox;EgfrLox/Lox;c-RafLox/Lox, did not develop PDAC after more than one year of 
age (Figure X). Furthermore, careful histological examination of their pancreas revealed even 
complete absence of PanIN lesions. In contrast, mice carrying either Egfr or c-Raf alleles in 
heterozygosis succumbed to the disease (Figure 27). 
 
Figure 27. Simultaneous deletion of Egfr and c-Raf prevents PDAC formation in a p53 deficient 
background. Survival of dox-untreated ElasK-RasG12Vgeo;p53Lox/Lox;Egfr+/Lox;c-RafLox/Lox (solid circles, n=5) 
mice, ElasK-RasG12Vgeo;p53Lox/Lox;EgfrLox/Lox;c-Raf+/Lox (grey circles, n=10) mice and ElasK-RasG12Vgeo; 
p53Lox/Lox; EgfrLox/Lox; c-RafLox/Lox (open circles, n=14) mice. 
G12Vgeo Lox/Lox +/Lox Lox/Lox 
G12Vgeo Lox/Lox Lox/Lox +/Lox 
G12Vgeo Lox/Lox Lox/Lox Lox/Lox   
p53 Egfr c-Raf
p53 Egfr Raf
p53 Egfr c-Raf
ElasKRas
ElasKRas
ElasKRas
; ; ;
; ; ;c-
; ; ;
10 20 40 5030 60 70
Su
rv
iva
l (
%
)
0
0
20
40
60
80
100
Age (weeks)
  
  
9. Publications
  
 
Molecular and Cellular Pathobiology
H-Ras and K-Ras Oncoproteins Induce Different
Tumor Spectra When Driven by the Same
Regulatory Sequences
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María T. Blasco1, Harrys K.C. Jacob1, Salvatore Fabbiano2,3, Nicoletta Potenza4,
Xos!e R. Bustelo2,3, Carmen Guerra1, and Mariano Barbacid1
Abstract
Genetic studies in mice have provided evidence that H-Ras
and K-Ras proteins are bioequivalent. However, human tumors
display marked differences in the association of RAS oncogenes
with tumor type. Thus, to further assess the bioequivalence
of oncogenic H-Ras and K-Ras, we replaced the coding region
of the murine K-Ras locus with H-RasG12V oncogene sequences.
Germline expression of H-RasG12V or K-RasG12V from the K-Ras
locus resulted in embryonic lethality. However, expression
of these genes in adult mice led to different tumor phenotypes.
Whereas H-RasG12V elicited papillomas and hematopoietic
tumors, K-RasG12V induced lung tumors and gastric lesions.
Pulmonary expression of H-RasG12V created a senescence-like
state caused by excessive MAPK signaling. Likewise, H-RasG12V
but not K-RasG12V induced senescence in mouse embryonic
ﬁbroblasts. Label-free quantitative analysis revealed that
minor differences in H-RasG12V expression levels led to dras-
tically different biological outputs, suggesting that subtle
differences in MAPK signaling confer nonequivalent functions
that inﬂuence tumor spectra induced by RAS oncoproteins.
Cancer Res; 77(3); 1–12. !2016 AACR.
Introduction
Mammals contain three Ras loci, H-Ras, K-Ras, and N-Ras, that
encode highly related proteins (1–4). Ras proteins are small
GTPases that function as mitogenic switches to control the trans-
mission of extracellular signals to the nucleus (1). They share
extensive homology at their N-terminal half, a region involved in
nucleotide binding and interaction with downstream effectors
(2). Their unique features reside in their carboxy-terminal half
that includes the hypervariable region and a terminal domain
known as the CAAX box (2). These structural motifs have been
implicated in differential transport, posttranslational processing,
and subcellular localization of the different Ras proteins (3, 4).
Early knockout data revealed signiﬁcant functional differ-
ences for the three Ras loci. Whereas H- and N-Ras were
dispensable for embryonic development, K-Ras was essential
(5–7). These observations did not establish whether these
differences were due to the intrinsic properties of their cognate
Ras proteins or their patterns of expression. This issue was
solved, at least in part, when Potenza and colleagues replaced
mouse K-Ras alleles by chimeric K/H-Ras alleles encoding
functional H-Ras proteins (8). These mice developed to adult-
hood despite the absence of K-Ras, indicating that the require-
ment for K-Ras alleles during embryonic development is pri-
marily due to their pattern of expression. Yet, these mice
displayed cardiovascular defects, thus raising the possibility
that H-Ras and K-Ras proteins might have differential signaling
properties, at least in certain tissues (8).
RAS genes have also attracted interest due to their involvement
in tumor development (1, 2). The overall incidence of each RAS
oncogene varies signiﬁcantly among tumor types (9). Whereas
KRAS is frequently mutated in pancreatic, colorectal, and lung
adenocarcinomas, HRAS oncogenes are found in a limited per-
centage of tumors from the salivary gland, urinary track, cervix, or
skin. On the other hand, NRAS oncogenes are present in mela-
nomas and hematopoietic tumors. To date, the molecular basis
for this incidence bias is still unresolved (9).
Mutant RAS genes also induce different phenotypes when
expressed in the germline of patients suffering from RASopathies,
a series of developmental defects that result from constitutive
activation of RAS signaling pathways (10, 11). Oncogenic muta-
tions in HRAS lead to relatively mild developmental defects in
Costello syndrome patients (12, 13). In contrast, those KRAS
mutations present in human tumors have not been found in
RASopathy patients, suggesting that such mutations may cause
embryonic lethality (14).
1Molecular Oncology Programme, Centro Nacional de Investigaciones
Oncol!ogicas (CNIO), Madrid, Spain. 2Centro de Investigaci!on del C!ancer and
Instituto de Biología Molecular y Celular del C!ancer, CSIC-Universidad de
Salamanca, Salamanca, Spain. 3Centro de Investigaci!on Biom!edica en Red de
C!ancer (CIBERONC), Salamanca, Spain. 4Department of Environmental, Bio-
logical and Pharmaceutical Sciences and Technologies (DiSTABiF), Second
University of Naples, Caserta, Italy.
Note: Supplementary data for this article are available at Cancer Research
Online (http://cancerres.aacrjournals.org/).
Current address for S. Fabbiano: Department of Cell Physiology andMetabolism,
Centre M!edical Universitaire (CMU) and Diabetes Centre, Faculty of Medicine,
University of Geneva, Geneva 1206, Switzerland.
Corresponding Authors: Matthias Drosten, Molecular Oncology Programme,
Centro Nacional de Investigaciones Oncol!ogicas, Melchor Fern!andez Almagro 3,
Madrid 28029, Spain. Phone: 349-1732-8000; Fax: 349-1732-8033; E-mail:
mdrosten@cnio.es; and Mariano Barbacid, mbarbacid@cnio.es
doi: 10.1158/0008-5472.CAN-16-2925
!2016 American Association for Cancer Research.
Cancer
Research
www.aacrjournals.org OF1
Similar results have been observed in mouse strains carrying
genetically engineered Ras mutations. Whereas expression of
resident K-Ras oncoproteins in the germline leads to early embry-
onic death, expression of an endogenous H-Ras oncogene is
well tolerated and leads to developmental defects very similar
to those observed in Costello patients (15–18). Likewise, germ-
line expressionof thepartially activatedK-RasV14I-mutant isoform
results in phenotypic defects that closely resemble those of Noo-
nan patients (19).
Here, we provide genetic evidence that the wild-type H-Ras and
K-Ras proteins are bioequivalent in spite of their different struc-
tural and biological properties. We have also compared the
spectrum of tumors elicited upon expression of the H-RasG12V
and K-RasG12V oncoproteins from the same mouse K-Ras locus.
These studies have revealed that these oncoproteins induce a
different spectrum of tumors primarily due to differences in the
intensity of MAPK signaling that results from subtle differences in
their levels of expression.
Materials and Methods
Mouse strains
Generation of K-Rasþ/LSLH-RasG12V mice (KHRasV12) is described
in Supplementary Information. KrasKI (8), HrasKI (8), H-Ras"/"
(5), K-Rasþ/LSLG12Vgeo (KV12; ref. 16), and p53lox/lox (20) geneti-
cally engineered strains have been described. hUBC-CreERT2,
Elas-tTA, and tetO-Cre transgenic strain have also been reported
(21, 22). Activation of the inducible CreERT2 recombinase was
achieved by feeding the mice with a tamoxifen-containing diet
(Harlan Laboratories). For activation of H-RasG12V and
K-RasG12V expression in lung tissue, mice were infected with
Adeno-Cre particles as described previously (23). Trametinib
(Mekinist) was purchased from Sellek Chemicals and was
administered orally daily (1 mg/kg) for 8 weeks. All mice were
maintained in a mixed 129Sv/J x C57BL/6j background and
housed in a barrier facility according to standards established
by the European Union. All animal experiments were approved
by the CNIO, the Carlos III Health Institute (Madrid, Spain),
and the Comunidad de Madrid Ethical Committees and per-
formed in accordance with the ARRIVE (Animal Research:
Reporting on In Vivo Experiments) guidelines.
Histopathology, IHC, and SA-b-Gal staining
Tissues were ﬁxed in 10% buffered formalin and embedded
in parafﬁn. Hematoxylin and eosin (H&E) staining and
immunohistochemical analyses were performed on 3-mm par-
afﬁn sections. For IHC, the following antibodies were used:
pErk1/2 (9101, Cell Signaling Technology), Active Caspase-3
(MAB835, R&D Systems), SPC (AB3786, Abcam), CC10 (T-18,
Santa Cruz Biotechnology), and CD3e (clone 145-2C11,
Abcam). Senescence-associated b-galactosidase (SA-b-Gal)
activity in cultured mouse embryonic ﬁbroblasts (MEF) as
well as in cryosections of lungs was detected by X-Gal staining
as described previously (24).
Southern and Western blot analysis
Southern blot analysis is described in Supplementary Infor-
mation. Western blot analysis of protein extracts obtained from
total lung tissue or MEFs was performed as described previously
(25). Primary antibodies used included: Pan-Ras (OP40, Merck
Millipore), H-Ras (clone 18, BD Transduction Laboratories),
pErk1/2 (9101), p53 (2524), pAkt (9271), Akt (9272; all from
Cell Signaling Technology), p19Arf (clone 5-C3-1, Upstate Bio-
technology), Erk1 (C16), p16INK4a (M-156; all from Santa Cruz
Biotechnology), and GAPDH (G8795, Sigma-Aldrich).
Statistical analysis
All statistical analyses were performed using an unpaired Stu-
dent t test. P values <0.05 were considered to be statistically
signiﬁcant (# P < 0.05, ### P < 0.001).
Results
H-Ras and K-Ras are bioequivalent proteins
Germline ablationof K-Ras results in embryonic lethality (6, 7).
Yet, expression of H-Ras proteins under the control of K-Ras–
regulatory sequences results in viable mice, thus illustrating that
H-Ras can replace K-Ras isoforms, for most biological activities
(8). Yet, these mice, designated as HrasKI, displayed dilated
cardiomyopathy and arterial hypertension when they reached
adulthood (8). These cardiovascular defects were initially attrib-
uted to the absence of K-Ras proteins in heart tissue. Subsequent
studies, however, revealed that germline expression of constitu-
tively active H-RasG12V led to similar cardiovascular defects in a
mouse model of Costello syndrome (17). Thus, we reasoned that
these cardiovascular defectsmight bedue toH-Ras overexpression
due to the presence of four H-Ras–coding alleles (the knocked-in
HrasKI alleles and the endogenous H-Ras alleles). To reduce the
load of H-Ras expression, we crossed HrasKI mice with H-Ras"/"
animals. HrasKI;H-Ras"/" mice displayed normal heart function
and no hypertension (Fig. 1A and B). In addition, these mice
displayed normal cardiomyocyte areas and did not accumulate
ﬁbrosis in their heart (Fig. 1C and D). These results indicate that
the cardiovascular defects of HrasKI mice were due to H-Ras
overexpression and not to differential activities between H-Ras
and K-Ras proteins.
Germline expression of the H-RasG12V oncoprotein from the
K-Ras locus results in embryonic lethality
Next, we interrogated whether their oncogenic isoforms,
K-RasG12V and H-RasG12V, also have similar properties. To this
end, we knocked in a cDNA encoding an H-RasG12V oncogene
within the ﬁrst coding exon of the K-Ras locus (Fig. 2A). We also
knocked in a lox-STOP-lox (LSL) cassette upstreamof the initiator
codon to prevent expression of H-RasG12V (Supplementary Fig.
S1A–S1C). Expression of the H-RasG12V cDNA clone and a geno-
mic DNA fragment containing the four H-Ras coding exons
resulted in similar expression levels, indicating that the H-Ras
intronic sequences do not play a signiﬁcant role in regulating
H-Ras expression (Fig. 2B and C). For simplicity, the wild-type
K-Rasþ/þmice and the targeted K-Rasþ/LSLG12Vgeo andK-Rasþ/LSLH-
RasG12V strains will be referred to hereafter as Kþ, KV12, and
KHRasV12, respectively.
Previous studies have indicated that expression of a K-RasG12V
oncogene in the mouse germline results in embryonic lethality
(16). In contrast, expression of the H-RasG12V oncogene, even in
homozygosity, is well tolerated during embryonic development
(17, 18). To determine whether this differential effect is an
intrinsic property of the K-RasG12V and H-RasG12V oncoproteins,
we crossed KHRasV12 mice to EIIA-Cre transgenics (26) to express
the H-RasG12V oncoprotein from the K-Ras locus in the germline.
These embryos were no longer viable and died right after implan-
tation, a time similar to that observed for embryos expressing an
Drosten et al.
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endogenous K-RasG12V oncoprotein (16). Hence, the ability of
mice, as well as of Costello syndrome patients, to tolerate expres-
sion of an oncogenic H-RasG12V protein during embryonic devel-
opment is dictated by the expression pattern of the H-Ras locus.
Expression of H-RasG12V from the K-Ras locus in adult mice
Next,we explored theoncogenic properties of theK-RasG12V and
H-RasG12V isoforms expressed from the K-Ras locus in adult mice.
To this end,we inserted in theKV12 andKHRasV12 strains a transgene
encoding the inducible CreERT2 recombinase under the control of
the human ubiquitin C promoter (21). We exposed KV12;hUBC-
CreERT2þ/T and KHRasV12;hUBC-CreERT2þ/T mice to a continuous
tamoxifen diet to ensure efﬁcient recombination of the targeted
K-Ras alleles. Under these conditions, KV12;hUBC-CreERT2þ/T
mice had a median survival of 24 weeks (Fig. 2D). In agreement
with previous studies (27), these mice displayed multiple lesions
in their lungs as well as abundant gastric papillomas (Fig. 2E). No
other tissue displayed signiﬁcant alterations at the histopathologic
level. KHRasV12;hUBC-CreERT2þ/T mice submitted to the same
tamoxifen treatment died 4 to 5 weeks earlier (Fig. 2D). These
mice did not develop detectable lesions in either lungs or
stomach (Fig. 2E) despite expression of the mutant H-RasG12V
protein in these tissues (Supplementary Fig. S1D). Instead, they
displayed papillomas on their footpads after approximately 2
months of treatment (Supplementary Fig. S1E). Moreover, they
had enlarged spleens and thymic tumors (Fig. 3). Tamoxifen-
treated control Kþ;hUBC-CreERT2þ/T mice did not display
detectable lesions for up to one year of age. These observations
indicate that oncogenic signaling initiated by K-RasG12V and
H-RasG12V oncoproteins expressed under the same regulatory
sequences has substantially different consequences on tumor
formation.
Expression of H-RasG12V from the K-Ras locus in adult mice
induces hematopoietic disorders
Postmortem characterization of tamoxifen-treated KHRasV12;
hUBC-CreERT2þ/T mice at humane endpoint revealed enlarged
spleens inﬁltrated with myeloid cell populations in 100% of the
animals (Fig. 3A andB). This phenotypewas not observed inKV12;
hUBC-CreERT2þ/T or Kþ;hUBC-CreERT2þ/T mice. Flow cytome-
try analyses of these inﬁltrates revealed a dramatic expansion of
CD11bþ and Gr1þ/CD11bþ double-positive cells indicative of
myeloproliferative disease (Fig. 3C; Supplementary Fig. S2A). This
increase in the myeloid cell compartment was accompanied by a
concomitant decrease in CD3þ T cells and CD19þ B cells (Supple-
mentary Fig. S2A). Analysis of committed progenitors in the bone
marrow of mice exposed to the tamoxifen diet for 3 months
revealed a signiﬁcant increase in the commonmyeloid progenitors
(CMP; Lin"/IL7Ra"/Sca-1"/c-Kitþ/FcgRlow/CD34þ) as well as a
slight expansion of the granulocyte–macrophage progenitor pop-
ulation (GMP; Lin"/IL7Ra"/Sca-1"/c-Kitþ/FcgRhigh/CD34þ; Sup-
plementary Fig. S2B). The common lymphoid progenitors (CLP;
Lin"/IL7Raþ/Sca-1low/c-Kitlow), themegakaryocyte–erythroid pro-
genitors (MEP; Lin"/IL7Ra"/Sca-1"/c-Kitþ/FcgRlow/CD34"), and
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LSK cells (Lin!/Sca-1þ/c-Kitþ), a population enriched in hemato-
poietic stem cells, did not display signiﬁcant changes. These obser-
vations indicate that H-RasG12V, but not K-RasG12V, is capable of
inducing myeloproliferative disease in adult mice via expansion of
a speciﬁc subset of committed progenitors in their bone marrow.
We also detected large tumor masses in the thymus in more
than 85% of KHRasV12;hUBC-CreERT2þ/T animals, a pathology
not observed in KV12;hUBC-CreERT2þ/T or Kþ;hUBC-CreERT2þ/T
mice (Fig. 3D). Histopathologic characterization revealed the
presence of T-cell lymphoblastic lymphoma (T-ALL), as deter-
mined by a uniform expansion of CD3þ T lymphocytes. More-
over, tumors displayed an increase in double-negative (DN)CD4/
CD8!, single-positive CD4þ, and single-positive CD8þ cells (Fig.
3E). In particular, when DN cells were further characterized, we
detected elevated DN1 (CD44þ/CD25!) and DN2 (CD44þ/
CD25þ) populations (Supplementary Fig. S3A). The characteristic
hyperactivation of the Notch pathway in T-ALL was also observed
as demonstrated by immunostaining of Hes1 (Supplementary
Fig. S3B; ref. 28). We also detected abundant lymphocyte inﬁl-
trates in a variety of organs, including lung, liver, kidney, and eye
(Supplementary Fig. S3C). These data indicate that in addition to
myeloproliferative disease, most mice expressing the H-RasG12V
oncoprotein from the K-Ras locus also developed T-ALL, a tumor
type not induced by the K-RasG12V isoform.
H-RasG12V driven from the K-Ras locus induces
pancreatic tumors
Expression of a resident K-RasG12V oncogene during late embry-
onic development in pancreatic acinar cells results in pancreatic
intraepithelial neoplasias (PanIN lesions) that occasionally prog-
ress to pancreatic ductal adenocarcinomas (PDAC; ref. 22). No
such lesionswere observed inH-Rasþ/G12V orH-RasG12V/G12Vmice
in which the H-RasG12V oncoprotein is expressed from its own
locus (17). To determine whether H-RasG12V could induce pan-
creatic lesions when expressed from the K-Ras locus, we crossed
KHRasV12 mice to Elas-tTA/tetO-Cre transgenic animals known to
selectively express Cre recombinase in acinar cells from E16.5
onwards (22). Analysis of serial pancreatic tissue sections of
KHRasV12;Elas-tTA/tetO-Cre animals at one year of age revealed
the appearance of focal low- and high-grade PanIN lesions
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(red dots; n ¼ 19), or KHRasV12;hUBC-CreERT2þ/T (blue dots; n ¼ 16) mice subjected to a continuous tamoxifen diet at 4 weeks of age (solid arrow). E, H&E
staining of lung and stomach sections obtained from Kþ;hUBC-CreERT2þ/T, KV12;hUBC-CreERT2þ/T, or KHRasV12;hUBC-CreERT2þ/T mice treated for 4 months with
tamoxifen diet. Asterisks indicate adenomas (lung) or papillomas (stomach) in KV12;hUBC-CreERT2þ/T animals (KV12). Arrowheads show the normal stratiﬁed
epithelium of the forestomach in Kþ;hUBC-CreERT2þ/T (Kþ) and KHRasV12;hUBC-CreERT2þ/T (KHRasV12) mice (scale bars, 200 mm).
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indistinguishable from those present in KV12;Elas-tTA/tetO-Cre
mice (Supplementary Fig. S4A). However, the number of lesions
was signiﬁcantly lower than in similar mice expressing the
K-RasG12V oncoprotein (Fig. 4A).
Loss of the tumor suppressor p53 accelerated tumor formation
in KHRasV12;Elas-tTA/tetO-Cre animals (22). These mice died of
PDAC tumors, although they survived longer than those mice
expressing the K-RasG12V oncoprotein (30 vs. 17 weeks average
survival, a 75% increase; Fig. 4B; Supplementary Fig. S4A). Com-
parative analysis of KHRasV12;p53lox/lox;Elas-tTA/tetO-Cre and
KV12;p53lox/lox;Elas-tTA/tetO-Cre mice at 10 weeks of age revealed
that the H-RasG12V-expressing animals displayed signiﬁcantly
fewer PanIN lesions and PDAC tumors than those expressing
K-RasG12V (Fig. 4C). These quantitative differences are likely to be
due to a reduction in the number of initiating events, as the
number of acinar–ductal metaplasias was signiﬁcantly higher in
acinar cell explants of KV12 mice than in those derived from
KHRasV12 animals (Fig. 4D; Supplementary Fig. S4B).
H-RasG12V failed to induce lung adenocarcinomas due to
excessive MAPK signaling
Systemic expression of H-RasG12V from the K-Ras locus did
not yield lung lesions, including hyperplasias or benign ade-
nomas. To rule out non–cell-autonomous effects, we infected
KHRasV12 and KV12 mice with Adeno-Cre particles to selectively
induce oncogene expression in lung tissue. Six months after
infection, none of the KHRasV12 mice displayed detectable
lesions in their lungs, whereas all KV12 animals had developed
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Figure 3.
H-RasG12V, but not K-RasG12V, induces
hematopoietic tumors in adult mice. A,
Representative images of spleens obtained from
Kþ;hUBC-CreERT2þ/T, KV12;hUBC-CreERT2þ/T,
or KHRasV12;hUBC-CreERT2þ/T mice treated for
4 months with tamoxifen diet. B, H&E staining of
spleen sections obtained from Kþ;hUBC-
CreERT2þ/T, KV12;hUBC-CreERT2þ/T, or KHRasV12;
hUBC-CreERT2þ/T mice treated for 4 months
with tamoxifen diet. White and red pulp are
indicated by arrows and arrowheads,
respectively (scale bars, 200 mm). C, Flow
cytometry analysis of Gr1þ and CD11bþ cells in
spleens obtained from Kþ;hUBC-CreERT2þ/T,
KV12;hUBC-CreERT2þ/T, or KHRasV12;hUBC-
CreERT2þ/T mice treated for 4 months with
tamoxifen diet. D, H&E (top and middle) and
CD3 immunohistochemical staining (bottom) in
thymus sections obtained from Kþ;hUBC-
CreERT2þ/T or KHRasV12;hUBC-CreERT2þ/T mice
treated for 4 months with tamoxifen diet. Scale
bars, 5 mm (top), 25 mm (middle, bottom).
E, Flow cytometry analysis of CD4þ and CD8þ
cells in thymuses obtained from Kþ;hUBC-
CreERT2þ/T or KHRasV12;hUBC-CreERT2þ/T mice
treated for 4 months with tamoxifen diet.
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multiple lesions, including lung adenocarcinomas (Supple-
mentary Fig. S4C and S4D).
Tamoxifen treatment of KV12;hUBC-CreERT2þ/T and
KHRasV12;hUBC-CreERT2þ/T mice for short periods of time
allowed us to analyze the immediate events that followed
expression of the K-RasG12V and H-RasG12V oncoproteins in
lung tissue. Four days after tamoxifen treatment, H-RasG12V
induced phosphorylation of the downstream Erk1/2 kinases
(pErk1/2) in more than 20% of the cells, whereas expression of
K-RasG12V only resulted in pErk1/2 immunostaining in less
than 5% of the cells (Fig. 5A). Similar results were obtained 7
days after treatment. These ﬁndings were not due to a differ-
ential number of cells expressing the K-RasG12V and H-RasG12V
oncoproteins as the levels of Cre-mediated recombination in
the lungs of KV12;hUBC-CreERT2þ/T and KHRasV12;hUBC-
CreERT2þ/T mice were similar (Supplementary Fig. S4E and
S4F). More importantly, when mice were analyzed 2 weeks after
tamoxifen treatment, the number of pErk1/2-expressing cells in
the lungs of KHRasV12 mice decreased dramatically, whereas
those present in KV12 lungs displayed a modest increase (Fig.
5A). These results were further conﬁrmed by Western blot
analysis (Fig. 5B). These observations were selective for lung
cells as we did not observe signiﬁcantly differential numbers of
pErk-expressing cells in other tissues with the possible excep-
tion of cells in the basal layer of the skin and in the white pulp
of the spleen (Supplementary Fig. S5A). To determine whether
these results were due to differential expression levels of the
two mutant proteins, we compared their relative levels of
expression in the lungs of KV12;hUBC-CreERT2þ/T and
KHRasV12;hUBC-CreERT2þ/T mice by a label-free quantiﬁcation
approach (29). This technique allowed us to determine their
relative amounts based on the detection of the shared peptide
(6-LVVVGAVGVGK-16) in which the underlined residue corre-
sponds to the activating valine (Supplementary Fig. S5B). As
illustrated in Fig. 5C, H-RasG12V is expressed at about 5-fold
higher levels than K-RasG12V. The higher levels of H-RasG12V
expression also resulted in increased levels of total GTP-bound
active Ras complexes as determined by RBD pull-down assays
(Fig. 5D).
Next, we examined whether the increased levels of GTP-bound
H-RasG12V may have an effect on the proliferation of H-RasG12V-
expressing cells that might prevent the appearance of hyperplastic
lesions. To this end, we used the recombinant K-RasH-RasG12V
allele as a molecular marker for the presence of H-RasG12V-
expressing lung cells. Exposure of 4-week-old KHRasV12;hUBC-
CreERT2þ/T mice to a tamoxifen diet for 4 weeks resulted in the
effective recombination of the K-RasLSLH-RasG12V allele, thus indi-
cating that a signiﬁcant fraction of lung cells expressed the H-
RasG12V oncoprotein (Fig. 6A). However, when these KHRasV12;
hUBC-CreERT2þ/T mice weremaintained in a diet lacking tamox-
ifen for an additional 8-weekperiod, those cells that contained the
recombined K-RasH-RasG12V allele diagnostic of H-RasG12V
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K-RasG12V and H-RasG12V oncoproteins expressed from the K-Ras locus induce pancreatic lesions. A, Number of low (P1) and high (P2/3) grade PanINs as
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Data, mean # SD. $$$ , P < 0.001 (unpaired Student t test).
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expression completely disappeared (Fig. 6A). These results were
selective for lung cells as the K-RasH-RasG12V recombined allele
remains present in other tissues, such as thymus, after the 8-week
period in theabsenceof tamoxifen (Fig. 6A). Todeterminewhether
the disappearance of the lung cells was due to excessive H-RasG12V
signaling, we treated KHRasV12;hUBC-CreERT2þ/T mice with a non-
limiting dose (1 mg/kg) of trametinib, a MEK inhibitor known to
effectively block MAPK signaling driven by Ras oncogenes (30).
Trametinibwasprovidedduring the8weeks inwhichmicewereno
longer exposed to tamoxifen. As illustrated in Fig. 6A, these mice
retained the K-RasH-RasG12V recombined allele, indicating that
expressionof theH-RasG12V oncoproteinwasno longer deleterious
for lung cells in the presence of the MEK inhibitor.
H-RasG12V expression in lung cells induces a senescence-like
arrest partially mediated by p53
The disappearance of H-RasG12V-expressing lung cells was not
due to apoptosis, as we could not detect increased levels of active
caspase-3 in the lungs of tamoxifen-treated KHRasV12 mice (Sup-
plementary Fig. S5C). Likewise, we did not detect SA-b-Gal
expression, a standard marker for oncogene-induced senescence
(OIS). Yet, we observed the induction of other senescence mar-
kers, such as p16Ink4a and p19Arf (Figs. 5B and 6B). These results
suggest that H-RasG12V expression may induce some sort of
noncanonical senescence-like state. Finally, we interrogated
whether this phenomenon could be mediated by p53. To this
end, we introduced p53lox alleles into KV12 and KHRasV12 mice. As
illustrated in Supplementary Fig. S6A and S6B, KHRasV12;p53lox/lox
mice developed some hyperplasias and occasional adenomas in
30% of the animals, all of which stained positive for type II
alveolar cell markers (Supplementary Fig. S6C). These results
indicate that induction of a senescence-like phenotype in lung
tissue by expression of the H-RasG12V oncoprotein from the K-Ras
locus is only partially mediated by p53.
H-RasG12V expressed from the K-Ras locus induces OIS in MEFs
Finally, we decided to compare the effect of expressing the
K-RasG12V andH-RasG12V oncoproteins from the sameK-Ras locus
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H-RasG12V expressed from the K-Ras locus induces robust downstream signaling in lung tissue.A, Top, immunohistochemical staining for pErkþ cells in lung sections
obtained from KV12;hUBC-CreERT2þ/T or KHRasV12;hUBC-CreERT2þ/T mice subjected to tamoxifen diet for the indicated time (scale bars, 250 mm); bottom,
quantiﬁcation of the percentage of pERKþ cells in the lung sections shown above obtained from KV12;hUBC-CreERT2þ/T (KV12; red bars; n ¼ 3) or KHRasV12;hUBC-
CreERT2þ/T (KHRasV12; blue bars; n ¼ 3) mice. Data, mean # SD. $$$ , P < 0.001 (unpaired Student t test). B, Western blot analysis of H-Ras, pErk1/2, Erk1/2,
pAkt, Akt, p16Ink4a, and p19Arf expression in total lung extracts obtained from KV12;hUBC-CreERT2þ/T or KHRasV12;hUBC-CreERT2þ/T mice exposed to tamoxifen
diet for the indicated time. GAPDH expression served as a loading control. C, Relative quantiﬁcation of the levels of expression of K-RasG12V and H-RasG12V
oncoproteins by label-free quantiﬁcation in lungs obtained from Kþ;hUBC-CreERT2þ/T (n¼ 6), KV12;hUBC-CreERT2þ/T (n¼ 6), or KHRasV12;hUBC-CreERT2þ/T (n¼ 6)
mice treated for 2 months with tamoxifen diet. The tryptic peptide LVVVGAVGVGK was used to detect expression of both K-RasG12V and H-RasG12V proteins.
Data, mean # SD. D, Total Ras-GTP levels in lungs obtained from KV12;hUBC-CreERT2þ/T or KHRasV12;hUBC-CreERT2þ/T mice treated with tamoxifen diet
for the indicated time. GAPDH was used as a loading control.
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inMEFs. Previous studies have shown that overexpressionof these
oncoproteins in MEFs readily induced OIS (31). However, when
they were expressed from their own endogenous promoters,
they failed to induce OIS (16, 17). We induced expression of
either K-RasG12V or H-RasG12V oncoproteins by infecting immor-
talized KV12 and KHRasV12 MEFs with Adeno-Cre particles, respec-
tively. As expected, K-RasG12V expression did not cause signiﬁcant
changes indownstream signaling (Fig. 7A). In contrast, expression
of H-RasG12V resulted in a sustained increase in the phosphory-
lation of the downstream substrates pErk and pAkt (Fig. 7A).
Moreover, whereas K-RasG12V expression had nodetectable effects
on proliferation, expression of H-RasG12V effectively inducedOIS,
leading to complete cessation of cell proliferation and SA-b-Gal
expression (Fig. 7B and C).
H-RasG12V expressing MEFs displayed increased levels of p53
(Fig. 7A). Yet, efﬁcient depletionof p53by short hairpinRNAshad
no effect on cell-cycle arrest or induction of senescence, indicating
that abrogation of p53 expression was not sufﬁcient to overcome
H-RasG12V–inducedOIS (Supplementary Fig. S7AC). Likewise,we
observed no signiﬁcant increase in the expression levels of
p16INK4a. However, ectopic expression of adenoviral E1A, an
oncoprotein known to target the p53 and Rb pathways (32), was
able to bypass OIS and to restore efﬁcient proliferation of MEFs
(Fig. 7B and C; Supplementary Fig. S7D). Furthermore, E1A
cooperated with H-RasG12V, but not with K-RasG12V, to transform
immortal MEFs (Fig. 7D; Supplementary Fig. S7E). In an effort to
provide a mechanistic explanation for the dramatic differential
effects induced by the K-RasG12V versus the H-RasG12V oncopro-
teins when expressed from the same locus, we established their
relative levels of expression using label-free quantiﬁcation tech-
niques. As illustrated in Fig. 7E, H-RasG12V was more efﬁciently
expressed (about 2.5-fold) than K-RasG12V.
To determine whether these minor differences might be
responsible for the drastically differential outputs, we decided
to explore how differential expression levels of the same onco-
protein, H-RasG12V, affected the biological behavior of MEFs.
Whereas H-RasG12V expressed from its own promoter had no
effect of MEF properties, including immortalization, prolifer-
ation, or senescence (17), H-RasG12V expression from the K-Ras
promoter in KHRasV12 led to rapid OIS (Fig. 7B and C). Western
blot analysis revealed that the amount of H-Ras protein (both
H-Ras and H-RasG12V) in KHRasV12 MEFs was 3-fold higher than
in H-RasG12V/G12V MEFs (Fig. 7F). As KHRasV12 MEFs also express
a wild-type H-Ras protein from its endogenous locus, the
amount of H-RasG12V expressed from the K-Ras locus in
KHRasV12 MEFs compared with that expressed from its own
locus in H-RasG12V/G12V MEFs is a mere 2-fold higher (1.9 !
0.7) than that expressed from its own locus. These observations
establish that relatively subtle increases in the levels of expres-
sion of the H-RasG12V oncoprotein can result in dramatically
different biological consequences.
Discussion
Early genetic studies revealed that the three Ras loci have
different biological properties. Whereas K-Ras is essential for
embryonic development, H-Ras and N-Ras are dispensable
(5–7). To determine whether these differences are due to the
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additional 8-week period (center) or treated daily with 1 mg/kg of trametinib, a selective MEK inhibitor (right). DNA isolated from thymus tissue was used as control.
The migration (open arrowheads) and sizes (solid arrowheads) of the diagnostic SphI þ KpnI DNA fragments for the recombined K-RasH-RasG12V allele that
expresses theH-RasG12V oncoprotein and the nonrecombinedK-RasLSLH-RasG12V allele that does not allowH-RasG12V expression are indicated. Note the disappearance
of the recombined K-RasH-RasG12V allele in lung but not thymus tissue. Lung tissue frommice treatedwith trametinib also retains the recombined K-RasH-RasG12V allele.
B, Relative expression levels of p16Ink4a and p19ArfmRNAs in total lung extracts from KV12;hUBC-CreERT2þ/T (KV12; red bars; n ¼ 3) or KHRasV12;hUBC-CreERT2þ/T
(KHRasV12; blue bars; n ¼ 3) mice exposed to tamoxifen diet for the indicated time, as determined by qRT-PCR analysis. GAPDH expression levels were used for
normalization. Data, mean ! SD. $$$ , P < 0.001 (unpaired Student t test).
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intrinsic properties of the different Ras protein isoforms or their
pattern of expression, Potenza and colleagues modiﬁed the
endogenous K-Ras alleles so they direct the synthesis of H-Ras
instead of K-Ras proteins (8). Thesemice developed to adulthood,
indicating thatH-Ras could effectively compensate for the absence
of the K-Ras proteins. Yet, these mice displayed cardiovascular
defects, including dilated cardiomyopathy associatedwith arterial
hypertension, attributed to the lack of K-Ras proteins in heart
tissue (8). However, as illustrated in this study, these cardiovas-
cular defectswere adirect consequence of theoverexpressionofH-
Ras proteins, as these mice carry four H-Ras–expressing alleles,
two endogenous H-Ras alleles, and two HrasKI alleles. Indeed,
elimination of the endogenous H-Ras alleles completely pre-
vented these cardiovascular defects. Moreover, HrasKI;H-Ras!/!
mice appear to be completely normal, indicating that the H-Ras
and K-Ras proteins are fully bioequivalent, at least under normal
homeostatic conditions. These observations are surprising con-
sidering the different properties of theH-Ras andK-Ras proteins in
subcellular transport, posttranslational processing, and localiza-
tion within the plasma membrane (3, 4). Whether their differ-
ential properties may play a role under stress conditions remains
to be determined.
The intense focus on RAS biology is due, at least in part, to their
involvement in human cancer. Over the years, scientists have been
bafﬂed by the distinct incidence of the various RAS oncogenes in
tumors (9). In an attempt to shed some light on this issue, we
expanded the early work of Potenza and colleagues (8), by gen-
erating anewconditionalmouse strain,KHRasV12, that expresses the
H-RasG12V oncoprotein from the endogenous K-Ras locus. Germ-
line expression of H-RasG12V from its own locus had no signiﬁcant
effect on embryonic development. Yet, these animals displayed
facial and cardiovascular defects reminiscent of patients with
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Figure 7.
H-RasG12V, but not K-RasG12V, expressed from the K-Ras locus induces senescence in MEFs. A,Western blot analysis of the indicated proteins expressed in KV12 or
KHRasV12 MEFs infected with Adeno-Cre particles for the indicated time. GAPDH expression served as a loading control. B, Growth curve of KV12 or KHRasV12 MEFs
infected with Adeno-GFP (open circles) or Adeno-Cre particles (closed circles) for the indicated time after stable infection with empty retroviruses (vector) or
retroviruses expressing the Ad5 E1A oncoprotein (E1A). Data, mean " SD. C, Percentage of SA-b-Gal–positive cells in KV12 or KHRasV12 MEFs stably infected
with empty retroviruses (V) or retroviruses expressing theAd5 E1A oncoprotein (E1A) 4 days after infectionwith Adeno-Cre particles. Data,mean" SD. ### , P <0.001
(unpaired Student t test). D, Focus formation in KV12 or KHRasV12 MEFs stably infected with empty retroviruses (V) or retroviruses expressing Ad5 E1A (E1A) 14 days
after infection with Adeno-Cre particles. Data, mean " SD. ### , P < 0.001 (unpaired Student t test). E, Relative quantiﬁcation of the levels of expression of the
K-RasG12V and H-RasG12V oncoproteins by label-free quantiﬁcation in KV12;hUBC-CreERT2þ/T (red bars; n ¼ 3) or KHRasV12;hUBC-CreERT2þ/T MEFs (blue bars;
n ¼ 3) 4 days after infection with Adeno-Cre particles. The tryptic peptide LVVVGAVGVGK was used to detect expression of K-RasG12V and H-RasG12V proteins.
Data, mean" SD. F,Western blot analysis of H-Ras protein expression (H-Ras and H-RasG12V) driven by the K-Ras locus in KHRasV12 MEFs upon infectionwith Adeno-
Cre particles for the indicated time and by the H-Ras locus in H-RasG12V MEFs. Expression of Ras effector proteins pErk1/2, Erk1/2, pAkt, and Akt was also
analyzed. GAPDH expression served as a loading control.
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Costello syndrome (17, 18). However, germline expression of
H-RasG12V from the endogenous K-Ras locus led to early embry-
onicdeathat a time similar to that observed for embryos expressing
an endogenous K-RasG12V oncoprotein (16). Thus, expression of
K-Ras and H-Ras oncoproteins from the K-Ras locus is equally
deleterious for embryonic development. These observations illus-
trate that the viability of H-Rasþ/G12V and H-RasG12V/G12V mice
must be due to a more restricted pattern of expression, lower
expression levels or a combination of both (17, 18).
Expression of K-RasG12V in embryonic acinar cells resulted in
the formation of low- and high-grade PanIN lesions and
occasional PDAC tumors (24). Expression of the H-RasG12V
oncoprotein from the K-Ras locus also resulted in the formation
of low- and high-grade PanIN lesions albeit at lower frequen-
cies, with no detectable PDAC tumors, at least by one year
of age. Whether the high-grade PanINs will eventually progress
to yield PDAC tumors in older animals remains to be deter-
mined. Recent studies have indicated that K-RasG12V, but not
H-RasG12V, promotes tumor formation by suppressing nonca-
nonical Wnt signaling (33). This property was used to repress
the transforming activity of K-RasG12V in pancreatic xenograft
tumor models with prostratin, a PKC activator (33). It will be
interesting to explore whether this natural product has differ-
ential activity in pancreatic lesions driven by K-RasG12V and
H-RasG12V oncoproteins.
Ubiquitous expression of H-RasG12V in adult KHRasV12 mice led
to a variety of tumors, mainly papillomas and hematopoietic
malignancies. More importantly, the pattern of tumors observed
in these mice was signiﬁcantly different to that present in KV12
animals, thus indicating that H-RasG12V and K-RasG12V oncopro-
teins have different transforming capabilities in different tissues.
Tamoxifen-treated adult KHRasV12;hUBC-CreERT2þ/T mice devel-
oped hematologic malignancies not observed in KV12;hUBC-
CreERT2þ/T animals, including myeloproliferative disease, a dis-
ease that resulted from expansion of the CMP population, as well
as T-ALL. Previous studies have reported that expression of a
resident K-RasG12D oncogene in the hematopoietic compartment
caused fatal myeloproliferative disease (34, 35) as well as T-ALL
upon bone marrow transplantation (36). In these studies, how-
ever, K-RasG12D expression was induced by anMx1-Cre transgene
known to express low levels of Cre recombinase activity during
embryonic development. Thus, it is possible that these different
resultsmight be due to the differential susceptibility of embryonic
hematopoietic precursors to K-Ras oncoproteins.
On the contrary, some tissues are susceptible to K-RasG12V,
but not to H-RasG12V–induced neoplastic lesions, such as the
lung alveoli and the stomach epithelium. The lack of lung
tumors in KHRasV12 mice appears to be a consequence of over-
activation of the MAPK signaling cascade by the H-RasG12V
oncoprotein. Indeed, H-RasG12V expression in type II alveolar
cells of KHRasV12 mice induced a signiﬁcantly more robust
phosphorylation of the Erk kinases than that observed upon
induction of the K-RasG12V oncoprotein in KV12 animals. This
increased signaling induced a noncanonical, senescence-like
state that prevented proliferation of the H-RasG12V–expressing
lung alveolar cells. Ablation of p53 in KHRasV12 mice resulted in
limited induction of hyperplastic lesions along with few ade-
nomas, but not in overt lung tumor development, thus indi-
cating that the senescence-like state was only partially mediated
by p53. These senescent H-RasG12V–expressing cells are short
lived as they could no longer be detected 8 weeks after the
induction of H-RasG12V expression. Likewise, IHC examination
of lung tissue of KHRasV12 mice 2 weeks after the induction of H-
RasG12V expression revealed a drastic reduction in the number
of pErk-positive cells. The fate of these cells remains unclear,
although the absence of active caspase-3 expression suggests
that they did not undergo apoptosis. Finally, exposure of
KHRasV12 mice to the MEK inhibitor trametinib prevented elim-
ination of the H-RasG12V–expressing cells, thus providing fur-
ther evidence that the senescence-like state of these H-RasG12V–
expressing lung cells was due to excessive MAPK signaling.
It has been proposed that the abundance of Ras isoforms can be
affected by differences in protein translation efﬁciency (37). K-Ras
mRNA is less efﬁciently translated than H-Ras due to the prefer-
ential usage of rare codons (37). Germline replacement of rare
codons in the K-Ras locus resulted in mice that expressed higher
levels of K-Ras proteins (38). Interestingly, these mice displayed
increased resistance to urethane-mediated carcinogenesis, sug-
gesting that increased levels of K-Ras oncoproteins had adverse
effects on lung tumorigenesis (38). Whether these observations
were due to the induction of a senescence-like state as described
here for the H-RasG12V oncoprotein remains to be determined.
Precise quantitative analysis of the relative amounts of H-RasG12V
and K-RasG12V proteins in lung tissue revealed that H-RasG12V was
present at 5-fold higher levels than K-RasG12V. Thus, it is possible
that these oncoproteinsmay have similar signaling properties and
their differential effects in lung tissue could be primarily due to
quantitative differences in their levels of expression. Whether the
differential results obtained in hematopoietic cells in which only
H-RasG12V was capable of inducing tumors is also due to quan-
titative differences remains to be determined. For instance, it is
possible that the hematopoietic precursors responsible for initi-
ating myeloproliferative disease and T-ALL may require higher
levels of MAPK signaling, such as those provided by H-RasG12V
expression. Yet, at this time, we cannot rule out that theH-RasG12V
and K-RasG12V oncoproteins may utilize differential signaling
pathways in these hematopoietic cells.
Previous studies have illustrated the presence of H-Ras onco-
genes in lung tumors of HrasKI mice exposed to urethane (39).
Indeed, these mice developed more lung tumors than wild-type
animals exposed to the same carcinogenic insult, a result
attributed to the frequent activation of H-Ras oncogenes
(39). This apparent conundrum could be explained by the
presence of lower levels of H-Ras protein in HrasKI mice.
Indeed, HrasKI is a chimeric allele made of H-Ras and K-Ras
sequences that contains K-Ras–derived rare codons in two of
the four coding exons. This fact may result in limited transla-
tion efﬁciency (9, 36, 37). Thus, HrasKI mice may express lower
levels of H-Ras as compared with those present in KHRasV12
animals that exclusively use H-Ras–derived codons. Alterna-
tively, urethane may induce mutations and/or epigenetic altera-
tions that prevent the development of the senescence-like state
induced by H-RasG12V expression in KHRasV12 mice.
Finally, in vitro studies also provided strong support for a
direct relationship between H-RasG12V- and K-RasG12V–induced
MAPK signaling and biological output. Expression of a resident
K-RasG12V oncoprotein in primary MEFs led to immediate
immortalization bypassing the replication-induced senescence
characteristic of wild-type cells (16). In contrast, expression of
the H-RasG12V oncoprotein from the K-Ras locus resulted in
canonical OIS leading to complete cessation of cell prolifera-
tion and expression of SA-b-Gal. This senescence phenotype
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was accompanied by a robust increase in the phosphorylation
of Erk1/2 and Akt. Quantitative analysis of the relative levels
of expression of the H-RasG12V and K-RasG12V oncoproteins in
KHRasV12 and KV12 MEFs, respectively, revealed 2.5-fold higher
levels of expression of H-RasG12V, thus raising the possibility
that differences other than levels of expression may account for
the differential biological outputs induced by these oncopro-
teins. However, comparative analysis of the levels of expression
of H-RasG12V in KHRasV12 MEFs, which induces irreversible OIS
versus H-RasG12V/G12V MEFs in which there are no signiﬁcant
biological changes, revealed a meager 2-fold difference in its
levels of expression. Thus, minor changes in the levels of
expression of the H-RasG12V oncoprotein can induce signiﬁ-
cantly different outputs. These results, taken together, under-
score the need to better understand the molecular mechanisms
that regulate the intensity of MAPK signaling to control the
detrimental effects induced by Ras oncoproteins during neo-
plastic development.
It is difﬁcult to reckon why the wild-type H-Ras and K-Ras
isoforms are bioequivalent in spite of their differential properties
relating to cellular trafﬁcking, posttranslational processing, and
subcellular localization, whereas their oncogenic counterparts
display differential transforming properties. It is conceivable that
cells tolerate an ample range of Ras signaling during normal
homeostasis providing that the differential signaling intensities
between the different Ras isoforms stay below a critical thresh-
old. In contrast, elevated signaling induced by Ras oncopro-
teins may activate "emergency" signals that either result in the
activation of negative feedback loops or in the induction of
OIS, ultimately leading to cell death. Activation of OIS and/or
feedback loops might be cell type dependent, leading to the
manifestation of different phenotypes ranging from senescence
to malignant transformation. Finally, it should be noted that
our observations do not eliminate the possibility that different
oncogenic Ras isoforms may also engage differential signaling
pathways. Understanding the differential outputs of H-Ras and
K-Ras oncogenes in different cell types will require a more
precise knowledge of the molecular mechanisms that control
their key effector pathways.
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